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Summary
Growth factors stimulate glucose transport; the increase in the rate is biphasic, with the 
early phase occurring immediately and lasting up to two hours.
3T3 -LI fibroblasts are a murine cell line which express a single facilitative 
monosaccharide transporter, G lutl. Insulin and platelet-derived growth factor (PDGF) 
stimulate cell proliferation in 3T3-L1 fibroblasts. These growth factors and the tumour 
promoter, 4fi-phorbol 12-myristate, 13-acetate (PMA), all stimulate 2-deoxyglucose 
uptake, in a similar manner. These effects are not additive, so the effects of these 
ligands on the rate of glucose transport may be mediated by a  similar signal 
transduction pathway.
The role of sn-l,2-diacylglycerol (DAG) and protein kinase C (PKC) in the early phase of 
insulin-, PDGF- and PMA-stimulated glucose transport was examined in 3T3-L1 
fibroblasts. Insulin has no effect on either DAG accumulation or PKC activity, so 
neither DAG nor PKC is necessary for insulin-stimulated glucose transport. PDGF 
stimulates both DAG accumulation and PKC activity; however, PDGF-stimulated 
glucose transport is unaffected by the down-regulation or the inhibition of PKC, so PKC 
is not necessary for PDGF-stimulated glucose transport. PMA also stimulates both DAG 
accumulation and PKC activity, and PMA-stimulated glucose transport is abolished by 
the down-regulation and the inhibition of PKC, so PKC is necessary for PMA-stimulated 
glucose transport. Thus, a signal transduction pathway involving PKC is not necessary 
for the early phase of insulin- or PDGF-stimulated glucose transport, but it is necessary 
for the early phase of PMA-stimulated glucose transport.
The role of mitogen-activated protein kinase (MAPK) in the early phase of insulin-, 
PDGF- and PMA-stimulated glucose transport was also examined in 3T3-L1 fibroblasts. 
Insulin, PDGF and PMA stimulate MAPK activity with the same dependancy on PKC as 
for the increase in the rate of glucose transport. In addition, insulin-, PDGF- and PMA- 
stimulated activation of MAPK precedes the increase in the rate of glucose transport.
Therefore, given th a t the activation of MAPK and the increase in the rate of glucose 
transport have the same dependency on PKC, and tha t the activation of MAPK precedes 
the increase in the rate of glucose transport, it is possible tha t the early phase of growth 
factor-stimulated glucose transport is mediated by a signal transduction pathway 
involving MAPK in 3T3-L1 fibroblasts.
Xenopus laevis oocytes also only express G lutl. Insulin-like growth factor-I (IGF-I) 
stimulates both glucose transport and MAPK activity in X. laevis oocytes. Again, the 
activation of MAPK precedes the increase in the rate of glucose transport.
In addition, the microinjection into X. laevis oocytes of recombinant p42maPk, purified 
MAPK kinase (MAPKK) or p39mos fusion protein, results in an increase in the rate of 
glucose transport. Since p39mos activates MAPKK, which in turn activates MAPK, it 
seems th a t components of a signal transduction pathway involving MAPK are able to 
stimulate glucose transport in X  laevis oocytes.
Furthermore, IGF-I-stimulated glucose transport is inhibited by the microinjection of 
CL 100, a protein tyrosine/ threonine phosphatase that is specific for MAPK.
Therefore, given th a t IGF-I stimulates both glucose transport and MAPK activity, that 
components of a signal transduction pathway involving MAPK also stimulate glucose 
transport, and th a t inhibition of MAPK activity abolishes IGF-I-stimulated glucose 
transport, it is likely tha t IGF-I-stimulated glucose transport is mediated by a signal 
transduction pathway involving MAPK in X. laevis oocytes.
The insulin and IGF-I receptors are tyrosine protein kinases of a similar structure, and 
either ligand can bind to either receptor, so it is likely tha t insulin- and IGF-I- 
stimulated glucose transport are mediated by a similar signal transduction pathway.
Therefore, given th a t it is possible tha t the early phase of growth factor-stimulated 
glucose transport is mediated by a signal transduction pathway involving MAPK in 
3T3 -LI fibroblasts, tha t it is likely th a t IGF-I-stimulated glucose transport is mediated 
by a signal transduction pathway involving MAPK in X. laevis oocytes, and tha t it is 
likely tha t insulin- and IGF-I-stimulated glucose transport are mediated by a similar
signal transduction pathway, it seems tha t the early phase of insulin-stimulated glucose 
transport in 3T3-L1 fibroblasts is, in fact, mediated by a pathway involving MAPK
Furthermore, PDGF, which also binds to a tyrosine protein kinase receptor, has similar 
effects to insulin on the rate of glucose transport and the activation of MAPK in 3T3-L1 
fibroblasts. Therefore, it is also likely th a t the early phase of PDGF-stimulated glucose 
transport is also mediated by a signal transduction pathway involving MAPK
This thesis concludes tha t the early phase of growth factor-stimulated glucose transport 
is mediated by a signal transduction pathway involving MAPK
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MAPK mitogen-activated protein kinase
MAPKAP kinase MAPK-activated protein kinase
MAPKK MAPK kinase
MAPKKK MAPKK kinase
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MEK MAPK/ ERK kinase
NCS newborn calf serum
4a-PDD 4a-phorbol 12,13-didecanoate
PDGF platelet-derived growth factor
PH pleckstrin homology domain
PKC protein kinase C
PLA phospholipase A
PLC phospholipase C
PLD phospholipase D
PMA 4fi-phorbol 12-myristate, 13-acetate
PP1 g glycogen-associated protein phosphatase -1
PtdCh sn - 1,2-phosphatidyl choline
PtdCh-PLC sn-1,2-phosphatidyl choline-specific phospholipase C
PtdCh-PLD sn-1,2-phosphatidyl choline-specific phospholipase D
Ptdlns sn-1,2-phosphatidyl inositol
Ptdlns 3'-K sn - 1,2-phosphatidyl inositol 3' -kinase
PtdIns(4)P sn-1,2-phosphatidyl inositol 4-phosphate
PtdIns(4,5)P2 sn-1,2-phosphatidyl inositol 4,5-bisphosphate
Ptdlns-PLC sn-1,2-phosphatidyl inositol-specific phospholipase C
PtdOH phosphatidic acid
RasGAP p21ms-GTPase activating protein
Sglt (SG LT ) active sodium/ monosaccharide transporter protein (gene)
SH Src homology domain
TAG triacylglycerol
TBST Tris buffered saline with Tween-20
TEMED N, N, N', N'-tetramethylethylenediamine
TRE phorbol ester responsive element
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Introduction
1.1 Cell proliferation
1.1.1 The somatic cell cycle
The somatic cell cycle is a complex series of events which culminates in nuclear division 
(mitosis) and cytoplasmic division (cytokinesis), producing two daughter cells, each with 
an identical complement of chromosomes to the parent cell. The process is highly 
coordinated so tha t cytoplasmic growth and one round of DNA replication are followed 
by mitosis then cytokinesis [Johnston et al., 1977]. In mammalian cells, the cell cycle is 
divided into the interphase (consisting of the S phase and two gaps of varying length:
G1 and G2), and the M phase. Cytoplasmic growth (the synthesis of new proteins, 
membranes and organelles) occurs throughout the interphase. DNA replication occurs 
during the S phase. Mitosis and cytokinesis occur during the M phase. In rapidly 
dividing human cells, the interphase takes about 24 hours and the M phase about 30 
minutes.
1.1.2 Control of the cell cycle 
Reasons for control
Cells only divide in specific conditions. If conditions are inappropriate for cell division, 
then, after reaching a critical point in G l, the cells exit from the cell cycle and enter a 
quiescent state, GO. They remain in GO until the correct conditions occur; thus the 
length of GO can vary considerably. This critical point is known as START in yeast and 
as the restriction point in mammalian cells. Entry and exit from GO is determined by 
the presence or absence of extracellular signals. These signals are different for 
unicellular and multicellular organisms.
The survival of a unicellular organism, such as the budding yeast, Saccharomyces 
cerevisiae, depends on rapid cell division. But, one of the conditions for cell division is 
th a t the cell m ust have a certain size. Hence, when cells are starved of an essential 
nutrient they will not pass through START, and so they enter GO [Johnston et al., 1977].
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In addition, budding yeasts also reproduce by conjugation. Consequently, when cells are 
exposed to mating pheromones, they enter GO [Reed, 1991].
The survival of a multicellular organism, such as man, depends on the survival of the 
organism as a whole. Again, the cells may only divide if they have a certain size. 
Division also requires a physiologically appropriate time and location, for example, 
during development or wound repair. Therefore, cell division in multicellular organisms 
is under greater control than in unicellular organisms, and consequently is influenced 
by more extracellular signals. These additional signals include growth factors [Pardee, 
1974] and anchorage to the extracellular matrix [Folkman and Moscona, 1978]. In the 
absence of these signals, cells enter GO. Cells will also enter GO when they touch other 
cells, a phenomenon known as contact inhibition. Furthermore, cells in multicellular 
organisms become senescent after a certain number of cell cycles.
Growth factor dependence
Growth factors are secreted by many cell types into the blood stream. Growth factors 
bind to specific membrane-spanning cell surface proteins which are expressed in a cell- 
specific manner. These receptors can be divided into groups, based on their structures, 
reflecting their different modes of action. Class I receptors are heteromers, each subunit 
having between four and six transmembrane domains. These receptors enclose anion or 
cation channels which open or close in response to ligand-binding [Barnard, 1992].
Class II receptors are monomers, each monomer having seven transm embrane domains. 
These receptors have an intracellular domain through which they bind to G proteins 
tha t are activated in response to ligand-binding [Hepler and Gilman, 1992]. Class III 
receptors are either monomers or formed from monomers, each monomer having a single 
transm embrane domain. These receptors have intrinsic intracellular protein tyrosine 
kinase or guanylate cyclase domains which are activated in response to ligand-binding 
[Yarden et al., 1986].
Growth factors are known to bind to G protein-coupled receptors and to tyrosine protein 
kinase receptors. Examples of growth factors which bind to G protein-coupled receptors 
include: the phospholipid, lysophosphatidic acid (LPA) [van Corven et al., 1989]; and 
the neuropeptides, bombesin [Battey et al., 1991] and a-thrombin [Vu et al., 1991]. 
Examples of growth factors which bind to tyrosine protein kinase receptors include: the
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polypeptides, epidermal growth factor (EGF), fibroblast growth factor (FGF), insulin, 
insulin-like growth factor-1 (IGF-I), and platelet-derived growth factor (PDGF) [Yarden 
etal., 1986].
The binding of a  growth factor to its receptor activates signal transduction pathways 
tha t stimulate the events of cell division. Some signal transduction pathways will be 
discussed in later chapters.
Since growth factor receptors are expressed in a cell-specific manner, and growth factors 
can only bind to their own receptors, a growth factor can only affect certain cell types. 
Thus, by controlling which growth factors are released, a multicellular organism can 
control which cell types divide.
Anchorage dependence
Cells are surrounded by the extracellular matrix, a network of macromolecules secreted 
by members of the connective-tissue cell family {Section 3.1.2). The extracellular matrix 
consists of adhesive fibrous proteins, such as fibronectin and laminin, and structural 
fibrous proteins, such as collagen and elastin, embedded in a polysaccharide 
glycosaminoglycan gel. The composition of the extracellular matrix depends on its 
location.
Cells bind to the adhesive proteins in the extracellular matrix and to proteins on the 
surface of other cells using integrins. Integrins are heterodimeric membrane-spanning 
proteins tha t are expressed in a cell-specific manner, and bind specifically to different 
extracellular proteins and to cytoskeletal proteins [Sastry and Horwita, 1993; Schaller 
and Parsons, 1993]. Since integrins are expressed in a cell-specific manner, integrins 
bind specifically to distinct subsets of extracellular proteins, and the composition of the 
extracellular matrix itself depends on its location, the interaction between extracellular 
proteins and integrins serves to anchor a particular cell type to a particular location.
Integrins are also involved in signal transduction. The binding of extracellular proteins 
to integrins induces changes in the intracellular pH, the intracellular free calcium ion 
concentration, tyrosine phosphorylation of cellular proteins and gene expression 
[Schaller and Parsons, 1993]. Since integrins have no enzymatic activity, these signals
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must arise from intermediary proteins; possible candidates are the non-receptor tyrosine 
protein kinases: focal adhesion kinase, p 1 2 5 ^ ^ ,  and Src, pGO^ [Zachary and 
Rozengurt, 1992; Schaller and Parsons, 1993].
In addition, growth factors regulate the affinity of integrins for their extracellular 
ligands [Sastry and Horwita, 1993] and cytoskeleton reorganisation [Ridley and Hall, 
1992; Ridley et al., 1992]. Thus, signal transduction pathways may link and integrate 
the growth factor and anchorage dependence of the cell cycle.
Loss of control
In tumour cells and transformed cultured cells, there is no control of the cell cycle. 
Consequently, these cells proliferate in the absence of growth factors and anchorage, 
and do not undergo senescence. In the case of tumour cells, loss of control of the cell 
cycle usually results from a combination of gene mutations occurring spontaneously, or 
in response to chemical carcinogens or radiation. Since there are several controlling 
factors in cell division, loss of control of the cell cycle usually requires four to six 
mutations; one mutation is not enough. In the case of cultured cells, loss of control of 
the cell cycle often results from transformation of the cell by a single mutated gene, 
since cultured cells already contain mutations tha t enable them to be maintained in 
culture. These mutations usually occur in the genes encoding proteins tha t are involved 
in the regulation of the cell cycle. This can occur in two ways: firstly, proteins that 
stimulate cell proliferation (the products of proto-oncogenes) become hyperactive (the 
products of oncogenes) [Bishop, 1985]; or secondly, proteins th a t inhibit cell proliferation 
(the products of tumour repressor genes) become inactive [Goodrich and Lee, 1992].
1.1.3 Early events of the cell cycle
The early events of the cell cycle prepare the cell for the increase in biosynthetic activity 
that leads to cytoplasmic growth and DNA replication, and include: an increase in the 
rate of transcription of intermediate-early genes [Greenberg and Ziff, 1984; Stumpo and 
Blackshear, 1986]; an increase in sodium/ proton exchange [Moolenaar et al., 1984a]; an 
increase in the intracellular free calcium ion concentration [Berridge and Irvine, 1989]; 
an increase in the phosphorylation of ribosomal protein S6 [Sturgill and Wu, 1991] and 
increase in the rate of transport of nutrients [Jimenez de Asua and Rozengurt, 1974].
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The increase in the rate of glucose transport forms the significant interest in this thesis.
The increase in the biosynthetic activity results in an increase in demand for nutrients 
such as amino acids, inorganic phosphate, nucleosides and monosaccharides, so an early 
event of G1 is an increase in the rates of transport of these nutrients [Jimenez de Asua 
and Rozengurt, 1974], When quiescent Swiss 3T3 cells are exposed to serum, the rate of 
glucose transport increases in a biphasic manner {Figure 1.1}. The early phase occurs 
during the first two hours of exposure to serum, during which the increase in the rate of 
glucose transport is rapid, reaching a maximum of approximately two fold by 60 to 
120 minutes. The late phase occurs during longer exposures to serum, during which the 
increase in the rate of glucose transport is rapid and maintained over several hours, 
reaching five to ten fold [Jimenez de Asua and Rozengurt, 1974]. The early phase is 
independent of protein synthesis, while the late phase is dependent on protein synthesis 
{Figure 1.1}.
A biphasic increase in the rate of glucose transport is also observed in response to many 
growth factors, for example: angiotensin II, EGF, thrombin and vasopressin in vascular 
smooth muscle cells [Low et al., 1992]; connective tissue-activating peptide-III and 
neutrophil-activating peptide-2 in 3T3-442A fibroblasts [Tai et al., 1992]; bombesin, FGF 
and PDGF in Swiss 3T3 fibroblasts [Takuwa et al., 1987; Kitagawa et al., 1989]; PDGF 
in Balb/c 3T3 fibroblasts [Rollins et al., 1988] and tumour necrosis factor-a in 3T3-L1 
fibroblasts [Cornelius et al., 1990],
A biphasic increase in the rate of glucose transport is also observed in response to 
tumour promoters, for example: 4fi-phorbol 12-myristate, 13-acetate (PMA) in Fisher 
ra t 3T3 fibroblasts [Flier et al., 1987].
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Figure 1.1 The effect of serum on the rate of deoxyglucose uptake
After incubation of quiescent Swiss 3T3 fibroblasts with foetal calf serum and with (□) or 
without (o) 10 mg/ml cyclohexunide, for the times shown, a 10 minute uptake of
2-deoxyglucose was measured [Jimenez de Asua and Rozengurt, 1974]. These results 
show th a t growth factor-stimulated glucose transport occurs in a biphasic manner and 
tha t the early phase occurs independently of protein synthesis, while the late phase is 
dependent on protein synthesis.
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1.2 Monosaccharide transport
1.2.1 Entry of small molecules into cells 
Diffusion, passive transport and active transport
Small molecules can pass through a lipid membrane in three ways: firstly, by simple 
diffusion; secondly, by facilitated diffusion (passive transport); and thirdly, by active 
transport {Figure 1.2}. The rate of simple diffusion is dependent on the size of the 
molecule and its relative solubility in non-polar solvents. Non-polar molecules, such as 
oxygen (32 Da) and small polar molecules, such as water (18 Da) diffuse rapidly across 
the membrane, while, larger, polar molecules, such as glucose (180 Da), diffuse slowly. 
Facilitated diffusion and active transport are protein-mediated; facilitated diffusion by 
facilitative transporter proteins or by channel proteins, and active transport by active 
transporter proteins. Transporter proteins undergo a conformational change after 
solute-binding in order to transfer th a t solute across the membrane. Transport across a 
membrane will only occur if the solute is able to bind to a transporter protein in tha t 
membrane. Channel proteins are water-filled pores th a t extend across the membrane; 
when they are open they allow solutes to pass through them. Transport across a 
membrane will only occur if the solute, which is usually an inorganic ion, has the correct 
charge and is small enough. These processes are faster than simple diffusion for larger 
hydrophilic solutes, such as monosaccharides, because the solute passes through the 
protein instead of the membrane so the size and solubility requirements of the 
membrane no longer apply. Facilitative transporter proteins and channel proteins, 
move a solute energetically downhill, across the membrane, tha t is, down the 
electrochemical gradient of the solute. However, active transporter proteins move a 
solute energetically uphill across the membrane, tha t is, up the electrochemical gradient 
of the solute. This is achieved by coupling solute transport to another process which is 
energy yielding and can drive solute uptake. Examples of such processes include the 
transport of a second solute down its electrochemical gradient, and the hydrolysis of 
ATP.
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Figure 1 =2 The movement of monosaccharides across membranes
Monosaccharides can pass through membranes in three ways:
a) Simple diffusion,
b) Facilitated diffusion,
c) Active transport.
The example shown is that of the movement of glucose across the plasma membrane of 
the epithelia of the small intestine brush border. The facilitative monosaccharide 
transporter located in the basolateral membrane is Glut2. The active monosaccharide 
transporter located in the apical membrane is Sgltl.
[Na+] = high 
[Glc] = low
Lumen of 
small intestine
Apical
membrane
[Na+] = low 
[Glc] = high
Lateral
membrane
Basal
membrane
Blood [Glc] = low
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Monosaccharides
Monosaccharides, and glucose in particular, are important nutrients, providing energy 
for metabolic processes in many organisms. Simple diffusion of monosaccharides is 
ubiquitous, but is too slow to meet the full energy requirements of the cell. However, 
facilitated diffusion of monosaccharides, through facilitative transporter proteins is 
common to most cells, and active transport is common in prokaryotes and some 
eukaryotes.
1.2.2 Mammalian transporter proteins
The majority of monosaccharides enter mammalian cells by facilitated diffusion, but 
active transport of monosaccharides also occurs in certain tissues.
Facilitative transporter proteins
To date, seven different genes for mammalian, facilitative monosaccharide transporter 
proteins have been identified, and are named according to their order of cloning:
GLUT1 [Mueckler et al., 1985; Bimbaum et al., 1986; Asano et al., 1988], GLUT2 
[Fukumoto et al., 1988; Thorens et al., 1988; Asano et al., 1989a], GLUT3 [Kayano et al., 
1988; Nagamatsu et al., 1992], GLUT4 [Bimbaum, 1989; Fukumoto et al., 1989; James 
et al., 1989], GLUT5 and GLUT6 [Kayano et al., 1990], and GLUT7 [Waddell et al.,
1992]. Six of the seven genes encode proteins, but GLUT6 is a pseudo-gene, with a DNA 
sequence most closely related to th a t of GLUT3 [Kayano et al., 1990]. Within mammals, 
the corresponding proteins are expressed in a tissue-specific manner [Table 1.1}, which 
is preserved across species. Furthermore, the expression of these transporter proteins 
can vary during development. For example, levels of G lutl are very high in most foetal 
tissues, decreasing between 40 to 80 percent in all tissues, except the brain, after birth 
[Asano et al., 1988]. The levels of other transporter proteins, such as Glut2 and Glut5, 
increase in their respective tissues during foetal development [Davidson et al., 1992]. 
Since different tissues have different requirements for monosaccharides, this 
distribution and variance suggests th a t the transporter proteins have different 
functions.
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Table 1.1 The major sites of expression of the mammalian facilitative
monosaccharide transporters
The data shown was obtained by Western blotting with antibodies which recognise 
G lutl [Bimbaum et al., 1986; James et al., 1989; Gould et al., 1992; Nagamatsu et al.,
1992]; Glut2 [Davies et al., 1987; Thorens et al., 1988; Orci et al., 1989]; Glut3 [Gould et 
al., 1992; Nagamatsu et al., 1992; Shepherd et al., 1992]; Glut4 [Fukumoto et al., 1989; 
James et al., 1989; Zorzano et al., 1989]; Glut5 [Davidson et al., 1992]; and Glut7 
[Waddell e ta l., 1992].
Isoform Tissues
G lutl Foetal tissues—cardiac and skeletal myocytes, hepatocytes, 
brown adipocytes;
Adult tissues—erythrocytes, endothelia and epithelia of the 
blood-tissue barriers (placenta, brain, nerve, retina, 
kidney, colon);
Cultured cells, transformed cells, tumour cells.
Glut2 Pancreatic C-cells;
Hepatocytes (sinusoidal membrane);
Epithelia (basolateral membrane) of kidney proximal 
tubules and small intestine brush border.
Glut3 Brain and neurones (rodents);
Brain, neurones, heart, liver and placenta (human).
Glut4 Skeletal and cardiac myocytes; 
Brown and white adipocytes.
Glut5 Epithelium (apical membrane) of the small intestine brush 
border;
Adipocytes and hepatocytes (low levels in human).
Glut7 Hepatocytes (endoplasmic reticulum membrane).
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Active transporter proteins
Two different genes for mammalian, active monosaccharide transporter proteins have 
been identified, and are named in order of their cloning: Sgltl [Hediger et al., 1989], 
and Sglt2 [Wells et al., 1992], Both encode proteins tha t are sodium ion/ sugar 
symporters. Sgltl is expressed in the apical membranes of the epithelia in the small 
intestine brush border and, to a lesser extent, the kidney nephron proximal tubule, 
while Sglt2 is expressed in the apical membranes of the epithelium of the kidney 
proximal tubule [Hediger et al., 1989; Wells et al., 1992].
The facilitative transporter proteins form the significant in terest in this thesis. 
Structure of the facilitative transporter proteins
A model, based on analysis of the G lutl amino acid sequence, has been proposed for the 
orientation of G lutl in the plasma membrane [Mueckler et al., 1985]. There are twelve 
transmembrane a-helical domains arranged so th a t the hydrophilic amino- and carboxy- 
termini are both intracellular. The loops between the putative transmembrane domains 
are very short, usually seven to fourteen amino acid residues long, except for two longer 
loops, one between transmembrane domains 1 and 2 (the first loop), and another 
between 6 and 7 (the middle loop). All of the transporter proteins have a single 
asparagine-linked, heterogeneous oligosaccharide on the first loop [Cairns et al., 1984; 
Mueckler et al., 1985]. Many of these features have been confirmed using antibodies 
specific to different regions of the transporter protein [Mueckler et al., 1985; Davies et 
al., 1987]. It is possible tha t the constraints imposed by the short loops produce a 
bilobular structure, consisting of two separate, but close groups of transmembrane 
helical domains: six nearer the amino-terminal and six nearer the carboxy-terminal. 
This has been observed using low resolution electron microscopy for lactose permease, 
which is a structurally related transporter protein from Escherichia coli [Li and Tooth,
1987].
There is a high level of amino acid sequence identity between the human, facilitative 
monosaccharide transporter proteins [Table 1.2], and the hydropathy plots are mostly 
superimposable. So, although Glut2 to Glut7 have been less well studied than Glutl, 
they are predicted to have a similar structure. A comparison of the amino acid residues 
for the human transporter proteins shows tha t 26 percent are invariant and 13 percent
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Table 1.2 The sequence identity between the mammalian facilitative
monosaccharide transporters
The data shown was derived from the amino acid sequences of human G lutl (492 amino 
acids) [Mueckler et al., 1985], Glut2 (524 amino acids) [Fukumoto et al., 1988], Glut3 
(496 amino acids) [Kayano et al., 1988], Glut4 (509 amino acids) [Fukumoto et al., 1989] 
and Glut5 (501 amino acids) [Kayano et al., 1990]. The human Glut7 has not been 
cloned, but ra t Glut7 (528 amino acids) has 68% sequence identity to ra t Glut2 [Waddell 
et al., 1992].
Isoform Glutl Glut2 Glut3 Glut4
Glut2 55.5
Glut3 64.0 52.0
Glut4 65.0 54.0 58.0
Glut5 42.0 40.0 39.0 42.0
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are conservative substitutions [Kayano et al., 1990]. These low variance amino acid 
residues (the 39 percent) are found mainly in the putative transmembrane domains, 
while the ones of high variance are found in the amino- and carboxy-termini, and also in 
the first loop [Kayano et al., 1990]. Glut5 is the most divergent; this is thought to be 
because it transports fructose rather than glucose. A comparison of the amino acid 
sequences for the transporter proteins between species shows th a t their amino acid 
sequences are also highly conserved (greater than 80 percent sequence identity) [Asano 
et al., 1988; Gould and Bell, 1990; Nagamatsu et al., 1992].
Kinetics of facilitated transport
The kinetics of facilitated transport can be described in a similar way to the kinetics of 
enzyme-catalysed reactions. A solute exists in an equilibrium between two 
compartments, as defined by a  membrane; the facilitative transporter protein 
accelerates the attainm ent of tha t equilibrium.
T + S „t^ l T S - ^ - > T  + Sfat
« - l
where T is the transporter protein, TS is the transporter-solute complex and Sext and 
Sint are the extracellular and intracellular solutes respectively. The substrates and the 
products of a biochemical reaction exist in an equilibrium; the enzyme accelerates the 
attainm ent of tha t equilibrium.
E + S” - * E S ———»E + P
where E is the enzyme, ES is the enzyme-solute complex, S is the substrates and P is 
the products. However, neither transporter proteins nor enzymes have any effect on the 
position of the equilibrium point.
Transport is dependent on the solute binding to the transporter protein. At low 
concentrations of solute, the rate of transport is almost proportional to the solute 
concentration. At a sufficiently high solute concentration the solute-binding sites 
become saturated, so the rate of transport reaches a maximum value, equivalent to 
Vmay. the maximum rate of an enzyme-catalysed reaction. Transporter kinetics can be 
described by the Michaelis-Menten equation:
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v=v   — ____
[S] + K ,
where V  is the rate of transport, Vmax is the maximum rate of transport, [S] is the 
extracellular solute concentration, and is the concentration of solute a t which the 
transport rate is half its maximal value.
Furthermore, facilitated transport is also inhibited by competitive or non-competitive 
and reversible or irreversible inhibitors. Again, the effects of inhibitors on protein - 
mediated transport can be described in a similar way to the effects of inhibitors on 
enzyme-catalysed reactions.
The kinetic properties of the mammalian, facilitative monosaccharide transporter 
proteins have been analysed by studying their expression in bacteria [Thorens et al.,
1988], cultured cells [Asano e ta l., 1989b] and Xenopus laevis oocytes [Birnbaum, 1989; 
Gould and Lienhard, 1989]. Only the D-enantiomers of glucose, galactose and fructose 
are transported [Gould and Lienhard, 1989]. D-Glucose is transported by G lutl, Glut2, 
Glut3, Glut4 and Glut7, D-galactose by G lutl, Glut2 and Glut3, and D-fructose by Glut2 
and Glut5 [Table 1.3}. Each transporter protein has a characteristic Km and Vmax for 
each monosaccharide tha t it is able to transport. The influx Km and the efflux Km for 
the transport of an individual monosaccharide by a single transporter protein may be 
different. For example, G lutl is asymmetric with respect to glucose, while Glut2 and 
Glut4 are symmetric with respect to glucose [Craik and Elliott, 1979; Taylor and 
Holman, 1981],
The fungal metabolite, cytochalasin B, which binds to all the mammalian transporter 
proteins, is a competitive inhibitor of glucose efflux mediated by all the transporter 
proteins [Bloch, 1973]. I t is also a non-competitive inhibitor of glucose influx mediated 
by G lutl, Glut2, Glut3 and Glut4 [Keller et al., 1989; Colville et al., 1993], of fructose 
influx mediated by Glut2 and of galactose influx mediated by Glut3 [Colville et al.,
1993]. However, it has no effect on fructose influx through Glut5 [Burant et al., 1992]. 
Phloretin is a competitive inhibitor for glucose efflux [Krupka, 1971; Basketter and 
Widdas, 1978].
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Table 1.3 Kinetic parameters of the mammalian facilitative monosaccharide
transporters
The data shown was obtained by measuring the zero-trans influx of 2-deoxy-D-glucose, 
galactose and fructose, and the equilibrium exchange of 3-O-methyl-D-glucose in 
X. laevis oocytes after microinjection of the mRNAs for G lutl [Gould and Lienhard, 
1989; Keller et al., 1989; Gould et al., 1991; Burant and Bell, 1992; Nishimura et al.,
1993], Glut2 and Glut3 [Gould et al., 1991; Burant and Bell, 1992; Colville et al., 1993], 
Glut4 [Keller et al., 1989; Burant and Bell, 1992; Nishimura et al., 1993] and Glut5 
[Burant et al., 1992]. ND: not determined.
Isoform Km (mM)
2-deoxy-D-
glucose
3-O-methyl-D-
glucose
D-galactose D-fructose
Glutl 7 17-26 17 Not
transported
Glut2 11-17 42 36-86 67
Glut3 1-2 11 6-8 Not
transported
Glut4 5 2-4 ND ND
Glut5 Not
transported
ND ND 6
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Functions of monosaccharide transporter proteins
Monosaccharide transporter proteins are important for the homeostatic control of the 
blood glucose concentration in mammals. Control of the blood glucose concentration is 
im portant because, if the concentration is too low, tissues tha t are highly dependent on 
glucose (such as the brain) will be damaged (hypoglycaemia), and if it is too high, 
glucose will be excreted by the kidneys (hyperglycaemia). The blood glucose 
concentration is controlled by balancing the entry and the exit of glucose from the blood 
stream.
Under physiological conditions, the blood glucose concentration is between 4.4 and 
6.7 mM (80 to 120 mg/ 100 ml). The rate of glucose transport through G lutl, Glut3 and 
Glut4 is normally a t a maximum because each of these transporters has a low Km for 
glucose relative to the physiological blood glucose concentration {Table 1.3}, and 
therefore each is normally saturated with glucose. However, the rate of glucose 
transport through Glut2 varies proportionally with the blood glucose concentration 
because it has a very high Km for glucose relative to physiological blood glucose 
concentrations {Table 1.3}, and therefore it is not normally saturated with glucose.
During the absorptive state, monosaccharides are absorbed from the lumen of the small 
intestine into the hepatic portal vein. They enter the epithelial cells of the small 
intestine by passing through the apical membrane, glucose and galactose via Sgltl and 
fructose via Glut5, and leave the epithelial cells by passing through the basolateral 
membrane, all three via Glut2 {Figure 1.1}. Consequently, the blood glucose 
concentration rises dramatically. The reabsorption of glucose from the proximal tubule, 
of the kidney, into the peritubular capillaries occurs in the same way as the absorption 
of dietary glucose. If the blood glucose concentration is very high, the transporter 
proteins will be saturated and glucose will be excreted.
In order to prevent excretion, glucose is stored as glycogen by the liver and skeletal 
muscles and as triacylglycerols (TAG) by adipocytes. The rate of glucose transport into 
the liver increases proportionally with the blood glucose concentration, since the liver 
expresses Glut2. The rate of glucose transport increases in adipocytes and skeletal 
muscle, by 20 to 30 fold and five fold respectively, in response to insulin which is 
released by the 13-cells of the islets of Langerhans. The insulin is released in response to
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high blood glucose concentrations. The insulin-stimulated glucose transport is mainly 
due to an increase in the rate of transport through Glut4 {Section 1.3.2}. In addition, 
Glut2 may have a role in insulin secretion, its high Km enabling the 13-cells of islets of 
Langerhans to sense changes in the blood glucose concentration [Holz and Habener, 
1992].
In the post-absorptive state, glucose is no longer absorbed from the small intestine, the 
blood glucose concentration is maintained by the efflux of glucose from the liver.
Glucose is formed there by glycogenolysis and gluconeogenesis. The last stage of these 
pathways, the dephosphorylation of glucose-6-phosphate by glucose-6-phosphatase, 
occurs in the lumen of the endoplasmic reticulum. Glut7, which is expressed in the 
membrane of the hepatic, endoplasmic reticulum, allows glucose to pass into the cytosol 
[Waddell et al., 1992]. Glut2, which is kinetically symmetric, allows glucose to leave the 
liver. Furthermore, the demand for glucose is reduced since most cells obtain energy 
from alternative sources; however, neurones remain dependent on glucose. During 
prolonged starvation, when blood glucose concentrations are lower than normal, 
neurones have priority access to glucose, over other cells, because the Km, for glucose, of 
Glut3 is lower than tha t of G lutl.
Since most cells express G lutl, which is saturated under physiological conditions, the 
rate of glucose transport into most cells does not increase significantly in response to the 
higher blood glucose concentrations. However, the rate of glucose transport, through 
G lutl, is regulated during processes such as cell division and cell differentiation, during 
which the rate of metabolism increases. For example, growth factors which regulate cell 
division also stimulate the rate of glucose transport in a biphasic manner {Section 1.1.3}.
1.3 Regulation of monosaccharide transport
1.3.1 Mechanisms
In certain conditions, the rate of glucose transport may be regulated; for example, the 
rate of transport through G lutl increases during cell division in response to growth 
factors {Section 1.1.3}, and the rate of transport through Glut4 increases during the
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absorptive state in response to insulin {Section 1.2.2}. There are three mechanisms by 
which rates of transport may be regulated: firstly, by increasing the number of 
transporter proteins a t the plasma membrane by increasing their translocation from an 
intracellular location [Suzuki and Kono, 1980]; secondly, by increasing the total number 
of transporter proteins through increased transcription, greater stability of mRNA, or 
increased translation; and thirdly, by increasing the activity of transporter proteins, in a 
manner analogous to the control of enzyme activity by an allosteric or covalent factor 
[Czech et al., 1992].
1.3.2 Changes in the intracellular location 
Cell proliferation: the early phase
The early phase of growth factor-stimulated glucose transport {Section 1.1.3} results
from the movement of existing G lutl from an intracellular site to the plasma membrane
[Yang et al., 1992; Yang and Holman, 1993]. For example, when quiescent 3T3-L1
fibroblasts are treated with insulin there is a two fold increase in G lutl in the plasma
ti
membrane, 25 percent of the total Glutl^present in the plasma membrane in the 
quiescent cells and 50 percent in insulin-treated cells [Yang et al., 1992]. Translocation 
of G lutl also occurs in response to the tumour promoter, PMA, in Swiss 3T3 fibroblasts 
[Kitagawa et al., 1985].
G lutl continually recycles between the plasma membrane and an intracellular site in 
both quiescent and growth factor-treated cells; the changes in the intracellular location 
result from regulation of the kinetics of endocytosis and, or exocytosis. For example, in 
3T3-L1 adipocytes, insulin stimulates G lutl exocytosis, increasing the rate constant by 
three fold, but only reduces the rate constant for G lutl endocytosis slightly [Yang and 
Holman, 1993],
However, the mechanism by which translocation occurs is not understood and little is 
known about the signal transduction pathways tha t mediate the early phase of growth 
factor-stimulated glucose transport.
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Blood glucose homeostasis
Insulin-stimulated glucose transport {Section 1.2.2} results primarily from the 
movement of Glut4 from an intracellular site to the plasma membrane [Holman et al., 
1990], although, skeletal myocytes and adipocytes express both G lutl and Glut4, and 
insulin stimulates the rapid movement of both transporters to the plasma membrane 
[Holman et al., 1990; Slot et al., 199la,b]. The greater significance of Glut4 for insulin - 
stimulated glucose transport arises because 95 percent of Glut4 is in an intracellular 
location in the basal state; tha t is, it is found in small tubulo-vesicular structures 
located near the traras-Golgi reticulum, as well as near the sarcolemma and transverse 
tubular system in myocytes [Slot et al., 1991a,b]. Consequently, there is the potential 
for large increases in the plasma membrane Glut4 level. For example, when brown 
adipose tissue is treated with insulin there is a 40 fold increase in Glut4 levels in the 
plasma membrane [Slot et al., 1991b]. In contrast, 20 percent of G lutl is found in the 
plasma membrane in the basal state [Yang et al., 1992]; consequently, the maximum 
possible increase in the plasma membrane G lutl level is approximately five fold. 
Furthermore, since Glut4 accounts for 90 percent of the total glucose transporter protein 
in adipocytes and myocytes [Zorzano et al., 1989], a small increase in the plasma 
membrane Glut4 level would be equivalent to all of the G lutl moving to the plasma 
membrane. However, since Glut4 probably has a higher intrinsic activity than G lutl, it 
may make an even greater contribution to the insulin-stimulated increase in the rate of 
glucose transport than can be explained by changes in the intracellular locations alone 
[Holman et al., 1990].
Glut4 is efficiently sequestered intracellularly in the absence of insulin. This is believed 
to be determined by a structural feature of Glut4, since the presence of Glut4 alone is 
sufficient for accurate localisation when expressed in 'non-insulin sensitive' cells such as 
3T3-L1 fibroblasts or Hep2 cells [Haney et al., 1991], Chinese ham ster ovary cells [Piper 
et al., 1992], NIH 3T3 fibroblasts [Hudson et al., 1992], PC12 cells [Hudson et al., 1993] 
andX. laevis oocytes [Thomas et al., 1993]. The precise intracellular targeting motif is 
disputed, with groups assigning it to either an amino-Phe sequence [Piper et al., 1992; 
Piper et al., 1993] or a carboxy-di-leucine sequence [Verhey and Bimbaum, 1994].
Glut4, like G lutl, recycles constitutively between the plasma membrane and an 
intracellular location in both quiescent and insulin-treated cells; insulin induces a
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redistribution of Glut4 by altering the kinetics of endocytosis and or exocytosis [Czech 
and Buxton, 1993; Yang and Holman, 1993]. For example, in 3T3-L1 adipocytes insulin 
stimulates Glut4 exocytosis, increasing the rate constant by nine fold, but only reduces 
the rate constant for Glut4 endocytosis slightly [Yang and Holman, 1993]. However, the 
expression of Glut4 in various 'non-insulin sensitive' insulin receptor positive cell types 
does not lead to insulin-responsive translocation, indicating the need for the expression 
of additional, and as yet, unidentified gene products to produce this response [Piper et 
al., 1992; Thomas et al., 1993].
Again, little is known about the signal transduction pathways tha t mediate the insulin- 
stimulated increase in the rate of glucose transport in adipocytes and muscle.
1.3.3 Changes in the total transporter level 
Cell proliferation: the late phase
The late phase of growth factor-stimulated glucose transport {Section 1.1.3} results from 
an increase in G lutl mRNA and concomitantly in G lutl protein [Hiraki et al., 1988; 
Rollins et al., 1988; Kitagawa et al., 1989; Mountjoy et al., 1989; Cornelius et al., 1990; 
Low et al., 1992; Tai et al., 1992], Growth factors stimulate the rate of transcription of 
GLUT1 [Hiraki et al., 1988; Rollins et al., 1988; Kitagawa et al., 1989] and possibly also 
increase the stability of G lutl mRNA [Rollins et al., 1988].
GLUT1 has several regulatory elements in the 5'-untranslated region. These include: a 
phorbol ester responsive element (TRE), three glucocorticoid response elements and four 
Spl hexamers [Williams and Birnbaum, 1988].
The transcription of genes with a TRE increases when the transcription factor activator 
protein-1 (AP-1) binds to the TRE. Phorbol esters and growth factors stimulate the 
transcriptional activity of AP-1 [Angel and Karin, 1991]. PMA-stimulated AP-1 activity 
is dependent on protein kinase C (PKC). Depletion of PKC abolishes the increase in the 
rate of glucose transport and the level of G lutl mRNA observed in response to PMA 
[Hiraki et al., 1988; Mountjoy et al., 1989], It is likely, therefore, th a t PMA-stimulated 
GLUT1 transcription is mediated by a signal transduction pathway involving PKC tha t 
leads to an increase in AP-1 activity. In contrast, depletion of PKC has no effect on the
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increase in the rate of glucose transport and the level of G lutl mRNA observed in 
response to growth factors [Hiraki et al., 1988; Rollins et al., 1988; Kitagawa et al.,
1989] or transformation [Hiraki et al., 1989], suggesting tha t PKC is not necessary for 
these responses. However, AP-1 activity can be regulated independently of PKC, by a 
signal transduction pathway involving mitogen-activated protein kinases (MAPK) 
{Section 5.1.1}. MAPK is activated in response to many growth factors, and therefore, it 
is likely tha t growth factor-stimulated GLUT1 transcription is mediated by a signal 
transduction pathway involving MAPK.
Transformation
Transformation of cultured cells by oncogenes results in a loss of control over the cell 
cycle. This leads to an increase in biosynthetic activity and an increase in demand for 
nutrients, including glucose. Therefore, an early event during transformation is an 
increase in the rate of glucose transport which also results from an increase in the level 
of G lutl mRNA and therefore G lutl protein [Birnbaum et al., 1986; Flier et al., 1987].
Transcription of GLUT1 in response to both growth factors and transformation occurs 
from the same initiation site [Williams and Bimbaum, 1988], and therefore regulation of 
transcription of GLUT1 during normal cell division and transformation appears to be 
mediated by similar pathways.
Oncogenes, which induce classical morphological transformation, such as v-fps,v-ras 
and v-src, lead to a four to ten fold increase in the rate of glucose transport; however, 
oncogenes which promote transformation weakly, such as c-myc, have no effect on the 
rate of glucose transport [Flier et al., 1987]. The normal cellular proteins corresponding 
to the first group of oncogenes, for example, p21c_ms and p60c' src, are thought to be 
involved in the signal transduction pathways tha t regulate the cell cycle. This further 
suggests tha t the regulation of GLUT1 transcription during normal cell division and 
transformation is mediated by similar pathways.
1.3.4 Changes in the intrinsic activity
Although, researchers agree tha t growth factor- and insulin-stimulated glucose 
transport occur primarily by translocation or by increases in the total transporter level
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{Sections 1.3.2 and 1.3.3}, it is possible tha t there may also be an increase in the 
intrinsic activity of the transporter proteins [Czech et al., 1992; Yang et al., 1992]. 
However, the physiological importance of activation is far from clear. There are no 
direct methods for measuring changes in intrinsic activity, and therefore a role for 
intrinsic activation is instead inferred when the changes in the intracellular location or 
the total level of the glucose transporter proteins are not sufficient to account for the 
whole of the observed increases in the rate of glucose transport.
The use of different cells and techniques for measurements of glucose transporter levels 
also complicates the issue, and consequently the contribution of changes in the intrinsic 
activity of transporter proteins to growth factor and insulin-stimulated glucose 
transport remains uncertain. However, in certain situations it would appear th a t the 
intrinsic activity of glucose transporter proteins is regulated. 3T3-L1 fibroblasts and 
Chinese ham ster ovary fibroblasts have similar basal rates of glucose transport. Both 
express only Glutl; however, there are ten times the number of G lutl transporters in 
the plasma membrane of 3T3-L1 fibroblasts than in Chinese ham ster ovary fibroblasts. 
Thus the basal rate of glucose transport appears to be suppressed in 3T3-L1 fibroblasts, 
perhaps as a result of an inhibitory regulator protein [Harrison et al., 1991],
The intrinsic activity of transporter proteins could be regulated by phosphorylation. 
G lutl is a substrate for PKC and undergoes phosphorylation in response to PMA in both 
3T3-L1 adipocytes [Gibbs et al., 1986] and human fibroblasts [Allard et al., 1987]. 
However, there is no change in the phosphorylation state of G lutl in response to insulin 
in 3T3-L1 adipocytes [Gibbs et al., 1986] nor in response to PDGF, insulin and EGF in 
human fibroblasts [Allard et al., 1987], suggesting tha t phosphorylation has no effect on 
the intrinsic activity of Glutl.
1.4 Aim
The aim of this work was to establish which signal transduction pathway mediates the 
early phase of growth factor-stimulated glucose transport. After characterisation of the 
early phase of insulin and PDGF-stimulated glucose transport in 3T3-L1 fibroblasts, the 
roles of a signal transduction pathway involving phospholipid hydrolysis and PKC
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activation and a signal transduction pathway involving MAPK activation were analysed. 
Finally, the role of a signal transduction pathway involving MAPK activation in IGF-I- 
stimulated glucose transport in X. laevis oocytes was also analysed.
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Materials and methods
2.1 Materials
All reagents used were of the highest quality available and were obtained from the 
following suppliers:
2.1.1 General reagents
Amersham International Pic, Aylesbury, Buckinghamshire, UK
PDGF (BB homodimer, human recombinant)
enhanced chemiluminescence (ECL) Western blotting detection reagents
Bio-Rad Laboratories Ltd, Hemel Hempstead, Hertfordshire, UK
cellophane membrane backing
N, N, N1, N'-tetramethylethylenediamine (TEMED)
prestained SDS-PAGE standards (myosin, fi-galactosidase, BSA and ovalbumin)
Boehringer Manheim, Lewes, Sussex, UK
ATP (519 979)
Calbiochem-Novabiochem (UK) Ltd, Nottingham, Nottinghamshire, UK
IGF-I (human recombinant, cell culture grade) 
sn -1,2-diacylglycerol (DAG) kinase (E. coli recombinant)
Fisons, Loughborough, Leicestershire, UK
acrylamide
ammonium persulphate
chloroform
ethanoic acid
Folin and Ciocalteu's phenol reagent
glucose
glycerol
glycine
Hepes
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hydrochloric acid 
methanol
N, N' methylene-bis-acrylamide
potassium chloride
SDS
sodium chloride
sodium dihydrogen orthophosphate dihydrate 
sodium EDTA 
sodium hydrogen carbonate 
trichloroacetic acid
Gibco BRL, Paisley, Lanarkshire, UK
Tris base 
urea
Hay man Ltd, Witham, Essex, UK
ethanol
Kodak Ltd, Hemel Hempstead, Hertfordshire, UK
RP X-Omat liquid fixer/ replenisher 
RP X-Omat liquid developer/ replenisher 
X-Omat AR film
Lipid Products, Nutley, Surrey, UK
phosphatidyl serine (grade 1)
Merck Ltd (BDH), Lutterworth, Leicestershire, UK
calcium chloride hexahydrate 
calcium nitrate tetrahydrate 
dimethyl sulphoxide 
magnesium chloride hexahydrate 
magnesium sulphate heptahydrate
SG60 pre-coated tic plates (10 x 20 cm, layer thickness of 0.25 mm) 
tetrn -sodium pyrophosphate decahydrate
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National Diagnostics, Aylesbury, Buckinghamshire, UK
Ecoscint scintillation fluid
Premier Brands UK, Knighton Adbaston, Staffordshire, UK
Marvel powdered milk
Schleicher & Schuell, Dassel, Germany
nitrocellulose membrane (0.45 |iM)
Sigma Chemical Company Ltd, Poole, Dorset, UK
BSA (A-7030)
Bromophenol blue 
cyclohex Imide 
cytochalasin B
2-deoxy- D-glucose 
digitonin
diisopropyl fluorophosphate (DFP) 
dithiothreitol
£rans-epoxysuccinyl-L-leucylainido(4-guanidino)-butane (E 64)
imidazole hydrochloride
insulin (porcine monocomponent)
3- O-methyl-D-glucose 
Pepstatin A
Pipes
protein A-agarose
413-phorbol 12-myristate, 13-acetate
4a-phorbol 12 ,13-didecanoate (4a-PDD)
sodium J3-glycerophosphate
sodium deoxycholate
sodium EGTA
sodium fluoride
sodium orthovanadate
sn - l-stearoyl-2-arachidonylglycerol
trichloroacetic acid
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Triton X-100 
Tween-20
Thomson & Joseph, Norwich, Norfolk, UK
tricane methene sulphate (MS 222)
Whatman International Ltd, Maidstone, UK
W hatman P81 ion-exchange chromatography paper
2.1.2 Animals 
South African Xenopus Facility, Noordhoek, Republic of South Africa
Female X. laevis toads (wild)
2.1.3 Antibodies 
Affiniti Research Products Ltd, Nottingham, Nottinghamshire, UK
mouse anti-MAPK monoclonal antibody 
mouse a n t i-p l2 5 ^ ^  monoclonal antibody
Amersham International Pic, Aylesbury, Buckinghamshire, UK
horseradish peroxidase (HRP)-conjugated sheep anti-mouse IgG antibody 
HRP-conjugated donkey anti-rabbit IgG antibody
Dupont (UK) Ltd, Stevenage, Hertfordshire, UK
125I-conjugated goat anti-rabbit IgG antibody
East Acres Biologicals, Southbridge, Massachusetts, USA
rabbit anti-human G lutl antibody
Sigma Chemical Company, Poole, Dorset, UK
rabbit anti-mouse IgG antibody
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2.1.4 Cells
American Type Culture Collection, Rockville, USA
3T3 -LI fibroblasts
2.1.5 Cell culture media and reagents 
Gibco BRL, Paisley, Lanarkshire, UK
Dulbecco's modified Eagle's medium (without sodium pyruvate, with 4500 mg/L glucose) 
(DMEM)
10000 U/ml penicillin, 10000 U/ml streptomycin solution 
trypsin
Flow Laboratories, Irvine, Ayrshire, UK
new bom calf serum (NCS)
2.1.6 Cell culture plastics 
AS Nunc, DK Roskilde, Denmark
50 ml centrifuge tubes 
6 cm 2 cell culture plates 
10 cm2 cell culture plates 
75 cm3 cell culture flasks 
6-well cell culture plates
Bibby Sterilin Ltd, Stone, Staffordshire, UK
sterile pipettes
13.5 ml centrifuge tubes
Corning Glass Works, Corning, New York, USA
6 cm2 cell culture plates 
10 cm2 cell culture plates
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75 cm2 cell culture flasks 
6-well cell culture plates
Costar, Cambridge, Massachusetts, USA
cryotubes
Sartorius AG, Gottingen, Germany
M inisart NML filters (0.2 pm)
2.1.7 Microinjection equipment
Pierce Warriner, Chester, Cheshire, UK
SpectraMesh (08-670-183, size 1000 microns)
Gamier Glass, Claremont, California, USA
glass capillary tubes (internal diameter 0.0285 inches, external diameter 0.048 inches, 
length 7.09 inches)
World Precision Instruments, New Haven, Connecticut, USA
PUL-1 system
Drummond Scientific Company, Broomall, Pennsylvania, USA
manual injection pipette (model 3-00-510-X)
Narishige Europe Ltd, Sydenham, London, UK
micromanipulator (model MN-153)
2.1.8 Radioactive materials
Amersham International Pic, Aylesbury, Buckinghamshire, UK
[y-32P]ATP (PB 108)
3-0-methyl-D-[l-3H]glucose
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2-deoxy-D-[2,6- 3H]glucose 
[3H] thymidine
Dupont (UK) Ltd, Stevenage, Hertfordshire, UK
3- 0-methyl-D-[l-3H]glucose 
2-deoxy- D- [2,6- 3H] glucose 
125I-conjugated goat anti-rabbit IgG antibody
2.2 Buffers and media
2.2.1 Cell culture media 
Serum-free DMEM
100 U/ml penicillin, 100 U/ml streptomycin in DMEM.
0.5% NCS/DMEM
100 U/ml penicillin, 100 U/ml streptomycin, 0.5% (v/v) NCS in DMEM.
10% NCS/DMEM
100 U/ml penicillin, 100 U/ml streptomycin, 10% (v/v) NCS in DMEM.
Sterile trypsin solution for cell passage
A solution of 25% (w/v) trypsin in PBS {Section 2.2.2} was filtered through a sterile 2 pM 
membrane and stored in 10 ml aliquots in sterile universal tubes a t -20°C.
2.2.2 Standard buffers 
Barths buffer
88 mM sodium chloride, 2.4 mM sodium hydrogen carbonate, 1.0 mM potassium 
chloride, 0.82 mM magnesium sulphate heptahydrate, 0.41 mM calcium chloride 
hexahydrate, 0.33 mM calcium nitrate tetrahydrate, 5.0 mM Hepes, pH 7.6.
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Barths buffer was autoclaved and stored a t room temperature.
DAG mass assay: Incubation buffer
250 mM imidazole pH 6.6, 250 mM sodium chloride, 62.5 mM magnesium chloride 
hexahydrate, 5.0 mM sodium EGTA.
Hanks buffered saline (HBS)
137 mM sodium chloride, 5.37 mM potassium chloride, 4.20 mM sodium hydrogen 
carbonate, 1.26 mM calcium chloride hexahydrate, 0.90 mM magnesium sulphate 
heptahydrate, 0.50 mM magnesium chloride hexahydrate, 0.35 mM sodium dihydrogen 
orthophosphate dihydrate, pH 7.4.
Hanks buffered saline with BSA and glucose (HBG)
10 mM glucose, 2% (w/v) BSA, 137 mM sodium chloride, 5.37 mM potassium chloride, 
4.2 mM sodium hydrogen carbonate, 1.26 mM calcium chloride hexahydrate, 0.90 mM 
magnesium sulphate heptahydrate, 0.50 mM magnesium chloride hexahydrate,
0.35 mM sodium dihydrogen orthophosphate dihydrate, pH 7.4.
Homogenisation buffer
80 mM sodium 13-glycerophosphate, 20 mM EGTA, 15 mM magnesium chloride, 0.5 mM 
sodium vanadate.
HPFEV
50 mM Hepes, 100 mM sodium fluoride, 10 mM tetra -sodium pyrophosphate 
decahydrate, 4 mM sodium EDTA, 2 mM sodium orthovanadate, pH 7.4.
HPFEV was stored in a dark bottle at 4°C.
Krebs Ringer buffered phosphate (KRP)
1.37 mM sodium chloride, 4.7 mM potassium chloride, 5.0 mM sodium dihydrogen 
orthophosphate dihydrate, 1.25 mM magnesium sulphate heptahydrate, 1.25 mM 
calcium chloride hexahydrate, pH 7.4.
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Phosphate buffered saline (PBS)
150 mM sodium chloride, 10 mM sodium dihydrogen orthophosphate dihydrate, pH 7.4. 
Protein concentration assay: Reagent A
0.025% (w/v) copper sulphate pentahydrate/ 0.05% (w/v) sodium potassium ta rtra te / 
2.5% (w/v) sodium carbonate/ 2.5% (w/v) SDS/ 0.2 M sodium hydroxide*
Reagent A was made from equal proportions of a) 0.1% (w/v) copper sulphate 
pentahydrate/ 0.2% (w/v) sodium potassium tartrate / 2.5% (w/v) sodium carbonate, b) 
10% (v/v) SDS, c) 0.8 M sodium hydroxide and d) water.
Protein concentration assay: Reagent B
A 1:5 dilution of Folin and Ciocalteu's phenol reagent in water.
Protein kinase C activity assay: Intracellular buffer
5.16 mM magnesium chloride hexahydrate, 94 mM potassium chloride, 12.5 mM Pipes,
12.5 mM sodium EGTA, 8.17 mM calcium chloride hexahydrate, pH 7.4.
2.2.3 SDS-PAGE buffers 
Electrode buffer
25 mM Tris-base, 192 mM glycine, 0.1% (w/v) SDS.
Sample buffer (for standard use)
93 mM Tris hydrochloride pH 6.8, 20 mM dithiothreitol, 1 mM sodium EDTA, 10% (v/v) 
glycerol, 2% (w/v) SDS, 0.002% (w/v) Bromophenol blue.
The dithiothreitol was added immediately before use.
Sample buffer (for phosphotyrosine-containing proteins)
93 mM Tris hydrochloride pH 6.8, 20 mM dithiothreitol, 1 mM sodium EDTA, 2.0 mM 
sodium pyrophosphate, 10% (v/v) glycerol, 2% (w/v) SDS, 0.002% (w/v) Bromophenol 
blue.
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The dithiothreitol was added immediately before use.
Sample buffer (for immunoprecipitation)
8 M urea, 93 mM Tris hydrochloride, pH 6.8, 2.0 mM sodium pyrophosphate, 20 mM 
dithiothreitol, 10 mM sodium EDTA, 10% (v/v) glycerol, 2% (w/v) SDS, 0.002% (w/v) 
Bromophenol blue.
The dithiothreitol was added immediately before use.
2.2.4 Protease inhibitor stocks 
Pepstatin A
1 mg/ml in DMSO.
E 64
10 mM in 2 mM sodium EDTA.
DFP
200 mM in isopropanol.
All of the protease inhibitor stocks were stored a t -20°C.
2.2.5 Western blot buffers 
Blot buffer
25 mM sodium dihydrogen orthophosphate dihydrate, pH 6.5.
First wash buffer
150 mM sodium chloride, 5 mM sodium dihydrogen orthophosphate dihydrate, 1 mM 
sodium EDTA, 0.1% (w/v) Triton X-100, pH 7.4.
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Second wash buffer
790 mM sodium chloride, 5 mM sodium dihydrogen orthophosphate dihydrate, 1 mM 
sodium EDTA, 0.1% (w/v) Triton X-100, pH 7.4.
Towbin buffer
25 mM Tris-base, 192 mM glycine, 20% (v/v) methanol, pH 8.3.
Tris buffered saline with 0.02% Tween-20 (TBST-1)
20 mM Tris, 150 mM sodium chloride, 0.02% (v/v) Tween-20, pH 7.4.
Tris buffered saline with 0.3% Tween-20 (TBST-2)
20 mM Tris, 150 mM sodium chloride, 0.3% (v/v) Tween -20, pH 7.4.
2.3 3T3-L1 fibroblast culture
2.3.1 Growth
3T3-L1 fibroblasts were grown on cell culture flasks and plates containing 10% (v/v) 
NCS/ DMEM {Section 2.2.1}. The medium was replaced every 2 days. The cells were 
kept a t 37°C in a humidified atmosphere containing 10% CO2 .
2.3.2 Passage
When the cells were subconfluent, they were removed from the plates using trypsin.
The medium was replaced with 2 ml of sterile 0.25% (w/v) trypsin in PBS {Section 2.2.2}. 
When some cells had started to float, a Pasteur pipette was used to loosen the 
remainder, and the action of the trypsin was stopped by the addition of a small volume 
of 10% (v/v) NCS/ DMEM {Section 2.2.1}. The cells were then diluted and mixed in a 
larger volume of 10% (v/v) NCS/ DMEM and seeded onto new cell culture dishes; for 
example, the cells from a 10 cm2 plate were seeded onto ten 10 cm2 plates.
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2.3.3 Preparation for experiment
For most experiments, quiescent, confluent cells were required; this was achieved by 
incubation of the cells in serum-free DMEM {Section 2.2.1} for 3 hours. For other 
experiments, preparation details are given with the method.
2.3.4 Long term storage
Confluent cells were removed from the plates using trypsin {Section 2.3.2}. The cells 
from a 75 cm3 flask were resuspended in 5 ml of 10% (v/v) NCS/ DMEM {Section 2.2.1}, 
and the suspension was spun a t 1000 g  a t room tem perature for 5 minutes; the 
supernatant was then removed. 10% (v/v) NCS/ DMEM containing 10% (v/v) glycerol 
was equilibrated in 10% carbon dioxide for 1 hour, and the cell pellet was resuspended 
in 1 ml of this medium. Aliquots of the suspension were put into cryotubes, packed in 
cotton wool and frozen overnight a t -80°C. The cryotubes were then transferred to liquid 
nitrogen for long-term storage.
Cells to be recovered from storage were thawed rapidly a t 37°C, and then the contents of 
each cryotube were resuspended in 10 ml of 10% (v/v) NCS/ DMEM on 10 cm2 plates.
2.4 Xenopus laevis maintenance and oocyte preparation
2.4.1 Maintenance
Female X, laevis were housed three to an aquarium (22 x 22 x 30 cm) in about 15 cm of 
distilled water, and had unrestricted access to the surface. The aquariums were kept in 
a quiet, environmentally controlled room, a t a water temperature of 18°C, on a 12 hour 
light/ dark cycle. The toads were fed, twice a week, on a diet of chopped, raw heart. The 
water in the aquariums was changed the day after feeding.
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2.4.2 Oocyte preparation
Anaesthesia and recovery
Female X. laevis were anaesthetised quickly by immersion in 0.15% (w/v) MS222 in a 
total of 500 ml distilled water supplemented with 25 ml of 0.5 M sodium bicarbonate to 
counteract the irritan t effect of the low pH of MS222. Anaesthesia was complete once 
the toad was immobile upon being placed on her back, occurring, typically, five to ten 
minutes after immersion. After surgery, the toad was rinsed in distilled w ater and 
placed in an aquarium containing sufficient water to cover the bottom of the tank  
without covering the toad's nostrils. The exposed skin was moistened periodically. 
Recovery was complete once full movement had returned, occurring, typically, within 
one hour of surgery.
Removal of ovarian tissue
The toad was placed on her back, a small slit (about 1 cm) was made in the lower third 
of the abdominal wall and the inner body cavity was opened gently. An oocyte lobe was 
located, and a small sample of it was removed. The oocytes were inspected under the 
microscope, and if healthy, more of the oocyte lobe was taken out and placed into Barths 
medium {Section 2.2.2} on a 6 cm2 cell culture plate. The incision was closed with 
stitches in the inner body wall and the outer dermis. Extracted oocyte lobes were cut 
into clumps about 5 mm long and placed on clean cell culture plates.
Isolation of individual oocytes
All the dissection procedures were carried out in Barths buffer under a binocular 
microscope using 10 x 23 magnification eyepieces. A 'swan-necked' light source was 
used to avoid heating the oocytes directly.
The oocytes isolated were in stages IV or V of development. Such oocytes are the 
largest, having a distinct boundary between the animal (dark brown) and vegetal (light 
green/ yellow) poles. The animal pole has uniform pigmentation.
An oocyte lobe consists of a central artery and connective tissue to which the oocytes are 
attached by a thin translucent stalk. Individual oocytes were removed from the 
connective tissue by manual dissection. The central artery was held using a pair of fine
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watchmakers forceps (INOX size 5), and a second pair of forceps was used to tease out 
individual oocytes from the connective tissue. Damaged oocytes were discarded 
immediately to prevent damage to others from the release of proteases. The isolated 
oocytes were transferred onto a clean cell culture plate for overnight incubation in 
Barths buffer a t 18°C. Again, damaged oocytes and debris were removed.
2.5 Protein preparation for microinjection
Brief details of the preparation of proteins for microinjection are given for completeness; 
however, they were not carried out by the author, but by others as acknowledged.
2.5.1 Recombinant p42maPk
The cloning, expression and purification of recombinant p42maPk was carried out at the 
University of Dundee1. p42maPk was cloned from a Swiss 3T3 fibroblast cDNA library 
[Stokoe et al., 1992a]. The full length p42maPk clone was expressed as a glutathione-S- 
transferase fusion protein in E. coli. The fusion protein was then purified by affinity 
chromatography using glutathione-Sepharose beads, and the p42maPk was cleaved from 
glutathione-S-transferase using thrombin, producing a p42maPk concentration of 
0.06 mg/ml [Stokoe et al., 1992a].
The recombinant p42maPk was maximally activated, to 800 U/mg, by incubation, for 
2 hours a t 30°C, in 50 mM Tris pH 7.3, 2 mM sodium EDTA, 2 mM sodium EGTA, 5% 
(v/v) glycerol, 0.3 mM sodium orthovanadate, 0.03% (w/v) Brij 35, 0.1% (v/v) 
2-mercaptoethanol, 6 i^M specific peptide inhibitor of cyclic AMP-dependent protein 
kinase containing MAPK kinase (MAPKK) (from purified rabbit skeletal muscle 
[Nakielny et al., 1992a]), 10 mM magnesium acetate and 0.2 mM adenosine
1 The active recombinant p42maPk was a gift from Professor P Cohen, Medical Research 
Council Protein Phosphorylation Unit, Department of Biochemistry, University of 
Dundee, Tayside, UK.
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5' -[y-thio]triphosphate (ATP[S]). The activated p42maPk was then concentrated to an 
activity of 450 units/ml by centrifugation through a Centricon 30 membrane. The 
activity of p42maPk is defined on the basis tha t one enzyme unit catalyses the 
phosphorylation of 1 nmole of myelin basic protein in 1 minute [Stokoe et al., 1992a].
2.5.2 Purified MAPKK
The purification of MAPKK from rabbit skeletal muscle after intravenous injection of 
insulin was carried out a t the University of Dundee2 [Nakielny et al., 1992a]. One unit 
of MAPKK activity is tha t amount which produces a 50 percent reactivation of MAPK in 
1 minute [Nakielny et al., 1992a].
2.5.3 Recombinant p39c_mos
The cloning, expression and purification of recombinant p39c_mos was carried out a t the 
Imperial Cancer Research Fund Laboratories, South Mimms3. The proto-oncogene, 
c-mos, was cloned from a l  laevis cDNA library. The full length c-mos clone was 
expressed as a fusion protein with the E. coli maltose-binding protein (MalE-Mos), in 
E coli [Nebreda and Hunt, 1993]. The fusion protein was then purified by affinity 
chromatography using an amylose affinity column (amylose specifically binds to the 
MalE) [Yew et al., 1992].
2 The purified MAPKK was a gift from Professor P Cohen, Medical Research Council 
Protein Phosphorylation Unit, Department of Biochemistry, University of Dundee, 
Dundee, Tayside, U K
3 The MalE-Mos fusion protein was a gift from Dr A R Nebreda, Imperial Cancer 
Research Fund, Clare Hall Laboratories, South Mimms, Hertfordshire, U K
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2.6 Microinjection of oocytes
Hollow needles with a diameter of approximately 0.5 pm were made from glass capillary 
tubes using an automatic needle puller (PUL-1). Each needle was mounted on a manual 
injection pipette attached to a micro-manipulator. Using a plastic pipette, oocytes were 
placed on a piece of SpectraMesh attached to a 6 cm2 cell culture plate, and then, using 
the glass needle, 50 nl of a water, a buffer or a protein solution {Section 2.5} was injected 
into the vegetal pole of the oocyte {see Section 2.1.7 for equipment details}.
2.7 DNA synthesis assay
DNA synthesis in 3T3-L1 fibroblasts was assayed by measuring the amount of 
incorporation of [3H]thymidine [Kitagawa et al., 1989] The fibroblasts were grown on 
6-well cell culture plates. After reaching 50% confluence, they were incubated firstly, in 
0.5% (v/v) NCS/ DMEM {Section 2.2.1} for 24 hours a t 37°C, then secondly, in serum-free 
DMEM {Section 2.2.1} for 3 hours a t 37°C, and thirdly, in serum-free DMEM containing
1 pCi/ml [3H]thymidine and the ligands (as indicated in the figure legends) for 24 hours 
at 37°C. The incubation was term inated by washing each well twice in 2 ml of ice-cold 
PBS {Section 2.2.2}. The proteins were precipitated by washing the cells three times in
2 ml of ice-cold 5% (w/v) trichloroacetate and twice in 2 ml of ice-cold ethanol. Finally, 
the precipitate was dissolved in 1 ml of 0.3 M sodium hydroxide, and Ecoscint was added 
before the measurement of [3H]thymidine incorporation.
2.8 Glucose transport assays
Transport of a solute is usually assayed using a mixture of the radioactive and the non­
radioactive forms. In the case of glucose, a mixture of the radioactive and non- 
radioactive forms of an analogue is used because the use of glucose is impractical since it 
is completely metabolised during glycolysis and the tricarboxylic acid cycle. The two 
most commonly used analogues (and radioactive forms) are 2 -deoxy-D-glucose (2-deoxy- 
D-[2,6-3H]glucose) and 3-O-methyl-D-glucose (3-0-[l-3H]methyl-D-glucose).
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2-deoxyglucose undergoes only the first step of glycolysis, phosphorylation by 
hexokinase, forming 2-deoxyglucose-6-phosphate which is trapped inside the cell {Figure 
2.1}. Therefore, uptake of 2-deoxyglucose consists of two steps, transport and 
phosphorylation. Since the Km of hexokinase for glucose i s ' lower than th a t of the 
glucose transporter protein, and ATP pools are not depleted when uptake times are 
short, glucose transport is usually the rate-limiting step, and so the phosphorylation 
step can be ignored [Kletzien and Perdue, 1974], Therefore, deoxyglucose 'uptake' will 
be taken to mean deoxyglucose 'transport', unless otherwise stated. In addition, the 
low. Km of hexokinase results in an intracellular deoxyglucose level which is too low for 
significant efflux, and the equilibrium between the concentrations of extracellular and 
intracellular deoxyglucose is never reached. As a consequence, assays of the rate of
2-deoxyglucose uptake measure only the influx. 2-deoxyglucose influx occurs with first 
order kinetics (linear), until the ATP levels have decreased sufficiently to become rate- 
limiting.
3-O-methylglucose is another glucose analogue used for kinetic studies. I t is non- 
metabolisable, resulting in influx and efflux, and it accumulates until equilibrium is 
reached {Figure 2.1}. Hence 3-O-methylglucose transport shows first order kinetics 
initially, then mixed order kinetics, then zero order kinetics when equilibrium has been 
reached. As a consequence, several different types of assay are possible, two of which 
are commonly used. Firstly, a zero-trans influx assay, which measures the rate of influx 
of 3-O-methylglucose into sugar-free cells. Influx follows first order kinetics, so the 
initial velocities can usually be used to estimate the Vmax and Km. Secondly, an 
equilibrium exchange assay, which can be used to overcome the problems where the 
initial influx occurs too fast for a zero-trans influx assay, for instance, when a 
transporter protein is over-expressed in a cell [Gould et al., 1991]. In such an assay, 
cells are incubated in various concentrations of unlabelled 3-O-methylglucose, until 
equilibrium is attained. The addition of labelled 3-O-methylglucose measures the rate of 
steady-state rate of transport. The transport values are converted to a rate  constant 
(&obs) using the first order rate equation:
.  ,  . fC „ -C „ l- [C « -C 0l 
" w ~ l n
where C^ is the radioactivity after full equilibration of the cellular water space, C* is the
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Figure 2.1 The transport of glucose analogues
a) 2-deoxyglucose undergoes the first step of glycolysis, phosphorylation by hexokinase, 
forming 2-deoxyglucose-6-phosphate which is trapped inside the cell.
(d G Ic ^
b) 3-O-methylglucose is not metabolised, therefore it may enter and leave the cell.
(^3-O-mGlc
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radioactivity a t time t and Co is the radioactivity a t time, 0. The rate constants 
obtained are used in Lineweaver-Burk plots by plotting 1/k 0bs [3 -O-mGlc] against 
l/[3-0-mGlc] to determine the K m and Vmax values.
Since a zero-trans influx assay measures influx and an equilibrium-exchange assay 
measures a combination of influx and efflux, the values for Km and Vmax produced by 
these two assays are characteristically different.
2.8.1 2-deoxyglucose uptake assay in 3T3-L1 fibroblasts
The rate of 2 -deoxyglucose uptake was assayed in 3T3-L1 fibroblasts [Gibbs et al., 1988]. 
Quiescent 3T3-L1 fibroblasts, grown on 6-well plates, were washed three times in 3 ml 
of KRP {Section 2.2.2} a t 37°C, then incubated in 1 ml of 1% (w/v) BSA/ KRP, for 1 hour, 
on a hotplate a t 37°C. The ligands were present for the times indicated in the figure 
legends. 2-deoxyglucose uptake was started by addition of 50 pi of 2-deoxyglucose (final 
concentration 100 pM; 0.25 pCi/ml) and was stopped rapidly, after 3 to 5 minutes 
incubation a t 37°C, by inverting the plates to remove the buffer, followed by immersion 
twice in ice-cold PBS {Section 2.2.2.}. The cells from each well were solubilised in 1 ml of 
1% (w/v) Triton X-100, by a 1 hour incubation with agitation, before the addition of 
Ecoscint and measurement of radioactivity. The uptake values were corrected for the 
non-specific association of 2-deoxy-D-[2,6-3H]glucose with the cells by subtracting the 
uptake in the presence of 10 pM cytochalasin B, a potent inhibitor of facilitated glucose 
transport [Bloch, 1973; Basketter and Widdas, 1978]. Cytochalasin B was present 
throughout the 1 hour incubation.
2.8.2 2-deoxyglucose uptake assay in X. laevis oocytes
The rate of 2-deoxyglucose uptake was assayed in X. laevis oocytes [Gould et al., 1991]. 
Groups of uninjected, buffer-injected or protein-injected oocytes were placed into 13.5 ml 
centrifuge tubes containing 450 pi of Barths buffer {Section 2.2.2} a t room temperature, 
with the ligands present for the times indicated in the figure legends. 2-deoxyglucose 
uptake was started by the addition of 50 pi 2-deoxyglucose (final concentration 100 pM, 
0.5 pCi per tube) and stopped rapidly, after a 1 hour incubation a t room temperature, by 
aspiration of the buffer. The oocytes were washed three times in 3 ml of ice-cold PBS
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{Section 2.2.2} containing 0.1 mM phloretin [Krupka, 1971; Basketter and Widdas,
1978], then placed into scintillation vials (one oocyte per vial) and solubilised in 0.5 ml of 
1% (w/v) SDS by overnight incubation with agitation, before addition of Ecoscint and 
measurement of radioactivity.
2.8.3 Zero -trans 3-O-methylglucose transport assay in X. laevis oocytes
The rate of 3 -O-methylglucose zero-trans transport was assayed in X  laevis oocytes
[Gould et al., 1991]. Groups of uninjected, buffer-injected or protein-injected oocytes 
were placed into 13.5 ml centrifuge tubes containing 450 pi of Barths buffer {Section 
2.2.2], for 1 hour, a t room temperature. 3-O-methylglucose transport was started by the 
addition of 50 pi 3-O-methylglucose (final concentration 100 pM, 1.0 pCi per tube) and 
stopped rapidly, after incubation of times between 0 and 8 hours, a t room temperature, 
by aspiration of the buffer. The oocytes were washed three times in 3 ml of ice-cold PBS 
{Section 2.2.2} containing 0.1 mM phloretin, then placed into scintillation vials (one 
oocyte per vial) and solubilised by overnight incubation in 0.5 ml of 1% (w/v) SDS with 
agitation before the addition of Ecoscint and measurement of radioactivity.
2.9 DAG mass assay
2.9.1 Lipid extraction
Total cellular lipids were extracted by a modification of the Bligh and Dyer lipid 
extraction, in which cellular extracts are dissolved in a monophase and then the organic 
and aqueous components separated between two phases [Bligh and Dyer, 1959]. 
Quiescent 3T3-L1 fibroblasts, grown on 6-well plates, were washed three times in 3 ml 
of HBS {Section 2.2.2} a t 37°C, then incubated in 1 ml of HBG {Section 2.2.2} for 1 hour 
on a hotplate a t 37°C. The ligands were present for the times indicated in the figure 
legends. The incubations were stopped rapidly by aspiration of the buffer then by 
addition of 500 pi of ice-cold methanol to each well. The cells were triturated  and the 
cell suspension from each well was transferred to a clean 2 ml Teflon capped glass vial. 
Each well was washed in a further 200 pi of ice-cold methanol and the suspension was
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added to the appropriate vial. A chloroform/ methanol (1:1, v/v) mixture was formed by 
the addition of 700 pi of chloroform to the cell suspension, the monophase was mixed 
and incubated on ice for 30 minutes. A chloroform/ methanol/ distilled water (1:1:0.8, 
v/v/v) mixture was formed by the addition of 585 pi of distilled water, the contents of 
each vial mixed and incubated on ice until two separate phases were seen. The lower 
phase (organic) of each sample was transferred, using Hamilton syringes, to a clean 
glass vial and stored overnight under nitrogen.
2.9.2 Quantification
sn -1,2-diacylglycerol (DAG) in mixed micelles was converted to [32P]phosphatidic acid 
using DAG kinase and the incorporation of 23P was measured [Preiss et al., 1986; 
Paterson et al., 1991].
Preparation of lipid/phosphatidyl serine/  Triton X-100 mixed micelles
720 nmoles of phosphatidyl serine was dried under vacuum in 2 ml glass tubes, then 
solubilised in 1.0 ml of 0.6% (w/v) Triton X-100 by sonication a t 4°C until no solid m atter 
remained (approximately 40 minutes). The solution was transferred to a larger glass 
tube and diluted by adding a further 1.5 ml of 0.6% (w/v) Triton X-100 to form 0.6%
(w/v) Triton X-100, 288 pM phosphatidyl serine.
The lipid extracts {Section 2.9.1} were dried under vacuum then solubilised in 50 pi of 
0.6% Triton X-100/ 288 pM phosphatidyl serine by sonication a t 4°C for 30 minutes.
Conversion to p 2P]phosphatidic acid
The reaction was carried out in a total volume of 100 pi of 0.3% (w/v) Triton X-100,
144 pM phosphatidyl serine, 50 mM imidazole hydrochloride pH 6.6, 50 mM sodium 
chloride, 12.5 mM magnesium chloride hexahydrate, 1 mM sodium EGTA, 10 mM 
dithiothreitol, 0.5 mM ATP (20 pCi/  mmol [y-32P]ATP) and 5 mU DAG kinase. This was 
achieved by addition of 20 pi of Incubation buffer {Section 2.2.2}, 10 pi of fresh 100 mM 
dithiothreitol and 10 pi of DAG kinase (5 mU) to each vial. The reaction was started by 
the addition to each vial of 10 pi of 5 pM ATP in 100 mM imidazole, pH 6.6, containing 
1.25 pCi [y-32p]ATP, the contents mixed and incubated for 30 minutes a t 30°C. The 
reaction was stopped by the addition of 470 pi of a chloroform/ methanol/ hydrochloric
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acid (15:30:2, v/v) mixture, and then left to stand for 10 min a t room temperature. The 
phases were split by the addition of 150 pi of chloroform followed by 1 ml of distilled 
water. The upper (aqueous) phase was removed and the lower (organic) phase was 
washed twice in 1.0 ml of distilled water before being dried under vacuum. The dried 
lipids were dissolved in 40 pi of a chloroform/ methanol (19:1, v/v) mixture and spotted 
onto a 10 x 20 cm Silica Gel 60 tic plate, previously activated by heating a t 120°C for 
1 hour. The plates were developed with a chloroform/ methanol/ ethanoic acid 
(130:30:15, v/v/v) mixture, then air-dried and autoradiographed. The area of silica 
corresponding to [32P]phosphatidic acid was scraped into a scintillation vial to which 
Ecoscint was added before measurement of radioactivity.
A standard curve (0 to 2000 pmoles) was constructed from 100 mM src-l-stearoyl-2- 
arachidonylglycerol in chloroform. This was treated in the same manner as the samples 
and was used to calculate the DAG level in each sample {Figure 2.2}.
2.10 Protein kinase C activity assay
Protein kinase C (PKC) activity was assayed by phosphorylation of a synthetic peptide 
substrate in permeablised cells [Heasley and Johnson, 1989; Alexander et al., 1990]. 
Quiescent 3T3-L1 fibroblasts, grown on 6-well plates, were washed twice in 3 ml of KRP 
{Section 2.2.2} at 37°C then incubated in 1 ml of 1% (w/v) BSA/ KRP for 1 hour on a 
hotplate a t 37°C. The ligands were present for the times indicated in the figure legends. 
The cells in each well were washed quickly in 1 ml of Intracellular buffer {Section 2.2.2} 
at 37°C, and then incubated, with occasional agitation, in 500 pi of Intracellular buffer 
containing 250 pM ATP, 1.0 pCi [y-32P] ATP, 200 pg/ml digitonin, and 200 pM PKC 
peptide substrate (sequence Pro-Leu-Ser-Arg-Thr-Leu-Ser-Val-Ala-Ala-Lys-Lys)4 [House 
et al., 1987] for 10 minutes on a hotplate a t 37°C. Reactions were stopped by the 
addition of 100 pi of 25% (w/v) trichloroacetic acid, the wells agitated, then incubated on
4 The PKC peptide substrate was a gift from Dr F G Rowan, Strathclyde Institute for 
Drug Research, University of Strathclyde, Glasgow, Strathclyde, U K
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Figure 2.2 A standard curve for the DAG mass assay
sn -l-stearoyl-2-arachidonylglycerol was used to construct a standard curve (from 0 to 
2000 pmoles) for the DAG mass assay {Section 2.9.2}. Each result shows the mean DAG 
mass level (± SD) for triplicate determinations. The SD for some of the results from this 
experiment are too small to be seen on the graph. A standard curve was prepared with 
each experiment.
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ice for 10 minutes. The cells were scraped off the plates, transferred to an Eppendorf 
tube and spun for 10 minutes a t 4°C a t 16 000 g. 100 pi of the supernatant was spotted 
onto 3 x 3 cm squares of P81 ion-exchange chromatography paper, then air-dried. The 
paper was washed three times in 75 mM orthophosphoric acid, then once in ethanol with 
agitation. The paper was dried and the associated radioactivity determined.
2.11 Down-regulation of protein kinase C
PKC activity was down-regulated by a long incubation in a high concentration of an 
active phorbol ester [Blackshear et al., 1985]. Quiescent 3T3-L1 fibroblasts, grown on 
6-well plates, were incubated in sterile 1% (w/v) BSA/ serum-free DMEM {Section 2.2.1} 
containing 1 pM PMA or 1 pM 4a-PDD (4a-phorbol 12, 13-didecanoate) (an inactive 
phorbol ester) for 16 hours a t 37°C. Each well was washed four times in 2 ml of 1% BSA/ 
serum-free DMEM a t 37°C, and then three times in 3 ml of KRP {Section 2.2.2} a t 37°C. 
The cells were then used for 2-deoxyglucose uptake assays or for the preparation of cell 
lysates.
2.12 Inhibition of protein kinase C activity
PKC activity was inhibited using a bisindolylmaleimide, Ro 31-82205 [Davis et al., 1989; 
Wilkinson et al., 1993]. Quiescent 3T3-L1 fibroblasts, grown on 6-well plates, were 
washed three times in 3 ml of KRP {Section 2.2.2} a t 37°C, and then incubated in 1 ml of 
1% (w/v) BSA/ KRP containing 1 pM Ro 31-8220 for 20 minutes on a hotplate at 37°C. 
Cells were then used for 2-deoxyglucose uptake assays.
5 The PKC inhibitor, Ro 31-8220, was a gift from Dr G Lawton, Roche Products Ltd, 
Welwyn Garden City, Hertfordshire, U K
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2.13 Protein preparation for Western blotting
2.13.1 Preparation of 3T3-L1 fibroblast membrane proteins
Quiescent 3T3-L1 fibroblasts, grown on 10 cm2 plates, were washed three times in 5 ml 
of KRP {Section 2.2.2} a t 37°C, then incubated in 3 ml of 1% (w/v) BSA/ KRP for 1 hour 
on a hotplate a t 37°C. The ligands were present for the times indicated in the figure 
legends. The incubations were terminated by washing three times in 3 ml of ice-cold 
PBS or HPFEV (for phosphotyrosine-containing proteins) {Section 2.2.2}. The cells were 
scraped into 4 ml of ice-cold PBS (or HPFEV) containing 1 pg/ml Pepstatin A, 10 jaM 
£r£ms-epoxysuccinyl-L-leucylamido(4-guanidino)-butane (E 64) and 200 pM diisopropyl 
fluorophosphate (DFP) {Section 2.2.4}. The cell lysates were homogenised by sonication, 
three times for 10 seconds with 15-second gaps, a t 60 W using a Dawe sonicator with a 
microtip (Lucas Dawe Ultrasonics Ltd, London, UK; model number: 7532-1), then spun 
at 1000 g  for 10 minutes a t 4°C. The supernatants were transferred to clean centrifuge 
tubes and the pellets (nuclei) discarded. The supernatants were spun a t 100 000 g  for 
1 hour a t 4°C and the resulting supernatant discarded. The pellets containing the 
membrane proteins were resuspended in 200 pi PBS containing 1 pg/ml Pepstatin A,
10 pM E 64 and 200 pM DFP. The samples were snap-frozen in liquid nitrogen and 
stored at -80°C.
Before use in SDS-PAGE, the protein concentration of each sample was measured 
{Section 2.14}. Each sample was then diluted with 4 x SDS-PAGE sample buffer 
{Section 2.2.3} containing 1 pg/ml Pepstatin A, 10 pM E 64 and 200 pM DFP.
2.13.2 Preparation of 3T3-L1 fibroblast lysates
Quiescent 3T3-L1 fibroblasts, grown on 6-well plates, were washed three times in 3 ml 
of KRP {Section 2.2.2} a t 37°C, then incubated in 1 ml of 1% (w/v) BSA/ KRP for 1 hour 
on a hotplate a t 37°C. The ligands were present for the times indicated in the figure 
legends. The incubations were terminated rapidly by inverting the plates to remove the 
buffer; the cells were then washed twice by immersion in ice-cold PBS {Section 2.2.2} (or 
ice-cold HPFEV {Section 2.2.2} for phosphotyrosine-containing proteins). The remaining
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buffer was aspirated and 750 pi of hot (70°C) SDS-PAGE sample buffer {Section 2.2.3} 
containing 1 pg/ml Pepstatin A, 10 pM E 64 and 200 pM DFP {Section 2.2.4} was added 
to each well. The DNA was sheared by drawing the lysate five times through a 21 gauge 
needle. The samples were transferred to Eppendorf tubes, then boiled for 5 minutes.
The samples were snap-frozen in liquid nitrogen and stored a t -80°C.
2.13.3 Immunoprecipitation of phosphotyrosine-containing proteins from 3T3-L1 
fibroblasts
Lysate preparation
Quiescent 3T3-L1 fibroblasts, grown on 10 cm2 plates, were washed three times in 5 ml 
KRP {Section 2.2.2} a t 37°C then incubated in 4 ml of 1% (w/v) BSA/ KRP for 30 minutes 
on a hotplate at 37°C. The ligands were present for the times indicated in the figure 
legends. The incubations were terminated by washing three times in 4 ml ice-cold 
HPFEV {Section 2.2.2}. The cells were scraped into 5 ml of ice-cold 0.05% (w/v) SDS/ 2% 
(w/v) Triton X-100/ HPFEV containing 1 pg/ml Pepstatin A, 10 pM E 64 and 200 pM 
DFP {Section 2.2.4}. The lysates were spun a t 100 000 g  for 30 minutes a t 4°C. The 
supernatants were transferred to new Eppendorf tubes, snap-frozen in liquid nitrogen 
and stored a t -80°C.
Immunoprecipitation
The phosphotyrosine-containing proteins were immunoprecipitated by incubating the 
supernatants with 50 pi of a rabbit anti-phosphotyrosine antibody6 [Pang et al., 1985] 
for 2 hours on ice then adding 50 pi of 50% Protein A-agarose in 1% (w/v) Triton X-100, 
and slowly rotating for 2 hours a t 4°C. The tubes were spun for 10 seconds a t 12 000 g  
and the supernatant discarded. The beads were washed three times in 1 ml of 1% (w/v) 
Triton X-100/ HPFEV, then once in 1 ml of 0.1% (w/v) Triton X-100/ HPFEV, then 
resuspended in 100 pi of 1.3 x SDS-PAGE sample buffer for immunoprecipitation 
{Section 2.2.3} containing 1 pg/ml Pepstatin A, 10 pM E 64 and 200 pM DFP. The
6 The rabbit anti-phosphotyrosine antibody was a gift from Dr G Lienhard, Dartmouth 
Medical School, Hanover , New Hampshire, USA.
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suspensions were incubated a t room temperature for 30 minutes, then the tubes were 
spun for 30 seconds a t 12 000 g, and the supernatant was transferred to new Eppendorf 
tubes, snap-frozen in liquid nitrogen and stored a t -80°C.
2.13.4 Preparation of X. laevis oocyte lysates
Lysates were prepared from groups of five uninjected oocytes [Nebreda and Hunt, 1993], 
The oocytes were placed into 13.5 ml centrifuge tubes containing 500 pi of Barths buffer 
{Section 2.2.2}, then incubated for 1 hour at room temperature. The ligands were 
present for the times indicated in the figure legends. The incubations were terminated 
rapidly by aspirating the buffer then washing twice in ice-cold HPFEV {Section 2.2.2}. 
Each group of five oocytes was homogenised in 250 pi of ice-cold Homogenisation buffer 
{Section 2.2.2} containing 1 pg/ml Pepstatin A, 10 pM E 64 and 200 pM DFP {Section 
2.2.4}. The lysates were spun for 8  minutes at 1 2  000 and the cleared supernatant 
was transferred to clean Eppendorf tubes and diluted with 50 pi of 2 x SDS-PAGE 
sample buffer for phosphotyrosine-containing proteins {Section 2.2.3} containing 1 pg/ml 
Pepstatin A, 10 pM E 64 and 200 pM DFP. The samples were snap-frozen in liquid 
nitrogen and stored at -80°C.
2.14 Protein concentration assay
The protein concentration of 3T3-L1 fibroblast membrane proteins {Section 2.13.1} was 
assayed after acid precipitation [Lowry et al., 1951; Peterson, 1977]. The volume of each 
protein sample was brought to 1  ml using the same buffer as in the preparation, then 
100 ml of 0.15% (w/v) sodium deoxycholate was added to each tube, the contents of each 
tube were mixed, then incubated a t room temperature for 10 minutes. 100 pi of 72% 
(w/v) trichloroacetic acid was added to each tube, the contents of each tubes were mixed, 
and the precipitates were collected by spinning at 3000 £  for 15 minutes a t 4°C. The 
supernatants were discarded and the tubes drained. The pellets were resuspended in 
200 pi of distilled water and 200 pi of Reagent A {Section 2.2.2} added, the contents of 
each tube mixed, then incubated a t room temperature for 1 0  minutes. 1 0 0  pi of 
Reagent B {Section 2.2.2} was added, the contents of each tube mixed and the 
absorbance (A7 5 0 ) measured after 30 minutes incubation a t room temperature. The
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concentration of the sample proteins was determined from a standard curve (from 0 to 
20 (ig) constructed from 1 mg/ml BSA and treated in the same manner as the protein 
samples of unknown concentration {Figure 2.3}.
2.15 Discontinuous SDS-polyacrylamide gel electrophoresis
Protein samples {Section 2.13} were analysed using a discontinuous system [Laemmli, 
1970].
2.15.1 Preparation of acrylamide gels
Acrylamide stock solution
The separating and stacking gels were made using an acrylamide/ N, N'-methylene-bis- 
acylamide (22.6% T, 2.66% C) stock solution, where the total monomer concentration, 
%T, was defined as:
_ mass of acrylamide + mass of crosslinker ^ 
total volume
and the crosslinker concentration, %C, was defined as:
„  ~ mass of crosshnker . „ „%C = -------------   --—------------------- — —  x 100
mass of acrylamide + mass cross linker
Separating gels
The separating gels used were of the following composition: 10% (w/v) acrylamide,
0.375 M Tris-hydrochloride, 0.1% (w/v) SDS, 0.05% (w/v) ammonium persulphate, 0.05% 
(v/v) N, N, N', N'-tetramethylethylenediamine (TEMED).
The casting apparatus for either the Bio-Rad mini-protean II dual slab cell 
electrophoresis unit (mini-gel: 7 x 8  cm) or the Hoefer SE 600 vertical slab 
electrophoresis unit (large gel: 14 x 16 cm) was assembled according to the 
manufacturers instructions.
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Figure 2.3 A standard curve for the Lowry protein concentration assay
BSA was used to construct a standard curve (from 0 to 20 pg) for the Lowry protein 
concentration assay {Section 2.13}. Each result shows the mean protein concentration 
(± SD) for triplicate determinations. A standard curve was prepared with each 
experiment.
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The monomer solution for the separating gel of two mini-gels was prepared by mixing 
2.98 ml of distilled water, 2.5 ml of 1.5 M Tris hydrochloride pH 8.8, 4.42 ml of 
acrylamide stock, 50 pi of 20% (w/v) SDS. Polymerisation was initiated by the addition 
of 50 pi of fresh 10% (w/v) ammonium persulphate and 5 pi of TEMED, the solution 
mixed, then poured into the casting apparatus.
The monomer solution for the separating gel of two large gels was prepared by mixing 
14.9 ml of distilled water, 12.5 ml of 1.5 M Tris hydrochloride pH 8.8, 22.1 ml of 
acrylamide stock and 250 pi of 20%(w/v) SDS. Polymerisation was initiated by the 
addition of 250 pi of fresh 10% (w/v) ammonium persulphate and 25 pi of TEMED, the 
solution mixed, then poured into the casting apparatus.
The monomer solution was carefully overlaid with water-saturated isobutanol to obtain 
a smooth surface . After polymerisation, the overlay was removed and the gel surface 
washed thoroughly with distilled water. Combs were placed in position.
Stacking gels
The stacking gels used were of the following composition: 5% (w/v) acrylamide, 0.125 M 
Tris hydrochloride, 0.1% (w/v) SDS, 0.05% (w/v) ammonium persulphate, 0.1% (w/w) 
TEMED.
The monomer solution for the stacking gel of two mini-gels was prepared by mixing 
4.15 ml of distilled water, 2.0 ml of 0.5 M Tris hydrochloride pH 6.8, 1.77 ml of 
acrylamide stock and 40 pi of 20% (w/v) SDS. Polymerisation was initiated by the 
addition of 40 pi of fresh 10% (w/v) ammonium persulphate and 8 pi of TEMED, the 
solution mixed, then poured into the casting apparatus.
The monomer solution for the stacking gel of two large gels was prepared by mixing 
15.6 ml of distilled water, 7.5 ml of 0.5 M Tris hydrochloride, pH 6.8, 6.6 ml of 
acrylamide stock and 150 pi of 20% (w/v) SDS. Polymerisation was initiated by the 
addition of 150 of pi fresh 10% (w/v) ammonium persulphate and 30 pi of TEMED, the 
solution mixed then poured into the casting apparatus.
After polymerisation, the combs were removed and the wells rinsed with distilled water.
55
2.15.2 Running conditions
Mini gels were subjected to electrophoresis a t a constant voltage of 150 V in Electrode 
buffer {Section 2.2.3} using a Bio-Rad mini-protean II dual slab cell electrophoresis unit.
Large gels were subjected to electrophoresis a t a constant current of 15 mA per 1.5 mm 
thick gel in Electrode buffer {Section 2.2.3} using a Hoefer SE 600 vertical slab 
electrophoresis unit.
2.15.3 Protein molecular weight standards
The molecular mass of proteins was estimated by comparing their mobility to tha t of 
pre-stained SDS-PAGE standards. The standards used were myosin (205 kDa), 
13-galactosidase (116.5 kDa), BSA (80 kDa) and ovalbumin (49.5 kDa).
_ distance moved by protein
Hjp —  “
distance moved by dye front
The calculated R f  value obtained for the individual SDS-PAGE standards was plotted 
against log (molecular mass) to produce a calibration curve from which the molecular 
mass of the unknown species can be determined by interpolation.
2.16 Western blotting
2.16.1 Mini-gels 
Glutl
G lutl was examined by Western blotting [Towbin et al., 1979] after separation of 
proteins on 10% mini-acrylamide gels by SDS-PAGE.
The gels were equilibrated by shaking in Blot buffer {Section 2.2.5} for 30 minutes. The 
proteins were transferred to a nitrocellulose membrane, a t a constant current of 250 mA 
for 3 hours, using a Bio-Rad Mini-Trans-Blot electrophoretic transfer cell. After the
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transfer, the non-specific binding sites were blocked by incubation in 3% (w/v) BSA/
First wash buffer {Section 2.2.5} for 30 minutes, then the blots were rinsed in F irst wash 
buffer. The blots were incubated overnight in 3% BSA/ First wash buffer containing a 
1:1000 dilution of a rabbit anti-human G lutl antibody tha t also recognises mouse 
G lutl7 [Davies et al., 1987], then washed several times in First wash buffer. The blots 
were incubated for 3 hours in 3% BSA/ First wash buffer containing 0.1 pCi/ml 125I- 
conjugated goat anti-rabbit IgG antibody, then washed several times in Second wash 
buffer {Section 2.2.5}. The blots were dried between two layers of a cellophane 
membrane backing, then placed next to X-Omat AR film in cassettes with an 
intensification screen and kept a t -80°C for 48 hours. The autoradiographs were 
developed using a X-Omat processor.
Glut2, Glut3 and G!ut4
Glut2, Glut3 and Glut4 were examined by Western blotting after separation of proteins 
on 10% mini-acrylamide gels by SDS-PAGE.
Western blotting was carried out as above with the following exceptions. The non­
specific binding sites were blocked by incubation in 5% (w/v) Marvel/ F irst wash buffer 
for 30 minutes. The antibodies were diluted in 1% Marvel/ F irst wash buffer. Glut2 was 
detected with a rabbit anti-human Glut2 antibody th a t also recognises mouse Glut2 
[Brant et al., 1992], used a t a  dilution of 1:66.6; Glut3 was detected with a rabbit anti­
mouse Glut3 antibody [Gould et al., 1992] used a t a dilution of 1:100 and Glut4 was 
detected with a rabbit anti-human Glut4 antibody th a t also recognises mouse Glut4 
[Brant et al., 1992], used a t a dilution of 1:66.6.
7 The rabbit anti-human G lutl antibody was a gift from Dr S Baldwin, University of 
Leeds, Leeds, Yorkshire, UK.
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2.16.2 Large gels
Glutl
G lutl was examined by Western blotting [Towbin et al., 1979] after separation of 
proteins on 10% large acrylamide gels by SDS-PAGE.
The gels were equilibrated by shaking in Blot buffer {Section 2.2.5} for 1 hour. The 
proteins were transferred to a nitrocellulose membrane, a t a constant current of 250 mA 
for 3 hours, using a Bio-Rad Trans-Blot electrophoretic transfer cell. After the transfer, 
the non-specific binding sites were blocked by incubation in 3% (w/v) BSA/ First wash 
buffer {Section 2.2.5} for 3 hours, then the blots were rinsed in F irst wash buffer. The 
blots were incubated overnight in 3% BSA/ First wash buffer containing a 1:1000 
dilution of a rabbit anti-human G lutl antibody tha t also recognises mouse G lu tl (from 
East Acres Biologicals), then washed several times in First wash buffer. The blots were 
incubated for 1 hour in 3% BSA/ First wash buffer containing a 1:4000 dilution of a 
horseradish peroxidase (HRP)-conjugated donkey anti-rabbit IgG antibody, then washed 
several times in Second wash buffer {Section 2.2.5}. The blots were submerged in 
enhanced chemiluminescence (ECL) detection solutions (according to the manufacturers 
instructions), drained, wrapped in cling-film and exposed to X-Omat AR film for 1 to 5 
minutes. The autoradiographs were developed using a X-Omat processor.
Phosphotyrosine-containing proteins
Phosphotyosine-containing proteins were examined by Western blotting after separation 
of proteins on 10% large acrylamide gels by SDS-PAGE.
Western blotting was carried out as above with the following exceptions. The gels were 
equilibrated in Towbin buffer {Section 2.2.5} and the proteins were transferred a t a 
constant current of 350 mA. TBST-1 and TBST-2 {Section 2.2.5} were used instead of 
First and Second wash buffers respectively; the antibodies were diluted in 0.2% BSA/ 
TBST-1. Phosphotyrosine was detected with a rabbit anti-phosphotyrosine antibody 
[Pang et al., 1985], used a t a dilution of 1:5000, MAPK with a mouse anti-MAPK 
antibody, used at a  dilution of 1:250 000, and p l 2 5 ^AK with a mouse anti-pl25^AK 
antibody, used a t a dilution of 1:5000. The anti-MAPK and anti-p 1 2 5 ^ ^  antibodies 
were detected using a HRP-conjugated sheep anti-mouse IgG antibody.
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Characterisation of the early phase of growth factor- 
stimulated glucose transport in 3T3-L1 fibroblasts
3.1 Introduction
In order to examine the signal transduction pathways th a t mediate the early phase of 
growth factor-stimulated glucose transport, the effects of insulin and PDGF on the rate 
of glucose transport in 3T3-L1 fibroblasts were characterised.
3.1.1 Insulin and PDGF 
Structure
Insulin and PDGF are both heterodimeric proteins. Insulin is formed from a single 
polypeptide, proinsulin, by the process of folding, stabilisation by disulphide bonds and 
proteolysis. In contrast, PDGF is formed from two homologous polypeptides encoded by 
distinct genes. These polypeptides combine to form three PDGF isoforms, AA, AB and 
BB; again the dimers are stabilised by disulphide bonds [Waterfield et al., 1983]. The 
amino acid sequence of the PDGF B-chain is similar to th a t of the transforming protein 
product of the Simian sarcoma virus, p28v'®s [Waterfield et al., 1983].
Functions
Insulin is released by the fi-cells of the Islets of Langerhans in response to a high blood 
glucose concentration. It reduces the blood glucose concentration by stimulating the 
influx of glucose into myocytes and adipocytes {Section 1.2.2}. I t also modifies the 
activity of many enzymes in these cells, so th a t the storage products, glycogen and 
triacylglycerol, are synthesised and not metabolised.
Insulin also stimulates the rate of proliferation of some cells, for example, BC3H-1 
myocytes [Standaert et al., 1987], Chinese ham ster ovary cells [Wilden et al., 1990], and 
Rat-1 cells [McClain, 1990].
PDGF is released from the a-granules of platelets during the platelet adherence and 
aggregation reactions tha t occur when blood vessels have been injured. It is thought to 
aid wound repair by stimulating: chemotaxis in monocytes, neutrophils, fibroblasts and 
vascular smooth muscle cells; the proliferation of fibroblasts and vascular smooth
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muscle cells; and the secretion of extracellular matrix constituents [Heldin and 
Westermark, 1990; Heldin, 1992].
PDGF is also involved in the development of the optic nerve by stimulating the 
proliferation of 0-2A progenitor cells, and by inhibiting their differentiation into type-2 
astrocytes or oligodendrites. It is released in the optic nerve by type-1 astrocytes. It 
may also have other roles in development, since PDGF receptors are expressed in 
embryonic tissue and placenta [Heldin, 1992].
The three PDGF isoforms may have similar or different effects to each other; for 
example, all three isoforms stimulate cell proliferation, but only PDGF-BB stimulates 
chemotaxis [Heldin, 1992].
Receptor structure
Both insulin and PDGF bind to tyrosine protein kinase receptors. The insulin receptor 
is an heterotetrameric glycoprotein consisting of two a-subunits and two B-subunits. It 
is formed from two identical polypeptides, each of which contains a collinear a- and fi- 
subunit. The precursor becomes the mature receptor by the process of dimerisation, 
stabilisation by disulphide bonds, proteolysis and glycosylation. The a-subunits are 
completely extracellular, while each of the B -subunits has a single membrane-spanning 
region. Each a-subunit has a single cysteine-rich domain and several other cysteine 
residues. There are also a few cysteine residues on the extracellular region of the 
B-subunit. The intracellular region of the B-subunit has a tyrosine protein kinase 
domain {Figure 3.1} [Ebina et al., 1985; Ullrich et al., 1985].
There are two insulin receptor isoforms which differ by a sequence of 12 amino acids 
near the carboxy-terminus of the a-subunit. These arise from alternative splicing of 
exon 11 of the insulin receptor gene. The isoforms are expressed in a tissue-specific 
manner, however, it is not known whether they have different functional roles [Seino 
and Bell, 1989; Goldstein and Dudley, 1990].
In contrast, there are two distinct receptors for PDGF: the PDGF a-receptor and the 
PDGF B-receptor [Yarden et al., 1986; Claesson-Welsh et al., 1989]. These are 
structurally similar glycoproteins with a molecular mass of 170 to 180 kDa. Both PDGF
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Figure 3.1 Tyrosine protein kinase receptors
A schematic representation of the structure of Class I, II and III tyrosine protein kinase 
receptors before ligand binding, represented by a) the EGF receptor (Class I), b) the 
PDGF B-receptor (Class II) and c) the insulin receptor (Class III). The carboxy-termini 
of Class I and II receptors and of the B-subunit of Class III receptors are cytosolic. The 
carboxy-termini of the a-subunits of Class III receptors are near the plasma membrane. 
Cysteine-rich domains are represented by hatched boxes, other cysteine residues in the 
extracellular domain are represented by closed circles. Tyrosine protein kinase domains 
are represented by dotted boxes [Ullrich et al., 1984; Ebina et al., 1985; Ullrich et al., 
1985; Ullrich et al., 1986; Yarden et al., 1986].
receptors have two extracellular cysteine-rich domains, a single membrane-spanning 
region and an intracellular tyrosine protein kinase domain, divided into two, by a 
sequence of approximately 100 amino acid residues known as the kinase insert region 
{Figure 3.1} [Yarden et al., 1986].
Ligand-binding
Most tyrosine protein kinase receptors must assemble into an oligomeric structure to 
permit the ligand-induced activation of the intrinsic tyrosine protein kinase. The 
majority of tyrosine protein kinase receptors, including both of the PDGF receptors, 
exist as monomers in the absence of ligand-binding. Upon ligand-binding these 
receptors dimerise, the two PDGF receptors forming all three combinations of receptor 
dimers, aa, aB and BB [Seifert et al., 1989]. The exact receptor dimer formed depends on 
the PDGF isoform: PDGF-AA forms aa, PDGF-AB forms aa and aB, and PDGF-BB 
forms all three [Seifert et al., 1989; Heidaran et al., 1991]. In contrast, as described 
above, the insulin receptor already exists as an heterotetramer in the absence of insulin- 
binding, and does not dimerise further.
Following PDGF-induced receptor dimerisation, or the binding of insulin to its receptor, 
there is a conformational change in the receptor which activates the intrinsic tyrosine 
protein kinase. This catalyses the tyrosine phosphorylation of both the intracellular 
region of the receptor (autophosphorylation) [Herrera and Rosen, 1986] and of other 
substrates [White et al., 1988]. In both cases, the autophosphorylation occurs in trans, 
th a t is, each tyrosine protein kinase domain catalyses the phosphorylation of the other 
polypeptide [Kelly et al., 1991].
The tyrosine phosphorylation creates binding sites for cytosolic proteins tha t contain a 
sequence motif of approximately 100 amino acids known as a Src homology-2 (SH2) 
domain [Koch et al., 1991]. Different SH2 domain-containing proteins bind to different 
phosphotyrosine residues, the specificity arising from the amino acid sequence 
surrounding the phosphotyrosine residue [Songyang et al., 1993].
In the case of PDGF, the SH2 domain-containing proteins bind directly to 
phosphotyrosine residues in the receptor dimers. The proteins tha t are known to bind to 
the phosphotyrosine residues in the PDGF B-receptor include: phospholipase C-y
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(PLC-y) [Meisenhelder et al., 1989; Wahl et al., 1989], the regulatory subunit (p85) of 
phosphatidylinositol-3'-kinase (PtdIns-3'-K) [Kashishian et al., 1992], the p21ras-GTPase 
activating protein (RasGAP) [Kazlauskas et al., 1990], members of the Src family of non­
receptor tyrosine protein kinases (p60src, p59^ n , and p62yes) [Kypta et al., 1990], the 
growth-factor receptor bound protein-2 (Grb2) [Lowenstein et al., 1992], and Syp (also 
known as SH2 domain-containing phosphotyrosine phosphatase-2, SH-PTP2) 
[Kazlauskas et al., 1993]. The phosphotyrosine residues within the PDGF 0-receptor to 
which some of these proteins bind have been identified {Figure 3.2}.
In the case of insulin, the SH2 domain-containing proteins do not bind directly to the 
insulin receptor. Instead, these proteins bind to the major substrate of the insulin 
receptor, insulin receptor substrate-1 (IRS-1). There are 21 potential phosphotyrosine 
sites in IRS-1, many of which occur in sequence motifs known to be consensus sequences 
for the binding of SH2 domain-containing proteins [Sun et al., 1991]. The proteins tha t 
bind to IRS-1 include: p85 [Backer et al., 1992a], Grb2 [Skolnik et al., 1993; Sun et al., 
1993a], Syp [Kuhne et al., 1993; Sun et al., 1993a], and Nek [Lee et al., 1993]. PLC-y 
and RasGAP do not appear to bind to IRS-1 [Lavan et al., 1992; Sun et al., 1993a]. The 
phosphotyrosine residues to which some of these proteins bind within IRS-1 have been 
identified {Figure 3.3}.
Beyond the receptor
Many of the SH2 domain-containing proteins are thought to have im portant roles in the 
signal transduction pathways tha t mediate the effects of ligands tha t bind to tyrosine 
protein kinase receptors [Heldin, 1991; Koch et al., 1991; Sun et al., 1993b]. The 
functions of some of these proteins will be discussed later.
The differences in the effects of the various polypeptide growth factors th a t bind to 
tyrosine protein kinase receptors may arise, in part, from the differences in the 
specificity or affinity of receptors for SH2 domain-containing proteins. This could 
account for the differences in the effects of the three PDGF isoforms; for example, the 
affinity of the PDGF B-receptor for RasGAP is five times higher than th a t of the PDGF 
a-receptor [Heidaran etal., 1993].
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Figure 3.2 The PDGF (3-receptor and the associated SH2 domain-containing proteins
A schematic representation of the specificity of interactions between the different SH2 
domain-containing proteins and the known autophosphorylation sites in the PDGF 
13-receptor [Kazlauskas and Cooper, 1989; Fantl et al., 1992; Kashishian et al., 1992; 
Ronnstrand et al., 1992; Kazlauskas et al., 1993; Mori et al., 1993; Vallus and 
Kazlauskas, 1993].
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Figure 3.3 IRS-1 and the associated SH2 domain-containing proteins
A schematic representation of the specificity of interactions between the different SH2 
domain-containing proteins and the known phosphorylation sites in IRS-1 [Skolnik et 
al., 1993; Sun et al., 1993a].
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3.1.2 Fibroblasts
The connective-tissue cell family
The connective-tissue cell family includes: fibroblasts, chondroblasts, osteoblasts, 
adipocytes and smooth muscle cells. All the members of the connective-tissue cell family 
develop from fibroblasts. It is not yet clear whether there is a single type of fibroblast 
which is able to differentiate into many cell types, or whether there are several distinct 
fibroblast lineages each able to differentiate into a different cell type. Cell 
differentiation, like cell proliferation, is regulated by growth factors and anchorage. For 
example, transforming growth factor - f t  induces differentiation of fibroblasts into 
chondrocytes, and growth hormone induces differentiation of fibroblasts into adipocytes.
The members of the connective-tissue cell family have im portant roles in the support 
and repair of most tissues and organs. Fibroblasts, chondroblasts and osteoblasts 
secrete the various macromolecules th a t form the extracellular matrix. Fibroblasts are 
irregular, branched cells dispersed in connective tissue throughout the body. They 
secrete a non-rigid, extracellular matrix rich in type I collagen. In response to growth 
factors, such as PDGF, which are released as a consequence of tissue injury, fibroblasts 
migrate to the site of injury (chemotaxis), proliferate and secrete large amounts of 
extracellular matrix, thus helping to repair the damaged tissue [Heldin and 
Westermark, 1990; Heldin, 1992].
Fibroblast cell lines
The Swiss 3T3 fibroblast cell line was isolated from mouse embryo connective tissue. 
These cells grow indefinitely in serial culture, but stop growing and enter GO once they 
form a confluent monolayer (contact inhibition) [Todaro and Green, 1963]. If these 
resting cells are maintained for several weeks, some of them will develop visible lipid 
droplets. The lipid-accumulating cells form less than one percent of the total cell 
population, and are not observed among proliferating cells [Green and Kehinde, 1974; 
Green and Meuth, 1974]. They resemble brown or immature white adipocytes; such 
adipocytes have abundant cytoplasm, a central nucleus and multiple droplets of lipid, 
while mature white adipocytes have little cytoplasm, an eccentric nucleus and a single 
large, central, droplet of lipid [Green and Kehinde, 1974; Green and Meuth, 1974].
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Several subclones tha t are able to convert with a high frequency to lipid-accumulating 
cells have been produced by serial selection of the cells from the lipid-rich areas of 
confluent, quiescent Swiss 3T3 fibroblasts (clone: Swiss 3T3-M) [Green and Kehinde, 
1974].
The 3T3-L1 cell line
The cells of the subclone 3T3-L1 convert spontaneously into lipid-accumulating cells 
within two to four weeks of reaching confluence [Green and Kehinde, 1974]. The rate 
and extent of differentiation of 3T3 -LI cells increases in response to insulin [Green and 
Kehinde, 1975], glucocorticoids such as dexamethasone [Rubin et al., 1978], inhibitors of 
cyclic AMP phosphodiesterase such as 3 -iso-butyl-1-methylxanthine [Rubin et al., 1978] 
and high concentrations of serum [Green and Meuth, 1974]. Exposure of confluent 
3T3-L1 cells to mixtures of these agents induces differentiation such th a t more than 90 
percent of the cells resemble fully mature white adipocytes within ten days [Rubin et al., 
1978; Frost and Lane, 1985].
The undifferentiated form of 3T3-L1 cells synthesise collagen [Green and Meuth, 1974]. 
The only monosaccharide facilitative transporter protein expressed by these cells is 
Glutl. The rate of glucose transport increases two to five fold in response to insulin and 
other growth factors arising from the translocation of G lutl {Section 1.3.2}. The rate of 
TAG synthesis is comparable to tha t observed in fibroblasts, and is insensitive to 
lipogenic and lcpolytic agents [Green and Kehinde, 1975; Mackall et al., 1976; Ahmad et 
al., 1979]. The number of insulin-binding sites is comparable to tha t in other fibroblast 
cell lines [Reed et al., 1977], Thus, the non-differentiated form of 3T3-L1 cells resembles 
fibroblasts.
In contrast, the differentiated form of 3T3-L1 cells expresses two monosaccharide 
facilitative transporter proteins, G lutl and Glut4 [Calderhead et al., 1990a]. The rate of 
glucose transport increases 20 fold in response to insulin [Calderhead et al., 1990a], 
arising mainly from the translocation of Glut4 {Section 1.3.2} [Holman et al., 1990]. 
However, the rate of glucose transport increases only two to five fold in response to 
growth factors [Gould et al., 1994] and phorbol esters [Gibbs et al., 1991]. The 
expression of various enzymes required for fatty acid and TAG synthesis is higher than 
tha t in non-differentiated cells [Mackall et al., 1976; Ahmad et al., 1979]. Consequently,
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the activities of these enzymes are ten to 50 fold higher and the rate of TAG synthesis 
itself is greater than in non-differentiated cells [Green and Kehinde, 1975; Mackall et 
al., 1976; Ahmad et al., 1979]. Furthermore, TAG synthesis is sensitive to Jcpogenic 
agents such as insulin [Ahmad et al., 1979], and is also sensitive to lipolytic agents such 
as adrenocorticotrophic hormone and B-adrengeric agents [Rubin et al., 1977]. The 
number of insulin-binding sites is comparable to tha t in hum an and ra t adipocytes, 
while the number of EGF-binding sites is comparable to th a t in fibroblasts [Reed et al., 
1977]. Thus, the differentiated form of 3T3-L1 cells resembles adipocytes.
3.2 Results
The effects of the growth factors, insulin and PDGF, on cell proliferation and the rate of 
glucose transport in 3T3-L1 fibroblasts were characterised.
3.2.1 The effect of growth factors on cell proliferation
The effects of insulin and PDGF on cell proliferation in 3T3-L1 fibroblasts were 
established by measuring DNA synthesis by means of the incorporation of 
[3 H]thymidine [Section 2.7}. NCS was used as a positive control. Insulin, PDGF and 
NCS all stimulated incorporation of [3 H]thymidine. The results, from a representative 
experiment, are shown in Table 3.1; the incorporation was stimulated 3.8 fold by 1 |iM 
insulin, 7.2 fold by 25 ng/ml PDGF and 8.3 fold by 20% NCS.
3.2.2 The effect of growth factors on the rate of glucose transport
The effect of insulin on the rate of glucose transport in 3T3-L1 fibroblasts was 
established by measuring the rate of 2-deoxyglucose uptake [Section 2.8.1}. The EC5 0  
value was typically 5.0 nM. At a concentration of 1 pM insulin, the rate of uptake 
increased rapidly. The increase in the rate was evident within one minute of exposure 
to insulin, reaching a maximum by 60 minutes. The maximal stimulation in the rate  in 
response to 1 pM insulin was 2.0 to 5.0 fold. A representative dose-response curve and a
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Table 3.1 The effect of insulin and PDGF on DNA synthesis in 3T3-L1 fibroblasts
After incubation of quiescent 3T3-L1 fibroblasts with 1 pCi [3 H]thymidine and 1 pM 
insulin, 25 ng/ml PDGF or 20% NCS for 24 hours, [3 H]thymidine incorporation was 
measured {Section 2.7}. Each result shows the mean [3 H]thymidine incorporation (± 
SD) for six determinations. This is a representative experiment from a group of four.
[3 H]thymidine incorporation 
(cpm per well)
Basal 5170 ±1500
Insulin 19600 ± 3000
PDGF 37100 ±9300
NCS 42900 ± 1100
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representative time course for insulin-stimulated 2  -deoxyglucose uptake are shown in 
Figures 3.4 and 3.5, respectively.
The effect of IGF-I on the rate of glucose transport in 3T3-L1 fibroblasts was established 
by measuring the rate of 2 -deoxyglucose uptake {Section 2 .8 .1 }. The EC5 0  value was 
typically 0.5 nM. The maximal stimulation in the rate in response to IGF -I was 4.0 to
5.0 fold. A representative dose-response curve for IGF-I-stimulated 2 -deoxyglucose 
uptake is shown in Figure 3.6.
The effect of PDGF on the rate of glucose transport in 3T3-L1 fibroblasts was 
established by measuring the rate of 2 -deoxyglucose uptake {Section 2.8.1}. The EC5 0  
value was typically 0.5 ng/ml. At a concentration of 25 ng/ml PDGF, the rate of uptake 
increased rapidly. The increase in the rate was evident within one minute of exposure 
to PDGF and reached a maximum by 60 minutes. The maximal stimulation in the rate 
in response to 25 ng/ml PDGF was 2.0 to 3.5 fold. A representative dose-response curve 
and a representative time course for PDGF-stimulated 2 -deoxyglucose uptake are shown 
in Figures 3.7 and 3.8, respectively.
3.2.3 The effect of a tumour promoter on the rate of glucose transport
The effect of PMA on the rate of glucose transport in 3T3 -LI fibroblasts was established 
by measuring the rate of 2 -deoxyglucose uptake {Section 2.8.1}. At a concentration of 
100 nM PMA, the rate of uptake increased rapidly. The increase in the rate was evident 
within one minute of exposure to PMA and reached a maximum by 60 minutes. The 
maximal stimulation in the rate in response to 100 nM PMA was 2.0 to 3.0 fold. A 
representative time-course for PMA-stimulated 2-deoxyglucose uptake is shown in 
Figure 3.9.
3.2.4 Identification of the facilitative monosaccharide transporter proteins 
expressed in 3T3-L1 fibroblasts
The presence of the monosaccharide facilitative transporter protein isoforms in 3T3-L1 
fibroblasts was established by Western blotting. Membrane proteins were prepared
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Figure 3.4 A dose response curve for insulin-stimulated 2-deoxyglucose uptake
After incubation of quiescent 3T3-L1 fibroblasts with insulin present in concentrations 
ranging from 0 to 1 fiM for 60 minutes, a 3 minute uptake of 2-dexoy-D-[2,6-3 H]glucose 
was measured {Section 2.8.1}. Each result shows the mean rate of specific 
2-deoxyglucose uptake (± SD) for triplicate determinations. Each result is expressed 
relative to the basal rate which was measured a t 11.6 ± 1.7 pmoles/ min/ 106  cells. This 
is a representative experiment from a group of five; basal rates varied from 6.0 to 49 
pmoles/ min/ 1 0 6  cells, the EC 5 0  value was typically 5 nM and the maximal stimulation 
was between 2.5 and 5.0 fold.
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Figure 3.5 A time course for insulin-stimulated 2-deoxyglucose uptake
After incubation of quiescent 3T3-L1 fibroblasts with 1 pM insulin present for the times 
shown, a 3 minute uptake of 2-dexoy-D-[2,6-3 H]glucose was measured {Section 2.8.1}. 
Each result shows the mean rate of specific 2-deoxyglucose uptake (± SD) for triplicate 
determinations. Each result is expressed relative to the basal rate which was measured 
at 48.5 ± 2.6 pmoles/ min/ 106  cells. This is a representative experiment from a group of 
four; basal rates varied from 6.0 to 49 pmoles/ min/ 106  cells and the maximal 
stimulation was between 2.5 and 5.0 fold.
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Figure 3.6 A dose response curve for IGF-l-stimulated 2-deoxyglucose uptake
After incubation of quiescent 3T3-L1 fibroblasts with IGF-I present in concentrations 
ranging from 0 to 1 pM for 60 minutes, a 3 minute uptake of 2-dexoy-D-[2,6-3 H]glucose 
was measured {Section 2.8.1}. Each result shows the mean rate of specific 
2-deoxyglucose uptake (± SD) for triplicate determinations. Each result is expressed 
relative to the basal rate which was measured at 6.3 ± 1.3 pmoles/ min/ 103  cells. This is 
a representative experiment from a group of three; basal rates varied from 6.0 to 49 
pmoles/ min/ 106  cells, the EC 5 0  value was typically 0.5 nM and the maximal 
stimulation was between 3.4 and 5.0 fold.
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Figure 3.7 A dose-response curve for PDGF-stimulated 2-deoxyglucose uptake
After incubation of quiescent 3T3-L1 fibroblasts with PDGF present in concentrations 
ranging from 0 to 25 ng/ml for 60 minutes, a 3 minute uptake of 2-dexoy- 
D-[2,6-3 H]glucose was measured {Section 2.8.1}. Each result shows the mean rate of 
specific 2-deoxyglucose uptake (± SD) for triplicate determinations. Each result is 
expressed relative to the basal rate which was measured a t 8.87 ±2.7 pmoles/ min/ 106  
cells. This is a representative experiment from a group of three; basal rates varied from
6 . 0  to 49 pmoles/ min/ 1 0 6  cells, the EC 5 0  value was typically 0.5 ng/ml and the maximal 
stimulation was between 2.5 and 5.0 fold.
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Figure 3.8 A time course for PDGF-stimulated 2-deoxyglucose uptake
After incubation of quiescent 3T3-L1 fibroblasts with 25 ng/ml PDGF present for the 
times shown, a 3 minute uptake of 2 -decxy-D-[2,6-3H] glucose was measured {Section 
2.8.1}. Each result shows the mean rate of specific 2-deoxyglucose uptake (± SD) for 
triplicate determinations. Each result is expressed relative to the basal rate which was 
measured a t 47.8 ± 1.9 pmoles/ min/ 106 cells. This is a representative experiment from 
a group of three; basal rates varied from 6.0 to 49 pmoles/ min/ 106 cells and the 
maximal stimulation was between 1.7 and 2.0 fold.
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Figure 3.9 A time course for PMA-stimulated 2-deoxyglucose uptake
After incubation of quiescent 3T3-L1 fibroblasts with 100 nM PMA present for the times 
shown, a 3 minute uptake of 2-dexoy-D-[2,6-3H]glucose was measured {Section 2.8.1}. 
Each result shows the mean rate of specific 2-deoxyglucose uptake (± SD) for triplicate 
determinations. Each result is expressed relative to the basal rate which was measured 
at 20.3 ± 2.6 pmoles/ m in/106 cells. This is a representative experiment from a group of 
three; basal rates varied from 6.0 to 49 pmoles/ min/ 106 cells and the maximal 
stimulation was between 2.5 and 3.0 fold.
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from 3T3-L1 fibroblasts {Section 2.13.1}. These membrane proteins and selected 
transporter protein standards were separated by SDS-PAGE {Section 2.15}, and then 
transferred onto nitrocellulose membranes. The membranes were probed with 
antibodies which recognised the different isoforms {Section 2.16.1}. The rabbit anti- 
G lutl antibody was raised against the carboxy-terminal 14 amino acids of hum an G lutl, 
but the antibody also recognises mouse G lutl [Davies et al., 1987]. The rabbit anti- 
Glut2 antibody was raised against a sequence of 14 amino acids in the carboxy-terminal 
region of human Glut2, but the it also recognises mouse Glut2 [Brant et al., 1992]. The 
rabbit anti-Glut3 antibody was raised against the carboxy-terminal 13 amino acids of 
mouse Glut3 [Gould et al., 1992]. The rabbit anti-Glut4 antibody was raised against the 
carboxy-terminal 16 amino acids of human Glut4, but again the antibody recognises 
mouse Glut4 [Brant et al., 1992]. Proteins were detected using a 125I-conjugated goat 
anti-rabbit IgG antibody {Section 2.16.1}.
When membrane proteins from 3T3-L1 fibroblasts were probed with the anti-G lutl 
antibody, the antibody recognised a broad band with an approximate, molecular mass of 
50 kDa. A representative Western blot is shown in Figure 3.10.
When membrane proteins from 3T3-L1 fibroblasts and the Glut2 standard (mouse liver 
membrane proteins [Marchmont et al., 1981]) were probed with the anti-Glut2 antibody, 
the antibody recognised a narrow band with an approximate, molecular mass of 56 kDa 
in the lanes containing the Glut2 standard. However, bands corresponding to Glut2 
were not observed in the lanes containing the 3T3-L1 fibroblast proteins, although there 
was a band with an approximate molecular mass of 50 kDa probably due to non-specific 
binding. A representative Western blot is shown in Figure 3.11a.
When membrane proteins from 3T3-L1 fibroblasts and the Glut3 standard (mouse brain 
membrane proteins [Gould et al., 1992]) were probed with the anti-Glut3 antibody, the 
antibody recognised a major band with an approximate, molecular mass of 48 kDa in the 
lanes containing the Glut3 standard. Other fainter bands of higher molecular mass 
were also observed, but these bands are not thought to be Glut3 [Gould et al., 1992]. 
However, bands corresponding to Glut3 were not observed in the lanes containing the 
3T3-L1 fibroblast proteins. A representative Western blot is shown in Figure 3.11b.
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Figure 3.10 The effect of insulin, PDGF and PMA on the total Glutl level
After incubation of quiescent 3T3-L1 fibroblasts with 1 pM insulin, 25 ng/ml PDGF or 
100 nM PMA for 60 minutes, membrane proteins were prepared {Section 2.13.1}. 
Approximately 60 pig of protein was loaded onto 10% (w/v) polyacrylamide mini-gels, 
the proteins were separated by SDS-PAGE {Section 2.15}, and then transferred onto 
nitrocellulose membranes. The membranes were probed with a rabbit anti-G lutl 
antibody, then with a 125I-conjugated goat anti-rabbit IgG antibody {Section 2.16.1}. 
This is a representative Western blot from a group of two membrane protein 
preparations.
Lane A: basal; Lane B: insulin; Lane C: vehicle (insulin); Lane D: PDGF; Lane E: 
vehicle (PDGF); Lane F: PMA.
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Figure 3.11 The monosaccharide facilitative transporter isoforms expressed in 3T3-L1 
fibroblasts
Membrane proteins were prepared from quiescent 3T3-L1 fibroblasts {Section 2.13.1}. 
The proteins were loaded onto 10% (w/v) polyacrylamide mini-gels, separated by SDS- 
PAGE {Section 2.15}, and then transferred onto nitrocellulose membranes. The 
membranes were probed with a) rabbit anti-Glut2, b) rabbit anti-Glut3 or c) rabbit 
anti-Glut4 antibodies, and then with an 125I-conjugated goat anti-rabbit IgG antibody 
{Section 2.16.1}. The standards used were mouse liver (Glut2), mouse brain (Glut3) 
and 3T3-L1 adipocyte (Glut4) membrane proteins. This is a representative experiment 
from a group of two membrane protein preparations.
Lanes A and B: 30 pg and 60 fig of 3T3-L1 fibroblast membrane proteins respectively; 
Lanes C and D: 30 pg and 60 pg of standard membrane proteins respectively.
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When membrane proteins from 3T3-L1 fibroblasts and the Glut4 standard (3T3-L1 
adipocyte membrane proteins [Gould et al., 1989]) were probed with the anti-Glut4 
antibody, the antibody recognised a band with an approximate, molecular mass of 
55 kDa in the lanes containing the Glut4 standard. However, bands corresponding to 
Glut4 were not observed in the lanes containing the 3T3-L1 fibroblast proteins. A 
representative Western blot is shown in Figure 3.11c.
3.2.5 The effect of insulin, PDGF and PMA on the total Glutl level
The effect of insulin, PDGF and PMA on the total G lutl level in 3T3-L1 fibroblasts was 
established by Western blotting. Membrane proteins were prepared from 3T3-L1 
fibroblasts after incubation in 1 |xM insulin, 50 j iM  hydrochloric acid (the vehicle for 
insulin), 25 ng/ml PDGF, 1 mM sodium acetate, 0.15 mM sodium chloride (the vehicle 
for PDGF) or 100 nM PMA, for 60 minutes {Section 2.13.1). The membrane protein 
samples were separated by SDS-PAGE {Section 2.15), and then transferred onto 
nitrocellulose membranes. The membranes were probed with the anti-G lutl antibody 
described above {Section 3.2.4} and then with an l 25I-conjugated goat anti-rabbit IgG 
antibody {Section 2.16.1). The level of G lutl in each sample was quantified by 
measurement of radioactivity.
The anti-G lutl antibody recognised a diffuse band with a molecular mass of 
approximately 50 kDa in each lane containing the 3T3-L1 fibroblast proteins. A 
representative Western blot is shown in Figure 3.10.
The G lutl level varied slightly in the untreated, agonist- and vehicle-treated samples. 
However, the results obtained by this method typically varied by ten percent, therefore 
it is unlikely tha t the relatively small differences observed in the G lutl level are 
significant. The results from a representative experiment are shown in Table 3.2.
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Table 3.2 The effect of insulin, PDGF and PMA on the total Glutl level
After incubation of quiescent 3T3-L1 fibroblasts with 1 jiM insulin, 25 ng/ml PDGF or 
100 nM PMA for 60 minutes, membrane proteins were prepared {Section 2.13.1}. 
Approximately 60 pg of protein was loaded onto 10% (w/v) polyacrylamide mini-gels, the 
proteins resolved by SDS-PAGE {Section 2.15}, and then transferred onto nitrocellulose 
membranes The membranes were probed with a rabbit anti-G lutl antibody, and then 
with a 125I-conjugated goat anti-rabbit IgG antibody {Section 2.16.1}. The level of G lutl 
in each sample was quantified by the measurement of radioactivity.
G lutl levels 
(cpm per band)
Basal 798
Insulin 767
Vehicle (insulin) 892
PDGF 1174
Vehicle (PDGF) 1144
PMA 1034
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3.3 Discussion
3.3.1 The effect of growth factors on cell proliferation
Most growth factors stimulate cell growth and proliferation. Some stimulate cell 
differentiation. Some, such as PDGF, affect the proliferation of many cell types, while 
others, such as erythropoietin, affect the proliferation of a single cell type. The ability of 
a growth factor to affect the proliferation of a given cell type depends on which growth 
factor receptors are expressed by that cell.
In order to establish whether or not insulin or PDGF could stimulate proliferation of 
3T3-L1 fibroblasts, DNA synthesis was measured. The incorporation of the radioactive- 
labelled DNA precursor [3H] thymidine into DNA was assayed after a 24 hour incubation 
in the presence of each of the two growth factors and NCS. [3H]thymidine incorporation 
was stimulated 3.8 fold in response to 1 pM insulin, 7.2 fold in response to 25 ng/ml 
PDGF, and 8.3 fold in response to 20% NCS {Table 3.1}. NCS which contains many 
growth factors and hormones, including PDGF, was the most potent stim ulant of 
proliferation in 3T3-L1 fibroblasts, and PDGF alone was nearly as potent; insulin alone 
had a lesser effect.
3.3.2 The effect of growth factors on the rate of glucose transport
The increase in the rate of growth factor-stimulated glucose transport is biphasic 
{Figure 1.1}. The early phase of insulin- and PDGF-stimulated glucose uptake, in 
3T3-L1 fibroblasts, was characterised by measuring the effects of insulin and PDGF on 
the rate of 2-deoxyglucose uptake. For insulin-stimulated 2-deoxyglucose uptake, the 
EC5 0  value was typically 5.0 nM {Figure 3.4}. At a concentration of 1 pM insulin, a 
maximal stimulation of the rate of 2-deoxyglucose uptake of 2.0 to 5.0 fold was observed 
within 60 minutes {Figure 3.5}. For PDGF-stimulated 2-deoxyglucose uptake, the EC 5 0  
value was typically 0.5 ng/ml {Figure 3.7}. At a concentration of 25 ng/ml PDGF, a 
maximal stimulation of the rate of 2-deoxyglucose uptake of 2.0 to 3.5 fold was observed 
within 60 minutes {Figure 3.8}. The EC 5 0  values and the magnitudes of the maximal
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increases in the rate of 2  -deoxyglucose uptake are in agreement with work carried out 
by other researchers in similar cells [Allard et al., 1987].
Insulin is closely related to two other growth factors, IGF -I and IGF -II. The IGF -I 
receptor is similar to, but distinct from, the insulin receptor; both the receptors are 
Subclass III tyrosine protein kinase receptors {Figure 3.1} [Ullrich et al., 1985; Ullrich et 
al., 1986]. Insulin binds with high affinity to its own receptor, with low affinity to the 
IGF-I receptor, and with very low affinity to the IGF-II receptor. IGF-I binds with 
highest affinity to its own receptor, with lower affinity to the IGF-II receptor, and with 
lowest affinity to the insulin receptor [Ullrich et al., 1986]. Despite the structural 
similarities of the insulin and IGF-I receptors and the ability to bind to each other's 
receptors, insulin and IGF-I are thought to have different physiological roles in 
mammals. Insulin is known to have an important role in the regulation of blood glucose 
concentrations and many metabolic pathways {Section 1.2.2}, while IGF-I is thought to 
be im portant in development, both for proliferation (osteocytes and myocytes) and 
differentiation (adipocytes, myocytes and chondrocytes). Furthermore, during the 
differentiation of 3T3-L1 fibroblasts into adipocytes, the level of the insulin receptor 
mRNA increases, while the level of the IGF-I receptor mRNA decreases; presumably 
affecting the levels of the corresponding proteins. Consequently, it is likely tha t the 
observed effects of insulin on cell proliferation and the rate of glucose transport in 
3T3-L1 fibroblasts occur as a consequence of insulin being able to bind to the IGF-I 
receptor.
This possibility was examined by comparing the dose-response curves for insulin- and 
IGF-I-stimulated 2-deoxyglucose uptake. If the effects of insulin are mediated by the 
IGF -I receptor then the EC5 0  value for insulin-stimulated 2-deoxyglucose uptake would 
be higher than the EC 5 0  value for IGF-I-stimulated 2-deoxyglucose. For insulin the 
value was typically 5.0 nM {Figure 3.4} and for IGF -I the value was typically 0.5 nM 
{Figure 3.6}, which supports the hypothesis tha t insulin-stimulated glucose transport is 
mediated by the IGF -I receptor in 3T3-L1 fibroblasts.
There are three PDGF isoforms {Section 3.1.1}. All the work presented in this thesis 
was performed using PDGF-BB. PDGF-BB binds to both the PDGF a- and B-receptor 
isoforms, leading to formation of all three receptor dimers {Section 3.1.1}. Preliminary
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work, using PDGF-AA showed that PDGF-AA also stimulated the rate of 2-deoxyglucose 
uptake in 3T3-L1 fibroblasts (results not shown). PDGF-AA is thought to bind to only 
the PDGF a-receptor isoform [Heldin, 1992]. Therefore, it is likely th a t 3T3-L1 
fibroblasts express this isoform. However, this has not been confirmed, nor has the 
presence of the PDGF 13-receptor isoform in 3T3-L1 fibroblasts. Both the PDGF receptor 
isoforms are expressed by NIH 3T3 fibroblasts [Heidaran et al., 1991], so it is expected 
that 3T3-L1 fibroblasts will also express both isoforms.
3.3.3 The effect of a tumour promoter on the rate of glucose transport
The tumour promoter PMA mimics the actions of DAG by binding to and activating PKC 
{Section 4.1.2], leading to cell proliferation [Nishizuka, 1984], The early phase of PMA- 
stimulated glucose transport in 3T3-L1 fibroblasts was characterised by measuring the 
affect of PMA on the rate of 2 -deoxyglucose uptake. At a concentration of 100 nM PMA, 
the maximal stimulation of the rate of uptake of 2.0 to 3.0 fold occurred within 
60 minutes {Figure 3.9}. This is similar in magnitude and timing to the early phase of 
insulin- and PDGF-stimulated glucose transport.
The effects of insulin, PDGF and PMA on the rate of 2-deoxyglucose uptake were not 
additive; th a t is, the incubation of 3T3-L1 fibroblasts with combinations of these ligands 
did not lead to significantly greater increases in the rate of uptake than incubation with 
any of the ligands alone (results not shown). Similar results were obtained concerning 
the effects of EGF, insulin, PDGF and PMA on 2-deoxyglucose uptake in human 
fibroblasts [Allard et al., 1987]. One interpretation of these results is th a t the early 
phases of insulin-, PDGF- and PMA-stimulated glucose transport are mediated by a 
common signal transduction pathway.
3.3.4 Identification of facilitative transporter proteins
The mammalian monosaccharide facilitative transporter protein isoforms are expressed 
in a tissue-specific manner {Table 1.1}. All cultured cells express G lutl, in fact, it is the 
only one known to be expressed in 3T3-L1 fibroblasts. Western blotting of 3T3-L1
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fibroblast membrane proteins confirmed tha t G lutl is the only transporter protein 
expressed by these cells {Figures 3.10 and 3.11}.
3.3.5 The mechanism by which growth factors stimulate glucose transport
There are three mechanisms by which the rate of transport can be altered {Section 
1.3.1}. Published work suggests that the early phase of growth factor-stimulated glucose 
transport occurs as a consequence of translocation of G lutl from an intracellular 
location to the plasma membrane and not as a consequence of an increase in the total 
level of G lutl {Section 1.3.2}. Western blotting of 3T3-L1 fibroblast membrane proteins 
with an antibody raised against Glutl, showed tha t there were only small differences in 
the total G lutl level after incubation with 1 pM insulin, 25 ng/ml PDGF and 100 nM 
PMA {Figure 3.10 and Table 3.2}. These differences could be due to experimental 
variation and are not large enough to account for the 2 to 5 fold increases observed in 
the rate of 2-deoxyglucose uptake {Sections 3.2.2 and 3.2.3}. Hence, the early phase of 
the growth factor-stimulated glucose transport probably occurs because of translocation 
of Glutl.
3.3.6 The basal rate of 2-deoxyglucose uptake
The basal rate of 2-deoxyglucose uptake varied between 6.0 to 49 pmoles/ min/ 10® cells. 
Other researchers have recorded similar variations when using cultured cells in the 
basal rate of 2 -deoxyglucose uptake and in the magnitude of the maximal increase in 
response to growth factors [Allard et al., 1987}. Recent research suggests tha t these 
variations may arise from a gradual increase in the intracellular sequestration of G lutl 
as the fibroblasts become confluent [Yang et al., 1992]. For example, the majority of 
G lutl is found a t the cell surface in preconfluent 3T3-L1 fibroblasts, and the proportion 
of G lutl a t the cell surface decreases as the cells become confluent. In addition, the 
basal rate of 2-deoxyglucose uptake decreases and the magnitude of insulin-stimulated 
2-deoxyglucose uptake increases as 3T3-L1 fibroblasts become confluent; these changes 
reflect the increase in intracellular sequestration of G lutl [Yang et al., 1992].
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3.3.7 Summary
Insulin and PDGF stimulate cell proliferation in 3T3-L1 fibroblasts, and these growth 
factors and the tumour promoter, PMA, all stimulate 2-deoxyglucose uptake in a similar 
manner. In each case, the increase occurs within minutes and reaches a maximum 
within 60 minutes of exposure to the agonist. The maximum increases in the rate of 
2-deoxyglucose uptake are between 2.0 to 5.0 fold.
3T3 -LI fibroblasts express only one facilitative monosaccharide transporter isoform, 
G lutl. The observed increases in the rate of 2-deoxyglucose uptake probably arise from 
the translocation of G lutl, but not because of an increase in the total level of G lutl.
Since insulin, PDGF and PMA all have similar effects to each other on the rate of 
glucose transport in 3T3-L1 fibroblasts, it is possible th a t the intracellular signal 
transduction pathways that mediate these effects are similar. The effects of many 
ligands tha t bind to plasma membrane receptors are mediated by signal transduction 
pathways tha t involve DAG and PKC. The effects of PMA are also mediated by PKC. 
Therefore, the possibility tha t the early phase of insulin-, PDGF- and PMA-stimulated 
glucose transport is mediated by a signal transduction pathway involving phospholipids 
and PKC was investigated and is discussed next.
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DAG and the activation of protein kinase C in 3T3-L1
fibroblasts
4.1 Introduction
The growth factors, insulin and PDGF, and the tumour promoter, PMA, all have similar 
effects on the rate of glucose transport in 3T3-L1 fibroblasts. The increase in the rate of 
glucose transport is evident within minutes of exposure to ligand, reaching a maximum 
within 60 minutes {Section 3.2.2}. This increase is likely to occur as a result of 
translocation of G lutl to the plasma membrane; it does not involve an increase in the 
total G lutl protein level {Section 3.2.5}.
Since these ligands have similar effects to each other on the rate of glucose transport in 
3T3-L1 fibroblasts, it is possible that the intracellular signal transduction pathways 
tha t mediate these effects are similar. The effects of many ligands tha t bind to plasma 
membrane receptors are mediated by signal transduction pathways tha t involve the 
hydrolysis of certain phospholipids. This produces DAG which binds to and activates 
PKC [Asaoka et al., 1992; Liscovitch, 1992]. The effects of PMA are also mediated by 
PKC [Nishizuka, 1984], Since the effects of insulin and PDGF on the rate of glucose 
transport are similar to those of PMA, it is possible tha t the effects of insulin and PDGF 
are also mediated by a signal transduction pathway involving DAG and PKC.
Therefore, the effects of insulin and PDGF on DAG accumulation and PKC activity, and 
the necessity of PKC in the early phase of insulin- and PDGF-stimulated glucose 
transport, were investigated.
4.1.1 Phospholipid hydrolysis 
Signal-activated phospholipases
Ligand-stimulated hydrolysis of phospholipids is catalysed by signal-activated 
phospholipases. Each signal-activated phospholipase catalyses the hydrolysis of a 
particular bond; for example, phospholipase A2  (PLA2 ) catalyses the hydrolysis of the 
ester bond at the sn-2 position, phospholipase C (PLC) catalyses the hydrolysis of the 
phosphoester bond a t the sn -3 position, and phospholipase D (PLD) catalyses the 
hydrolysis of the bond between the phosphate group and the polar headgroup {Figure 
4.1a}. Consequently, the hydrolysis of a given phospholipid by different signal-activated 
phospholipases produces different types of products {Figure 4.1b}. Furthermore, each
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signal-activated phospholipase catalyses the hydrolysis of a particular group of 
phospholipids; for example, the phosphatidyl inositol-specific PLC (Ptdlns-PLC) 
isozymes catalyse the hydrolysis of phosphatidyl inositols; significantly, sn -1,2- 
phosphatidyl inositol 4,5-bisphosphate (PtdIns(4,5)P2) produces D-myo -inositol 1,4,5- 
trisphosphate (Ins(l,4,5)P3) and DAG. The phosphatidyl choline-specific PLC (PtdCh- 
PLC) isozymes catalyse the hydrolysis of sn-1,2-phosphatidyl choline (PtdCh), the 
products being phosphocholine (ChP) and DAG. The PtdCh-specific PLD (PtdCh-PLD) 
isozymes also catalyse the hydrolysis of PtdCh, but the products are choline (Ch) and 
phosphatidic acid (PtdOH) [Exton, 1990].
Phosphatidyl inositol hydrolysis
The Ptdlns -PLC family members are the most well characterised signal-activated 
phospholipases. The amino acid sequences of 16 distinct isozymes are known. 
Comparison of these sequences shows tha t they form three subfamilies, PLC-B, PLC-y 
and PLC S . The members of each subfamily have distinct catalytic properties and 
modes of activation [Rhee and Choi, 1992].
The PLC-fi isozymes are activated in response to ligands th a t bind to G protein-linked 
receptors, particularly those receptors which bind to the members of the Gq family {see 
Section 5.1.3 for a more detailed description of the activation of G proteins}. The 
activation of a Gq leads to activation of PLC-fil [Smrcka et al., 1991; Sternweis and 
Smrcka, 1992].
The PLC-y isozymes are activated in response to ligands tha t bind to tyrosine protein 
kinase receptors [Rhee and Choi, 1992]. The activation of a tyrosine protein kinase 
leads to phosphorylation of the receptor and association of PLC-yl, via its SH2 domains, 
with certain phosphotyrosine-containing sequences in the receptor [Section 3.1.1}. For 
example, PLC-yl associates with Tyr-1021 in the PDGF 3 - receptor {Figure 3.2} 
[Ronnstrand et al., 1992].
Association of PLC-yl with a tyrosine protein kinase receptor is followed by its 
phosphorylation on residues Tyr-771, Tyr-783 and Tyr-1254. However, its catalytic 
activity is not altered by tyrosine phosphorylation [Rhee and Choi, 1992]. In quiescent
90
Figure 4.1 Phospholipids and signal-activated phospholipases
a) A typical phospholipid, consisting of a DAG moiety linked via a  phosphodiester bond 
to a polar headgroup. Phospholipids differ from one another with respect to the 
structure of the polar headgroup and the composition of the fatty acids. The polar 
headgroup may be choline, ethanolamine, Ins(4,5)P2> phosphatidic acid or serine. The 
fatty acid in the src-1 position usually is saturated (R) and th a t in the sn-2 position 
unsaturated (R'). The sites of hydrolysis by some signal-activated phospholipases are 
also shown.
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cells, PLC-yl-catalysed hydrolysis of PtdIns(4)P and PtdIns(4,5)P2 is inhibited by 
profilin, a small soluble actin-binding protein which also binds to these phospholipids 
with high affinity, but not to any other phospholipids [Goldschmidt-Clermont et al.,
1991]. However, after tyrosine phosphorylation, PLC-yl can catalyse the hydrolysis of 
the profilin-associated phosphatidyl inositols [Goldschmidt-Clermont et al., 1991]. In 
addition, the association of profilin with phosphatidyl inositols inhibits the interaction of 
profilin with actin. Consequently, the profilin released after PLC-yl-catalysed 
hydrolysis of profilin-associated phosphatidyl inositols can bind to actin, and may have a 
role in mediating growth factor-stimulated rearrangements of the cytoskeleton and 
membrane ruffling.
The products of PLC-catalysed hydrolysis of PtdIns(4,5)P2 are Ins(l,4,5)P3 and DAG. 
Ins(l,4,5)P3 is a soluble molecule which binds to a receptor tha t encloses a calcium ion 
channel (a Class I receptor) {Section 1.1.2}. The receptor is found in the membrane of 
calcium ion-sequestering organelles [Taylor and Marshall, 1992]. Ins(l,4,5)P3 opens the 
channel, thus stimulating the transport of calcium ions from the intracellular stores into 
the cytosol, leading to a rise in the intracellular, free calcium ion concentration 
[Moolenaar et al., 1984b; Berridge, 1993]. The activity of many intracellular proteins, 
including th a t of some PKC isozymes, is regulated by calcium ion binding. DAG, the 
other product of PtdIns(4,5)P2 hydrolysis, also has a role in the stimulation of PKC 
activity {Section 4.1.2} [Kikkawa et al., 1989]. However, hydrolysis of PtdIns(4,5)P2 is 
transient, therefore the increases in Ins(l,4,5)P3 mass and the intracellular, free 
calcium ion concentration are also transient [Takuwa et al., 1987]. This is thought to be 
a negative feedback effect of PKC [Price et al., 1989] which catalyses the 
phosphorylation of PLC-B, thus preventing its interaction with Gq [Ryu et al., 1990], and 
of PLC-yl, thus preventing its tyrosine phosphorylation [Park et al., 1992].
Phosphatidyl choline hydrolysis
Many ligands stimulate a rapid, transient increase in the Ins(l,4,5)P3 level, but a 
sustained increase in the DAG level. For example, in bombesin-treated Swiss 3T3 
fibroblasts, the increase in Ins(l,4,5)P3 mass reaches a maximum in five to ten seconds, 
and returns to the basal level by 30 seconds. The increase in the DAG level is biphasic; 
the first phase of DAG accumulation parallels the increase in Ins(l,4,5)P3 mass, while 
the second phase arises after 30 seconds, but remains above the basal level for a t least
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four hours [Takuwa et al., 1987; Cook et al., 1990]. A similar profile of DAG 
accumulation is observed in PDGF- and vasopressin-treated Swiss 3T3 fibroblasts [Price 
et al., 1989] and in a-thrombin-treated IIC9 fibroblasts [Wright et al., 1988; Pessin and 
Raben, 1989; Ha and Exton, 1993].
Other ligands have no effect on PtdIns(4,5)P2 hydrolysis, but stimulate a slow and 
sustained increase in the DAG level. Such a profile of DAG accumulation is observed in 
IIC9 fibroblasts in response to PDGF-BB [Ha and Exton, 1993], EGF and low 
concentrations of a-thrombin [Wright et al., 1988], and in EGF-treated Swiss 3T3 
fibroblasts [Cook et al., 1991]. In Swiss 3T3 fibroblasts treated with the tumour 
promoter, PMA, there is also a slow, sustained increase in the DAG level, in the absence 
ofPtdIns(4,5)P2 hydrolysis [Cook et al., 1991].
The slow, sustained increase in accumulation of DAG occurs because of an increase in 
the hydrolysis of PtdCh. The fatty acid composition of Ptdlns and PtdCh are different, 
Ptdlns having a higher content of stearic and arachidonic acids, while PtdCh has a 
higher content of palmitic, oleic and linoleic acids [Patton et al., 1982]. Analysis of the 
molecular species of DAG produced in response to various ligands shows th a t the 
sustained increase in DAG mass arises from the hydrolysis of PtdCh [Pessin and Raben, 
1989; Exton, 1990]. In addition, many ligands stimulate accumulation of Ch and of ChP, 
suggesting th a t ligand-stimulated hydrolysis of PtdCh is catalysed by both PLC and 
PLD {Figure 4.1}. The activation of PtdCh-PLC produces DAG directly, while the 
activation of PtdCh-PLD produces DAG indirectly, following the hydrolysis of PtdOH by 
phosphatidic acid phosphohydrolase [Cook et al., 1991]. However, in most cells 
PtdCh-PLD activity reaches a maximum between two to five minutes, suggesting tha t 
the majority of the DAG formed arises from another source, most likely through the 
activation of PtdCh-PLC [Cook and Wakelam, 1989; Exton, 1990; Cook et al., 1991; 
McKenzie et al., 1992].
PtdCh-PLC and PtdCh-PLD are activated in response to ligands th a t bind to G protein- 
linked receptors. The activation may involve direct coupling of the phospholipase to the 
receptor by a G protein [Bocckino et al., 1987]. PtdCh-PLC and PtdCh-PLD are also 
activated in response to ligands that bind to tyrosine protein kinase receptors. It is not 
known how activation of these phospholipases is coupled to these receptors, except tha t
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tyrosine protein kinase activity is necessary [Cook and Wakelam, 1992]. In addition, 
PKC may have a role in the receptor-mediated activation of PtdCh-specific 
phospholipases, although this is more likely to be a positive feedback effect [Cook and 
Wakelam, 1989; Price et al., 1989; Cook et al., 1991; Conricode et al., 1992]. In contrast, 
PMA-stimulated PtdCh-specific phospholipase activation is likely to be mediated by 
PKC, since PMA binds directly to PKC [Cook et al., 1991].
Thus, signal-activated phospholipases catalyse the hydrolysis of various phospholipids. 
The Ptdlns-PLC isozymes catalyse the hydrolysis of PtdIns(4,5)P2> producing 
Ins(l,4,5)P3 and DAG, both of which are involved in the activation of PKC. However, 
PKC inhibits Ptdlns-PLC activity, therefore the accumulation of Ins(l,4,5)P3 is 
transient. In contrast, the accumulation of DAG is often biphasic; the first phase is 
rapid but transient and corresponds to the hydrolysis of PtdIns(4,5)P2» while the second 
phase is sustained and corresponds to the hydrolysis of PtdCh, catalysed by the 
PtdCh-PLC and PtdCh-PLD isozymes. The activity of these phospholipases is 
potentiated by PKC [Figure 4.2}.
4.1.2 Protein kinase C 
The mammalian isozymes
The mammalian PKC family contains at least twelve isozymes, nine of which have been 
cloned. Comparison of the amino acid sequences shows tha t the isozymes comprise 
three subfamilies. Furthermore, the members of each subfamily have distinct kinetic 
characteristics [Bell and Burns, 1991; Asaoka et al., 1992; Dekker and Parker, 1994], 
The 'classical' PKC subfamily consists of four isozymes, a, Cl, CII and y. Activation of 
these isozymes is dependent on calcium ion, the normal intracellular, free calcium ion 
concentration being too low for activation to occur. Activation of these isozymes also 
requires the membrane phospholipid, phosphatidyl serine, a cofactor, and DAG, an 
activator, which increases the affinity of these isozymes for calcium ions.
Cis -unsaturated fatty acids and lysophosphatidyl choline also enhance the activity of 
these isozymes. The 'novel' PKC subfamily consists of five isozymes, 5, e, t|, 0 and p. 
Activation of these isozymes occurs independently of calcium ions, but requires 
phosphatidyl serine and DAG. The 'atypical' PKC subfamily consists of three isozymes, 
£, X and i. These isozymes are not fully characterised; however, it is known tha t
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Figure 4.2 Signal transduction pathways involving phospholipid hydrolysis and PKC 
activation
A schematic representation of the activation of Ptdlns-PLC, PtdCh-PLC and PtdCh-PLD 
in response to ligands that bind to G protein-coupled receptors. These phospholipases 
are also activated in response to ligands that bind to tyrosine protein kinase receptors.
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activation of the ^-isozyme occurs independently of calcium ions and DAG.
Furthermore, this isozyme is not activated in response to phorbol esters [Bell and 
Burns, 1991; Asaoka et al., 1992; Dekker and Parker, 1994].
PMA directly binds to and activates the 'classical' and 'novel' PKC isozymes. This 
activation occurs in the absence of changes in the intracellular, free calcium ion 
concentration [Nishizuka, 1984], and leads to a slow, sustained accumulation of DAG 
[Cook et al., 1991].
The PKC isozymes are expressed in a tissue-specific manner. PKC-a, PKC-8 and PKC-£ 
are ubiquitous, while others are restricted to one or to a few tissues. Consequently, each 
cell type expresses a  characteristic subset of isozymes. This suggests tha t there is a 
divergence in function between the isozymes [Asaoka et al., 1992; Dekker and Parker, 
1994]. However, the combination of isozymes expressed by most cells is yet to be 
determined.
Different ligands activate different combinations of PKC isozymes in the same cell; for 
example, in a-thrombin-treated IIC9 fibroblasts PKC-a and PKC-e are activated, but in 
PDGF-BB-treated IIC9 fibroblasts only PKC-e is activated. The activation of PKC-a is 
transient, while th a t of PKC-e is sustained. This reflects the effects of these ligands on 
phospholipid hydrolysis; in a-thrombin-treated IIC9 fibroblasts DAG accumulation is 
biphasic, while in PDGF-BB-treated IIC9 fibroblasts it is monophasic, being slow in 
onset and sustained. Thus, the activation of PKC-a occurs in response to hydrolysis of 
Ptdlns, while the activation of PKC-e occurs in response to hydrolysis of PtdCh. The 
difference in the patterns of isozyme activation arises from the differing requirements of 
the two PKC isozymes for calcium ions and the differing effects of hydrolysis of the two 
phospholipids on the intracellular, free calcium ion concentration [Ha and Exton, 1993].
Activation
The PKC isozymes have a carboxy-terminal catalytic domain and an amino-terminal 
regulatory domain. Within the regulatory domain, there is a sequence of amino acids, 
termed the pseudo-substrate site, which resembles the consensus phosphorylation site 
for PKC, but differs in that it contains an alanine residue instead of the serine/ 
threonine residue th a t is the site of phosphorylation. When the enzyme is cytosolic or
96
membrane-bound through interaction with phospholipid cofactors, the pseudo-substrate 
site interacts with the substrate-binding site in the catalytic domain with relatively high 
affinity, thus inhibiting interaction of the substrate-binding site with substrates, and so 
inhibits the kinase activity. When a lipid activators, such as DAG, binds to PKC, the 
affinity of the pseudo-substrate site for the substrate binding-site is lowered, thus 
allowing substrates to compete more effectively [Bell and Bums, 1991; Dekker and 
Parker, 1994].
Substrates
The myristoylated alanine-rich C kinase substrate (MARCKS), is a good substrate for 
PKC, but not for other kinases [Stumpo et al., 1989]. In quiescent cells, MARCKS binds 
to actin filaments, cross-linking them. MARCKS also binds to calmodulin but, only in 
the presence of calcium ions; phosphorylation of MARCKS prevents it binding to 
calmodulin. The binding of MARCKS to actin filaments is disrupted by both 
phosphorylation and calcium ion-calmodulin binding. Thus, an increase in the 
intracellular, free calcium ion concentration and the activation of PKC leads to the 
release of MARCKS from the plasma membrane and major cytoskeletal rearrangement 
[Aderem, 1992a,b; Blackshear, 1993].
Glycogen synthase kinase-3J3 (GSK-3B) activity is inhibited by PKC-catalysed 
phosphorylation [Goode et al., 1992]. GSK-3C catalyses the phosphorylation of c-Jun, a 
component of the transcription factor AP-1, and so inactivates it. Therefore, PKC- 
catalysed phosphorylation of GSK-3B activates c-Jun, leading to an increase in the 
transcriptional activity of AP-1.
However, each PKC isozyme has a different affinity for a given substrate. For example, 
PKC-a, PKC-BI, PKC-J3II and PKC-y catalyse the phosphorylation of GSK-3B, while 
PKC-e cannot significantly catalyse the phosphorylation of this enzyme [Goode et al.,
1992]. Again, detailed information concerning the substrate specificity of the PKC 
isozymes has not yet been determined.
Thus, the response of a cell to a ligand which activates PKC-dependent signal 
transduction pathways depends on the ability of that ligand to activate the different
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PKC isozymes, which PKC isozymes are expressed by the cell, and which substrates of 
the expressed PKC isozymes are also expressed.
4.1.3 The relationship with cell proliferation
The results of early work on signal transduction pathways involving phospholipid 
hydrolysis and PKC activation lead to the suggestion tha t these events may mediate cell 
proliferation. In many cells a given ligand stimulates DAG accumulation, PKC activity 
and cell proliferation, for example, bombesin, PDGF and phorbol esters in Swiss 3T3 
fibroblasts [Cook and Wakelam, 1989; Cook et al., 1990; Larrodera et al., 1990], LPA 
and phorbol esters in HF fibroblasts [van Corven et al., 1989] and a-thrombin in Chinese 
ham ster fibroblasts [Magnaldo et al., 1988], Transformation of cells with oncogenes 
such as v-ro$,v-src, v-fms,v-ras and v-sis, also leads to DAG accumulation [Wolfman et 
al., 1987].
In support of this hypothesis, the exogenous addition of the PtdCh-PLC from Bacillus 
cereus to Swiss 3T3 fibroblasts stimulates both PtdCh hydrolysis and the rate of cell 
proliferation [Larrodera et al., 1990], In addition, the overexpression of PKC in Rat 6 
fibroblasts results in many phenotypic changes, for example, an increase in the rate of 
cell proliferation and the loss of anchorage-dependence, both in the absence and 
presence of PMA [Housey et al., 1988]. Furthermore, the rate of cell proliferation 
increases in response to PMA in Swiss 3T3 fibroblasts; this effect is abolished by the 
depletion of PKC, and is restored by the microinjection of PKC [Pasti et al., 1986].
However, the activation of Ptdlns-PLC is not necessary for growth factor-stimulated cell 
proliferation. For example, the mutation of the tyrosine residue in the PLC-y binding 
site of the FGF receptor inhibits the FGF-stimulated hydrolysis of PtdIns(4,5)P2 and 
increase in the intracellular free calcium ion concentration, bu t has no effect on FGF - 
stimulated cell proliferation. Furthermore, a major requirement for a signal 
transduction pathway that mediates cell proliferation is tha t it remains active for many 
hours following ligand activation [Van Obberghen-Schilling et al., 1985; Zhan et al.,
1993]. Thus, the transient increase in the DAG level due to the hydrolysis of 
PtdIns(4,5)P2> may be sufficient to mediate some of the early events of the cell cycle, but
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it is not sufficient to stimulate or to maintain growth factor-stimulated cell proliferation 
[van Corven et al., 1989; Seuwen et al., 1990].
Furthermore, the activation of either PtdCh-PLC or PtdCh-PLD is also not sufficient for 
cell proliferation. For example, the activities of PtdCh-PLC and PtdCh-PLD increases 
without any effect on the rate of cell proliferation in response to carbacol, a muscarinic 
agonist, in Chinese ham ster fibroblasts transfected with the human M l muscarinic 
acetylcholine receptor [McKenzie et al., 1992]. In addition, the activation of either 
PtdCh-PLC or PtdCh-PLD is not necessary for growth factor-stimulated cell 
proliferation. For example, the rate of cell proliferation increases without any change in 
the activities of PtdCh-PLC or PtdCh-PLD in FGF- and PDGF-treated Chinese ham ster 
fibroblasts [McKenzie et al., 1992],
In addition, PKC may not be necessary for growth factor-stimulated cell proliferation; 
for example, the rate of cell proliferation increases in Swiss 3T3 fibroblasts in response 
to PDGF and in HF fibroblasts in response to lysophosphatidic acid after depletion of 
PKC [van Corven et al., 1989].
However, PKC is probably necessary for PMA-stimulated cell proliferation, since the 
depletion of PKC abolishes the effect of PMA on cell proliferation in Swiss 3T3 
fibroblasts [Pasti et al., 1986]. In PMA-treated T-cells, there is a sustained increase in 
PKC activity and an increase in the rate of cell proliferation, however, in DAG-treated 
T-cells, there is only a transient increase in PKC activity, with no effect on cell 
proliferation [Berry et al., 1990]. This suggests tha t only a sustained activation of PKC 
is sufficient to stimulate cell proliferation, indeed multiple additions of DAG stimulate 
T-cell proliferation [Berry et al., 1990].
Therefore, Ptdlns-PLC, PtdCh-PLC and PtdCh-PLD are not necessary or sufficient to 
stimulate the rate of cell proliferation. In contrast, PKC is not necessary, but may be 
sufficient for an increase in the rate of cell proliferation. However, these effects may be 
sufficient to stimulate some of the early events of cell proliferation such as the early 
phase of growth factor-stimulated glucose transport.
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4.1.4 The relationship with glucose transport
Since the early phase of growth factor-stimulated glucose transport is an early event of 
the cell cycle, it is possible tha t it could be mediated by a signal transduction pathway 
involving DAG and PKC. In support of this hypothesis, the addition of DAG, to primary 
adipocytes, stimulates the rate of glucose transport. The most effective DAGs are sn- 
1,2-ditetradecanoylglycerol, s/i-1,2-dihexadecenoylglycerol and sn -1,2- 
dioctadecenolyglycerol [Str&lfors, 1988]. In addition, 1-monooleoylglycerol, a DAG 
kinase inhibitor, stimulates the rates of glucose transport and of cell proliferation in 
Swiss 3T3 fibroblasts [Takuwa et al., 1988], The rate of glucose transport also increases 
after the exogenous addition of Ptdlns-PLC from B. cereus to primary adipocytes 
[Str&lfors, 1988], or of PtdCh-PLC from Clostridium perfringens to ra t epitrochlearis 
muscle [Henriksen et al., 1989] or BC3H-1 myocytes [Standaert et al., 1988]. However, 
the exogenous addition of Ptdlns-PLC, from Staphylococcus aureus or Bacillus 
thuringiensis, to BC3H-1 myocytes has no effect on the rate of glucose transport 
[Standaert et al., 1988]. PMA also stimulates the rate of glucose transport in many cell 
types [Flier et al., 1987].
PDGF is able to activate signal transduction pathways involving phospholipid 
hydrolysis and PKC activation, although the precise pathway activated depends on the 
cell type. PDGF has no effect on the hydrolysis of Ptdlns or PtdCh in Chinese ham ster 
lung fibroblasts [McKenzie et al., 1992], but stimulates the hydrolysis of PtdCh in IIC9 
fibroblasts [Wright et al., 1988; Pessin and Raben, 1989; Ha and Exton, 1993] and 
stimulates the hydrolysis of both Ptdlns and PtdCh in Swiss 3T3 fibroblasts [Price et al.,
1989]. However, it is not known whether a signal transduction pathway involving DAG 
and PKC mediates the early phase of PDGF-stimulated glucose transport.
Some groups claim tha t a signal transduction pathway involving DAG and PKC 
mediates the early phase of insulin-stimulated glucose transport. However, many other 
groups do not see any effect of insulin on these processes.
Insulin stimulates the de novo synthesis of phospholipids in BC3H-1 myocytes [Farese et 
al., 1984], but has no effect on Ptdlns hydrolysis in BC3H-1 myocytes [Farese et al.,
1985], ra t hepatocytes [Sakai and Wells, 1986] or adipocytes [Augert and Exton, 1988].
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In agreement with this, insulin has no effect on the intracellular free calcium ion 
concentration in BC3H-1 myocytes [Farese et al., 1985] or HF fibroblasts [Moolenaar et 
al., 1984b]. Insulin is reported to stimulate DAG accumulation by de novo synthesis and 
by the hydrolysis of PtdCh in BC3H-1 myocytes, ra t adipocytes [Farese et al., 1985] and 
soleus muscle [Ishizuka et al., 1990]. However, other studies show no effect of insulin on 
DAG mass in ra t adipocytes [Augert and Exton, 1988] or on PtdCh hydrolysis in Swiss 
3T3 fibroblasts [Price et al., 1989].
Insulin is reported to stimulate the activation of PKC in BC3H-1 myocytes, ra t 
adipocytes [Acevedo-Duncan et al., 1989; Ishizuka et al., 1989; Vila et al., 1989; Cooper 
et al., 1990; Egan et al., 1990], and soleus muscle [Ishizuka et al., 1990]. Insulin- 
stimulated glucose transport is abolished by the PKC inhibitors, staurosporine and 
polymixin B in ra t muscle [Ishizuka et al., 1990] and by staurosporine, H-7 and 
sangiuamyan in ra t adipocytes and BC3H-1 myocytes [Standaert et al., 1990]. However, 
insulin is also reported to have no effect on PKC activity in ra t epitrochlearis muscle 
[Henriksen et al., 1989], or in HIRC-B fibroblasts, BC3H-1 myocytes, 3T3-L1 adipocytes, 
and H35 hepatoma cells transfected with the MARCKS protein [Blackshear et al., 1991]. 
Furthermore, the down-regulation of PKC has no effect on many insulin-stimulated 
responses in many cell types including 3T3-L1 fibroblasts, 3T3-L1 adipocytes, H35 
hepatoma cells, HIRC-B cells, HIR 3.5 cells, Chinese ham ster ovary T-cells, or BC3H-1 
myocytes [Blackshear et al., 1985; Stumpo and Blackshear, 1986; Blackshear et al.,
1990; Lai et al., 1990; Blackshear et al., 1991; Stumpo and Blackshear, 1991].
Thus, it is not clear whether a signal transduction pathway involving DAG and PKC is 
activated in response to insulin, and therefore whether such a signal transduction 
pathway mediates the early phase of insulin-stimulated glucose transport. Nor is it 
clear whether such a signal transduction pathway mediates the early phase of PDGF- 
stimulated glucose transport. In order to examine whether the early phase of growth 
factor-stimulated glucose transport is mediated by a signal transduction pathway 
involving DAG and PKC, several approaches were taken. Firstly, the effects of insulin 
and PDGF on DAG mass were established. Secondly, the effects of these growth factors 
on PKC activity were determined. Finally, the requirement of the early phase of growth 
factor-stimulated glucose transport for PKC was examined.
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4.2 Results
4.2.1 The effect of growth factors on DAG accumulation
The effects of insulin and PDGF on DAG accumulation were established by measuring 
total DAG mass levels in 3T3-L1 fibroblasts. The lipids were extracted after incubation 
of 3T3-L1 fibroblasts in 1 pM insulin or 25 ng/ml PDGF {Section 2.9.1}. The lipid 
extracts were incubated with DAG kinase and [y-32P]ATP, thus catalysing the 
phosphorylation of DAG to produce [32P]-labelled PtdOH. The lipids in each sample 
were separated by tic and the [32P]-labelled PtdOH was located by autoradiography.
The amount of [32P]-labelled PtdOH was quantified by liquid scintillation counting 
{Section 2.9.2}. The standard curve was linear from 0 to 2000 pmoles of sn-l-stearoyl-2- 
arachidonylglycerol {Figure 2.2}.
At a concentration of 1 pM insulin there was no change in DAG mass a t any time 
between 15 seconds and 60 minutes of exposure to insulin. A representative time-course 
for the effect of insulin on the DAG mass level is shown in Figure 4.3.
At a concentration of 25 ng/ml PDGF, DAG mass increased rapidly. The increase in 
DAG mass was evident within 1 minute of exposure to PDGF and reached a maximum 
by 10 minutes, after which it declined slowly. The DAG mass was still significantly 
above the basal level after 60 minutes. The maximal stimulation of DAG accumulation, 
observed in response to 25 ng/ml PDGF, was 1.5 to 1.7 fold. A representative time 
course for the effect of PDGF on DAG mass levels is shown in Figure 4.4.
4.2.2 The effect of a tumour promoter on DAG accumulation
The effect of PMA on DAG accumulation was established by measuring total DAG mass 
levels in 3T3-L1 fibroblasts {Section 2.9}. At a concentration of 100 nM PMA, DAG mass 
increased rapidly. The increase in DAG mass was evident within 1 minute of exposure 
to PMA and was still increasing by 60 minutes. The increase in DAG mass, observed in 
response to 100 nM PMA a t 60 minutes, was 2.8 to 3.0 fold. A representative time- 
course for the effect of PMA on DAG mass is shown in Figure 4.5.
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Figure 4.3 A time course for insulin-stimulated DAG accumulation
After incubation of quiescent 3T3-L1 fibroblasts with 1 pM insulin present for the times 
shown, the lipids were extracted and the DAG mass measured {Section 2.9}. Each result 
shows the mean DAG mass level (± SD) for triplicate determinations. Each result is 
expressed relative to the basal level which was measured a t 223 ± 24 pmoles/ 106 cells. 
This is a representative experiment from a group of six; basal levels were between 140 
and 260 pm oles/10 6 cells.
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Figure 4.4 A time course for PDGF-stimulated DAG accumulation
After incubation of quiescent 3T3-L1 fibroblasts with 25 ng/ml PDGF present for the 
times shown, the lipids were extracted and the DAG mass measured {Section 2.9}. Each 
result shows the mean DAG mass level (± SD) for triplicate determinations. Each result 
is expressed relative to the basal level which was measured a t 101 ± 13 pmoles/ 106 
cells. This is a representative experiment from a group of seven; basal levels varied 
from 140 to 260 pmoles/ 106 cells and the maximal stimulation was between 1.5 and 1.7 
fold (at 10 minutes).
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Figure 4.5 A time course for PMA-stimulated DAG accumulation
After incubation of quiescent 3T3-L1 fibroblasts with 100 nM PMA present for the times 
shown, the lipids were extracted and the DAG mass measured {Section 2.9}. Each result 
shows the mean DAG mass level (± SD) for triplicate determinations. Each result is 
expressed relative to the basal level which was measured a t 188 ± 9.4 pmoles/ 106 cells. 
This is a representative experiment from a group of four; basal levels varied from 140 to 
260 pmoles/ 106 cells and the maximal stimulation was between 2.8 and 3.0 fold.
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4.2.3 The effect of growth factors and a tumour promoter on PKC activity
The effects of insulin, PDGF and PMA on PKC activity were established by the 
measurement of incorporation of [32P] into a peptide substrate of PKC {Section 2.10}. 
This was carried out with permeabilised 3T3-L1 fibroblasts which had been previously 
incubated for 16 hours in 1 pM 4a-PDD, an inactive phorbol ester, or in 1 pM PMA, an 
active phorbol ester {Section 2.11}. After the 16 hour incubation in 4a-PDD, there was 
no change in PKC activity in response to 1 pM insulin, but PKC activity increased 1.7 
fold in response to 25 ng/ml PDGF and 3.8 fold in response to 100 nM PMA. After the 
16 hour incubation in 1 pM PMA there was no change in PKC activity in response to 
1 pM insulin, 25 ng/ml PDGF or 100 nM PMA. The results of a representative 
experiment are shown in Table 4.1.
4.2.4 The effect of PKC on growth factor and tumour promoter-stimulated glucose 
transport
The requirement of insulin-, PDGF- and PMA-stimulated glucose transport for PKC 
activity was established by measuring the rate of 2-deoxyglucose uptake after down- 
regulation or inhibition of PKC.
Down-regulation of PKC
The rate of 2 -deoxyglucose uptake was measured in 3T3-L1 fibroblasts acutely treated 
with 1 pM insulin, 25 ng/ml PDGF or 100 nM PMA {Section 2.8.1} after a 16 hour 
incubation in 1 pM 4a-PDD or 1 pM PMA {Section 2.11}. After the 16 hour incubation in 
1 pM 4a-PDD, the rate of 2-deoxyglucose uptake increased 1.5 to 5.0 fold in response to 
1 pM insulin, 1.5 to 4.0 fold in response to 25 ng/ml PDGF and 1.5 to 4.0 fold in response 
to 100 nM PMA. After the 16 hour incubation in 1 pM PMA, the rate of 2-deoxyglucose 
uptake increased 1.5 to 2.5 fold in response to 1 pM insulin and 1.5 to 2.5 fold in 
response to 25 ng/ml PDGF, but there was no change in response to 100 nM PMA. 
Furthermore, the basal rate of 2 -deoxyglucose uptake was 2.0 to 4.0 fold higher after the 
16 hour incubation in 1 pM PMA than after the 16 hour incubation in 1 pM 4a-PDD.
The results from a representative experiment are shown in Table 4.2.
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Table 4.1 The effect of insulin, PDGF and PMA on PKC activity, after the down- 
regulation of PKC
After incubation of quiescent 3T3-L1 fibroblasts with 1 pM 4a-PDD or 1 pM PMA 
overnight {Section 2.11}, then with 1 pM insulin, 25 ng/ml PDGF or 100 nM PMA for 
10 minutes, PKC activity was measured {Section 2.10}. Each result shows the mean 
PKC activity (± SD) for triplicate determinations. This is a representative experiment 
from a group of four. * p < 0.05; t- not significant.
PKC activity 
(cpm incorporated/ min)
4a-PDD PMA
Basal 72.0 ±1.5 73.5 ± 2.0
Insulin 77.5 ± 3.5+ 74.5 ± 1.5+
PDGF 125 ± 2.0* 73.0 ±1.5+
PMA 274 ± 3.5* 74.5 ±2.1+
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Table 4.2 The effect of insulin, PDGF and PMA on the rate of 2-deoxyglucose
uptake, after the down-regulation of PKC
After incubation of quiescent 3T3-L1 fibroblasts with 1 pM 4a-PDD or 1 pM PMA for 
16 hours {Section 2.11}, then with 1 pM insulin or 25 ng/ml PDGF for 15 minutes or 
with 100 nM PMA for 60 minutes, a 5 minute uptake of 2-deoxy-D-[2,6-^H]glucose was 
measured {Section 2.8.1}. Each result shows the mean rate of specific 2-deoxyglucose 
uptake (± SD) for triplicate determinations. This is a representative experiment from a 
group of five; basal rates varied from 6.0 to 21 pmoles/ min/ 106 cells after a 16 hour 
incubation in 1 pM 4a-PDD and from 31 to 80 pmoles/ min/ 106 cells after a 16 hour 
incubation in 1 pM PMA. Basal rates were between 2.4 and 5.0 fold higher after a 
16 hour incubation in 1 pM PMA than in 1 pM 4a-PDD. * p < 0.05; t : not significant.
Rate of 2-deoxyglucose uptake 
(pmoles/ min/ 10^ cells)
4a-PDD PMA
Basal 7.9 ± 1.3 31.6 ±5.8
Insulin GO o ±4.0* 69.6 ±5.4*
PDGF 30.6 ±1.7* 624 ±4.4*
PMA 30.9 ±4.4* 41.8 ± 4.6 ^
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Inhibition of PKC
The rate of 2-deoxyglucose uptake was measured in 3T3-L1 fibroblasts treated with 
1 pM insulin, 25 ng/ml PDGF or 100 nM PMA {Section 2.8.1} after a 15 minute 
incubation with or without Ro 31-8220, a PKC inhibitor {Section 2.12}. In control cells, 
the rate of 2-deoxyglucose uptake increased 3.0 to 4.6 fold in response to 1 pM insulin, 
4.8 to 9.4 fold in response to 25 ng/ml PDGF and 2.0 to 3.0 fold in response to 100 nM 
PMA. After the 15 minute incubation in 3 pM Ro 31-8220, the rate of 2-deoxyglucose 
uptake increased 2.7 to 7.7 fold in response to 1 pM insulin and 4.0 to 6.8 fold in 
response to 25 ng/ml PDGF, but there was no change in response to 100 nM PMA. 
Incubation in 3 pM Ro 31-8220 had no effect on the basal rate of 2 -deoxyglucose uptake. 
The results from a  representative experiment are shown in Table 4.3.
4.2.5 The effect of PKC on the total Glutl level
The effect of PKC on the total G lutl protein level was established by Western blotting. 
Lysates were prepared from 3T3-L1 fibroblasts {Section 2.13.2} treated with 1 pM 
insulin, 25 ng/ml PDGF or 100 nM PMA after a 16 hour incubation in 1 pM 4a-PDD or 
1 pM PMA {Section 2.11}. The proteins were separated by SDS-PAGE {Section 2.15}, 
then transferred onto nitrocellulose membranes. The membranes were probed with a 
rabbit anti-G lutl antibody (East Acres), then with a HRP-conjugated donkey anti-rabbit 
IgG antibody. The sites of antibody binding were visualised using a ECL detection 
system {Section 2.16.2}.
When proteins from 3T3-L1 fibroblasts were probed with the anti-G lutl antibody, the 
antibody recognised a broad band with a molecular mass of approximately 50 kDa.
After the 16 hour incubation in 1 pM 4a-PDD, there was no change in the total G lutl 
level in response to 1 pM insulin, 25 ng/ml PDGF or 100 nM PMA. After the 16 hour 
incubation in 1 pM PMA, there was also no change in the total G lutl level in response to 
1 pM insulin, 25 ng/ml PDGF or 100 nM PMA. However, the basal total G lu tl level was 
clearly higher after the 16 hour incubation in 1 pM PMA than after the 16 hour 
incubation in 1 pM 4a-PDD. Representative Western blots are shown in Figure 4.6.
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Table 4.3 The effect of insulin, PDGF and PMA on the rate of 2-deoxyglucose
uptake, after the inhibition of PKC
After incubation of quiescent 3T3-L1 fibroblasts with 1 |iM Ro 31-8220 for 15 minutes 
{Section 2.12}, then with 1 pM insulin or 25 ng/ml PDGF for 15 minutes or with 100 nM 
PMA for 60 minutes, a 5 minute uptake of 2-deoxy-D-[2,6-3H] glucose was measured 
{Section 2.8.1}. Each result shows the mean rate of specific 2-deoxyglucose uptake (± 
SD) for triplicate determinations. This is a representative experiment from a group of 
three; basal rates varied from 6.1 to 28.3 pmoles/ min/ 106 cells. * p < 0.05; +: not 
significant.
Rate of 2-deoxyglucose uptake 
(pmoles/ min/ 10^ cells)
Control Ro 31-8220
Basal 9.0 ±3.9 11.1 ±2.8
Insulin 36.8 , ±4.1* 31.6 ±2.0*
PDGF 72.6 ±8.3* 51.2 ±9.2*
PMA 29.6 ±7.1* 15.0 ±2.1 +
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Figure 4.6 The effect of PKC on the total Glutl level
After incubation of quiescent 3T3-L1 fibroblasts with a) 1 fiM 4a-PDD or b) 1 pM PMA 
for 16 hours {Section 2.11}, and then with A) 1 pM insulin, B) 25 ng/ml PDGF or C)
100 nM PMA present for the times shown, lysates were prepared {Section 2.13.2}. 
Approximately 0.03 mg of protein was loaded onto 10% (w/v) polyacrylamide large gels, 
the proteins were separated by SDS-PAGE {Section 2.15}, and then transferred onto 
nitrocellulose membranes. The membranes were probed with a rabbit anti-G lutl 
antibody, then with a HRP-conjugated donkey anti-rabbit IgG antibody. The sites of 
antibody binding were visualised using an ECL detection system {Section 2.16.2}.
These are representative Western blots from groups of two lysate preparations.
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4.3 Discussion
In order to examine whether the early phase of growth factor-stimulated glucose 
transport is mediated by a signal transduction pathway involving DAG and PKC, 
several approaches were taken. Firstly, the effects of insulin and PDGF on DAG 
accumulation were determined. Secondly, the effects of these growth factors on PKC 
activity were established. Finally, the requirement of the early phase of growth factor- 
stimulated glucose transport for PKC was examined, using pharmacological reagents 
tha t either deplete cellular PKC or inhibit its activity.
4.3.1 The effect of growth factors and a tumour promoter on DAG accumulation
Insulin stimulated the rate of 2-deoxyglucose transport in 3T3-L1 fibroblasts, the 
maximum rate occurring a t a concentration of 1 fiM insulin {Figure 3.4}. Incubation of 
3T3 -LI fibroblasts in the same concentration of insulin for times between 0 and 
60 minutes had no effect on the DAG mass level {Figure 4.3}. It was possible th a t the 
passages of 3T3-L1 fibroblasts used in the experiments with insulin had lost the ability 
accumulate DAG in response to ligands. However, an increase in the DAG mass level 
occurred in cells from the same passage in response to PDGF (results not shown). 
Therefore these cells had a functional signal transduction pathway leading to DAG 
accumulation. It was also possible that these cells had become insulin-insensitive. 
However, an increase in 2-deoxyglucose transport in response to 1 pM insulin, with 
characteristics as previously described, occurred in cells from the same passage (results 
not shown). Therefore these cells were insulin-sensitive.
If the early phase of insulin-stimulated glucose transport is mediated by a pathway 
involving DAG, then there should be an increase in the DAG mass level under the same 
conditions that the maximal increase in the rate of 2 -deoxyglucose transport occurred, 
that is by 60 minutes in response to 1 pM insulin {Figure 3.5}. This did not occur, 
suggesting tha t the early phase of insulin-stimulated glucose transport is not mediated 
by a signal transduction pathway involving DAG.
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PDGF stimulated the rate of 2-deoxyglucose transport in 3T3-L1 fibroblasts, the 
maximal rate occurring a t a concentration of 25 ng/ml PDGF {Figure 3.7}. Incubation of 
3T3-L1 fibroblasts in the same concentration of PDGF also led to an increase in the 
DAG mass level. DAG accumulation was evident within 1 minute of exposure to PDGF 
and reached a maximum by 10 minutes, after which it declined slowly. The DAG mass 
was still significantly above the basal level after 60 minutes {Figure 4.4}. If the early 
phase of PDGF-stimulated glucose transport is mediated by a signal transduction 
pathway involving DAG, then the increase in the DAG mass level should precede the 
increase in the rate of 2-deoxyglucose transport. This would appear to be the case 
{Figure 4.7}. This suggests that the early phase of PDGF-stimulated glucose transport 
could potentially be mediated by a signal transduction pathway involving DAG.
PMA also stimulated the rate of 2-deoxyglucose transport in 3T3-L1 fibroblasts {Figure 
3.9}. Incubation of 3T3-L1 fibroblasts in 100 nM PMA also led to an increase in the DAG 
mass level. DAG accumulation was evident within 1 minute of exposure to PMA and 
reached a maximum by 60 minutes {Figure 4.5}. If the early phase of PMA-stimulated 
glucose transport is mediated by a signal transduction pathway involving DAG, then the 
increase in the DAG mass level should precede the increase in the rate of 2-deoxyglucose 
transport. This would appear to be the case {Figure 4.8}. This suggests th a t the early 
phase of PMA-stimulated glucose transport could potentially be mediated by a signal 
transduction pathway involving DAG.
The source of the DAG formed in response to PDGF and PMA was not analysed. 
However, the initial rates of DAG accumulation were the similar in response to PDGF 
and PMA {Figures 4.4 and 4.5}. Since activation of signal-activated phospholipases 
occurs in a time-dependent manner [Liscovitch, 1992], it is likely tha t PDGF and PMA 
stimulated the activation of the same phospholipase or groups of phospholipases. Since 
Ptdlns-PLC-catalysed hydrolysis of Ptdlns is generally transient [Cook et al., 1990], and 
PMA inhibits Ptdlns-PLC activity [Price et al., 1989] it would seem likely th a t the DAG 
accumulation observed in response to PDGF and PMA was formed by the hydrolysis of 
PtdCh and not by the hydrolysis of Ptdlns.
Since PDGF is able to stimulate the hydrolysis of both Ptdlns and PtdCh in some cells, 
further analysis is necessary to confirm this hypothesis and to establish w hether the
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Figure 4.7 A comparison of the time courses for PDGF-stimulated 2-deoxyglucose
uptake and DAG accumulation
After incubation of quiescent 3T3-L1 fibroblasts with 25 ng/ml PDGF for the times 
shown, either a 3 minute uptake of 2-deoxy-D-[2,6-3H]glucose was measured {Section 
2.8.1} or the lipids were extracted and the DAG mass measured {Section 2.9}. Each 
result shows the mean rate of specific 2-deoxyglucose uptake (± SD) (o), or the mean of 
the DAG mass level (± SD) (□) for triplicate determinations. Each result is expressed 
relative to the basal levels, which were measured a t 47.8 ± 1.9 pmoles 2-deoxyglucose/ 
min/ 10 6 cells and 101 ± 13 pmoles DAG/ 106 cells. These are representative 
experiments from groups of three and six respectively; basal levels varied from 6.0 to 49 
pmoles 2-deoxyglucose/ min/ 106 cells and 140 to 260 pmoles DAG/ 106 cells.
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Figure 4.8 A comparison of the time courses for PMA-stimulated 2-deoxyglucose
uptake and DAG accumulation
After incubation of quiescent 3T3-L1 fibroblasts with 100 nM PMA present for the times 
shown, either a 3 minute uptake of 2-deoxy-D-[2,6-3 H]glucose was measured {Section 
2.8.1} or the lipids were extracted and the DAG mass measured {Section 2.9}. Each 
result shows the mean rate of specific 2-deoxyglucose uptake (± SD) (o), or the mean of 
the DAG mass level (± SD) (□) for triplicate determinations. Each result is expressed 
relative to the basal levels, which were measured a t 20.3 ± 2.6 pmoles 2-deoxyglucose/ 
min/ 10 6  cells and 188 ± 9.4 pmoles DAG/ 106  cells. These are representative 
experiments from groups of three and six respectively; basal levels varied from 6.0 to 49 
pmoles 2-deoxyglucose/ min/ 106  cells and 140 to 260 pmoles DAG/ 106  cells.
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hydrolysis of PtdCh in PDGF- and PMA-treated 3T3-L1 fibroblasts is catalysed by a 
PLC or a PLD.
The observation that insulin did not stimulate any rapid transient increase in DAG 
mass in 3T3-L1 fibroblasts is in agreement with the observation tha t PLC-yl does not 
bind to the insulin receptor after autophosphorylation, or to IRS-1 after tyrosine 
phosphorylation [Sun et al., 1993a; Vallus and Kazlauskas, 1993]. This result is also in 
agreement with the work of several groups who have observed no effect of insulin on 
Ptdlns hydrolysis in BC3H-1 myocytes [Farese et al., 1985], ra t hepatocytes [Sakai and 
Wells, 1986] or ra t adipocytes [Augert and Exton, 1988], or on the cytoplasmic free 
calcium ion concentration in BC3H-1 myocytes [Farese et al., 1985] or HF fibroblasts 
[Moolenaar et al., 1984b].
Farese and colleagues have reported that insulin stimulates PtdCh hydrolysis and DAG 
accumulation in BC3H-1 myocytes, ra t adipocytes and soleus muscle [Farese et al.,
1985; Ishizuka et al., 1990]. It is possible tha t insulin, like PDGF-BB has different 
effects upon PtdCh hydrolysis in different cells, so tha t insulin is able to stimulate 
PtdCh hydrolysis in some cells but not in others. However, other researchers do not 
observe any changes in PtdCh hydrolysis or DAG accumulation in insulin-treated rat 
adipocytes [Augert and Exton, 1988], thus it is unlikely tha t these are cell-specific 
differences.
4.3.2 The effect of growth factors and a tumour promoter on PKC activity
Several methods can be used to measure PKC activity. These include measurement of 
changes in the intracellular location of PKC (translocation), of changes in the PKC 
activity in different intracellular locations and of changes in the total PKC activity.
Changes in the intracellular location of PKC can be established by Western blotting of 
PKC in membrane and cytosolic extracts. The correlation of translocation of PKC with 
its activation is based upon the assumption tha t PKC isozymes are activated by binding 
to a cofactor, phosphatidyl serine, and an activator, DAG, both of which are located in 
the cytosolic face of the plasma membrane. Therefore cytosolic PKC is inactive while 
membrane PKC is active. However, association of PKC with the plasma membrane does
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not necessarily reflect its activation, since PKC may be membrane bound by association 
with its cofactor, phosphatidyl serine, in the absence of its activator, DAG [Bell and 
Bums, 1991]. Consequently, changes in the intracellular location of PKC may occur 
without any change in the PKC activity [Halsey et al., 1987; Heidenreich et al., 1990]. 
Furthermore, some isozymes of PKC undergo translocation to sites other than the 
plasma membrane, such as the nucleus or cytoskeleton, in response to ligands [Dekker 
and Parker, 1994]. In addition, some isozymes of PKC are rapidly down-regulated in 
response to ligands [Dekker and Parker, 1994]. Therefore, measurement of the 
intracellular location of PKC is not a reliable indication of PKC activation.
Changes in the PKC activity in different intracellular locations can be established by 
measuring the phosphorylation of a substrate by membrane and cytosol extracts or by 
PKC partially purified from membrane and cytosolic extracts. M easurement of the PKC 
activity in membrane and cytosolic extracts is also based on the assumption tha t 
translocation of PKC correlates with its activation. Activation of PKC occurs by 
allosteric means. Therefore, disruption of the cell may allow the allosteric activators to 
dissociate from the kinase, and so, measurement of PKC activity in a cell extract does 
not measure the activation state that existed in the cell, but the amount of the enzyme 
present in tha t fraction. Therefore, measurement of the activity of PKC in various 
intracellular fractions is not a reliable indicator of PKC activation.
Changes in the total PKC activity also can be established by measuring the PKC activity 
in total cellular extracts, however, as discussed above, this approach is also flawed. The 
total PKC activity can also be measured in  vivo, for example, by measuring the 
phosphorylation of an endogenous specific substrate for PKC, such as MARCKS 
[Blackshear, 1993]. A disadvantage of this approach is th a t some cells such as 3T3-L1 
adipocytes and H35 hepatoma cells express relatively low amounts of this protein 
[Blackshear et al., 1991]. This can be overcome by using cells which stably express 
MARCKS [Blackshear et al., 1991]. An alternative approach is to measure the 
phosphorylation of small synthetic peptide substrates in permeabilised cells [Heasley 
and Johnson, 1989; Alexander et al., 1990]. The sequence of such peptides can be based 
on the phosphorylation site of a substrate of PKC [House et al., 1987; Heasley and 
Johnson, 1989] or on the pseudo-substrate site of a PKC isozyme [Heidenreich et al.,
1990]. Permeabilisation of cells allows rapid access of small peptides to the interior
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without disrupting mechanisms of signal transduction [Alexander et al., 1989]. A 
disadvantage of this approach is that each PKC isozyme has a different substrate 
specificity. However, on balance, this is the best available approach to establish the 
effect of ligands on PKC activity.
The estimates of PKC activity presented in this thesis were made by measuring the 
phosphorylation of a synthetic peptide in digitonin-permeabilised cells {Section 2.10}. 
The peptide used for this analysis (Pro-Leu-Ser-Arg-Thr-Leu-Ser-Val-Ala-Ala-Lys-Lys) 
was derived from a peptide corresponding to residues one to ten of glycogen synthase 
[House et al., 1987]. The Km values of ra t brain PKC, rabbit muscle multifunctional 
calmodulin-dependent protein kinase and bovine heart cyclic AMP-dependent protein 
kinase for this peptide are 4.1 pM, 18 pM and 2726 pM respectively [House et al., 1987]. 
Therefore, this peptide is a good substrate of PKC, but not of multifunctional 
calmodulin-dependent protein kinase or of cyclic AMP-dependent protein kinase. 
Unfortunately, the affinities of the individual PKC isozymes for this peptide are 
unknown; this caveat should be kept in mind during the interpretation of these results.
Quiescent 3T3-L1 fibroblasts from the same passage were incubated with insulin, PDGF 
or PMA present a t concentrations sufficient to stimulate a maximum increase in the 
rate of 2-deoxyglucose uptake and in the case of the latter two, to stim ulate DAG 
accumulation. Incubations with ligand were carried out for 10 minutes, before 
permeabilisation and the addition of the peptide substrate. Given th a t increases in the 
rate of 2-deoxyglucose uptake and DAG accumulation were evident by 10 minutes of 
exposure to the ligands, this should be sufficient time to allow for any relevant 
activation of PKC.
The cells were also pre-incubated for 16 hours in 1 pM PMA in order to evaluate the 
effectiveness of a long incubation in a high concentration of phorbol ester as a method to 
deplete cellular PKC activity. For a control, cells were simultaneously incubated with 
1 pM 4a-PDD, an inactive phorbol ester. In cells incubated with 1 pM 4a-PDD, PKC 
activity increased in response to 25 ng/ml PDGF and 100 nM PMA, but did not change 
in response to 1 pM insulin. In cells incubated with 1 pM PMA, PKC activity did not 
change in response to 1 pM insulin, 25 ng/ml PDGF or 100 nM PMA [Table 4.1}. These
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results suggest th a t PDGF and PMA can stimulate PKC activity in 3T3-L1 fibroblasts, 
while insulin does not.
The observation th a t both PDGF and PMA stimulate PKC activity in 3T3-L1 fibroblasts 
is in agreement with the work of several other groups who observe an increase in the 
phosphorylation of MARCKS in response to PDGF and PMA in 3T3-L1 fibroblasts, 
3T3-L1 adipocytes, BC3H-1 myocytes, and Swiss 3T3 fibroblasts [Rozengurt et al., 1983; 
Blackshear et al., 1985; Spach et al., 1986]. These groups also failed to observe any 
effect of insulin on the phosphorylation of MARCKS in these cells or in HIRC-B 
fibroblasts, BC3H-1 myocytes, or H35 hepatoma cells after transfection with MARCKS 
[Spach et al., 1986; Blackshear et al., 1991]. However, Farese and colleagues have 
reported tha t insulin stimulates PKC activity in BC3H-1 myocytes, ra t adipocytes, and 
soleus muscle [Acevedo-Duncan et al., 1989; Ishizuka et al., 1989; Vila et al., 1989; 
Cooper et al., 1990; Ishizuka et al., 1990].
These differences in the activation of PKC could arise from differences in the 
methodology used. Firstly, Farese and colleagues correlate translocation, measured 
either by Western blotting or assay of PKC activity in cell extracts, with PKC activation. 
As discussed previously, this is a flawed approach. Indeed Farese and colleagues 
observed tha t different methods of PKC purification lead to differences in the measured 
PKC activity [Cooper et al., 1990]. Secondly, the differences in observed PKC activity 
could arise from the use of different substrate proteins in the PKC activity assays, since 
each PKC isozyme has a different substrate specificity. Therefore, if  the activity of a 
PKC isozyme increases in response to insulin, it is possible th a t it catalyses the 
phosphorylation of only certain substrates. Unfortunately, the substrate specificity of 
each PKC isozyme is unknown.
The differences in results could also arise from the use of different cells, since the PKC 
isozymes are expressed in a tissue-specific manner. Unfortunately, the PKC isozymes 
expressed by most cells, including 3T3-L1 fibroblasts, are unknown. It is also possible 
tha t different signal transduction pathways mediate the change in the rate of glucose 
transport in cells tha t respond to insulin by increased proliferation and cells tha t 
respond to insulin with a 'classical' hormonal response (skeletal muscle and adipocyte 
cells). Indeed, Farese and colleagues consider BC3H-1 myocytes to be a model of such a
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hormonal response. However, these cells differ considerably from skeletal muscle. 
Skeletal muscle expresses both G lutl and Glut4, however, BC3H-1 myocytes express 
only G lutl [Calderhead et al., 1990b]. The rate of glucose transport in skeletal muscle 
increases eight to ten fold in response to insulin [Henriksen et al., 1989], mainly as a 
consequence of translocation of Glut4 [Slot et al., 1991a], but only two to three fold in 
BC3H-1 myocytes as a consequence of translocation of G lutl [Calderhead et al., 1990b]. 
Furthermore, insulin stimulates the proliferation of BC3H-1 myocytes [Standaert et al., 
1987]. Therefore, BC3H-1 myocytes are not a good model of a 'classical' hormonal 
response to insulin. Thus, it is unlikely th a t the differences in the activation of PKC 
observed in 3T3-L1 fibroblasts and BC3H-1 myocytes are due to different roles of insulin 
in these cells.
Some groups have disputed the validity of studies using a long incubation with a high 
concentration of a phorbol ester to deplete cellular PKC activity, on the basis th a t this 
technique may be applicable only to certain PKC isozymes. However, PMA can bind to 
and stim ulate the activity of all the classical and novel PKC isozymes, therefore, if such 
treatm ent can cause the degradation of one such isozyme, it is likely tha t it will also 
cause the degradation of the other classical and novel PKC isozymes. The results 
presented in this thesis suggest tha t this technique depletes cellular PKC activity. 
Furthermore, analysis of Western blots prepared with an anti-PKC antibody or 
measurement of specific phorbol ester binding show tha t a long incubation in a high 
concentration of a phorbol ester does result in depletion of cellular PKC [Blackshear et 
al., 1985]. In addition, many processes known to be mediated by PKC are abolished by 
such treatment, for example, PMA-stimulated c-fos induction in 3T3-L1 adipocytes 
[Stumpo and Blackshear, 1986] and HIRC-B cells [Stumpo and Blackshear, 1991], PMA- 
stimulated MARCKS protein phosphorylation in 3T3-L1 fibroblasts [Blackshear et al., 
1985], and PMA-stimulated Raf-1 kinase phosphorylation in HIR 3.5 cells [Blackshear 
et al., 1990]. Therefore, this appears to be a valid technique for depletion of the classical 
and novel PKC isozymes [Blackshear et al., 1991]. However, the atypical PKC isozymes 
are probably unaffected by this treatment, since phorbol esters do not activate them, 
and probably do not bind to them. Unfortunately, little is known about the regulation of 
such isozymes, except th a t they appear to be activated independently of DAG, 
phosphatidyl serine and phorbol esters, and therefore are probably not activated by the 
signal transduction pathways described.
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Therefore, the PKC isozymes that are expressed by 3T3-L1 fibroblasts and th a t catalyse 
phosphorylation of the peptide described, are activated in response to PDGF and PMA, 
but not in response to insulin. Furthermore, the activity of these isozymes is abolished 
by a long incubation in a high concentration of PMA, a technique referred to as down- 
regulation of PKC. However, since it is not known which PKC isozymes catalyse the 
phosphorylation of the peptide used in the assay presented or which are expressed by 
3T3-L1 fibroblasts, it is not possible to be more precise in the interpretation of these 
results.
4.3.3 The effect of PKC on growth factor- and tumour promoter-stimulated glucose 
transport
The requirement of the early phase of insulin-, PDGF- and PMA-stimulated glucose 
transport for PKC activity in 3T3-L1 fibroblasts was established in two ways. The rate 
of 2-deoxyglucose uptake was measured in 3T3-L1 fibroblasts treated with 1 pM insulin, 
25 ng/ml PDGF or 100 nM PMA, firstly, after the down-regulation of PKC and secondly, 
after the inhibition of PKC.
In both cases, cells from the same passage were incubated with the ligand present at 
concentrations sufficient to stimulate a maximal increase in the rate of 2 -deoxyglucose 
uptake and in the case of the latter two, to stimulate DAG accumulation. Incubations 
with insulin and PDGF were carried out for 30 minutes, while incubations with PMA 
were carried out for 60 minutes, before measurement of the rate of 2 -deoxyglucose 
uptake. Given th a t the maximum increase in DAG accumulation occurs by 10-minutes 
in response to PDGF and by 60 minutes in response to PMA, this should be sufficient 
time to allow for any relevant activation of PKC.
In each case, in the control cells the rate of 2-deoxyglucose uptake increased in response 
to insulin, PDGF and PMA. However, after down-regulation or inhibition of PKC, the 
rate of 2-deoxyglucose uptake increased in response to 1 pM insulin and 25 ng/ml PDGF, 
but did not change in response to 100 nM PMA {Tables 4.2 and 4.3}. Therefore, these 
results suggest th a t PKC is not necessary for the early phase of insulin- or PDGF- 
stimulated glucose transport, but that it is necessary for the early phase of PMA- 
stimulated glucose transport.
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In agreement with the results presented here, other studies of the early phase of growth 
factor-stimulated glucose transport have shown th a t the down-regulation of PKC has no 
effect on the rate of 3-O-methylglucose transport in response to insulin, EGF, FGF and 
PDGF in Swiss 3T3 fibroblasts [Kitagawa et al., 1986; Kitagawa et al., 1989], or on the 
rate of 2-deoxyglucose uptake in BC3H-1 myocytes [Standaert et al., 1988].
However, Farese and colleagues observe partial inhibition of insulin-stimulated glucose 
transport BC3H-1 myocytes, ra t adipocytes and soleus muscle treated with PKC 
inhibitors [Ishizuka et al., 1990; Standaert et al., 1990]. Therefore, they suggest tha t 
insulin-stimulated glucose transport is mediated by a PKC-dependent pathway. In this 
work, the PKC inhibitors used were polymyxin B, staurosporine, H-7, and sangivamycin.
The indolocarbazole, staurosporine is a bacterial metabolite which is a non-selective 
protein kinase inhibitor. The IC5 0  values for ra t brain PKC, bovine h eart cyclic AMP- 
dependent protein kinase and ra t brain calcium/ calmodulin-dependent protein kinase 
for staurosporine are 0.1 pM, 0.12 pM and 0.04 pM respectively [Davis et al., 1989]. 
Staurosporine also inhibits the PDGF receptor tyrosine protein kinase with an IC5 0  
value of 0.02 pM [Secrist et al., 1990], therefore staurosporine is a general protein 
kinase inhibitor. Furthermore, staurosporine effects cell morphology, causing cells to 
round up and to detach from plate within 1  hour, consistent with staurosporine being a 
general protein kinase inhibitor [Susa et al., 1992]. Thus, loss of an ligand-stimulated 
response after treatm ent of cells with staurosporine does not necessarily imply th a t PKC 
is necessary for tha t response to occur.
H-7, is a isoquinoline-sulphonamide derivative which prevents ATP binding to PKC. 
However, H -7 only partially inhibits PKC activity and has no effect on some PKC 
mediated events [Susa et al., 1992]. Therefore, loss of an ligand-stimulated response 
after treatm ent of cells with H-7 also does not necessarily imply th a t PKC is necessary 
for tha t response to occur.
Ro 31-8220 is a bisindolylmaleimide derivative of staurosporine. I t is a more potent 
inhibitor of PKC and shows a higher selectivity for PKC. The in vitro IC5 0  values of rat 
brain PKC, bovine heart cyclic AMP-dependent protein kinase and ra t brain calcium/ 
calmodulin-dependent protein kinase for Ro 31-8220 are 0.01 pM; 1.5 pM and 17 pM
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respectively [Davis et al., 1989]. Ro 31-8220 can penetrate the cell and prevent PKC- 
mediated effects. The in vivo IC5 0  values of PMA-stimulated phosphorylation of pp47 in 
platelets and inhibition of CD3 down-regulation for Ro 31-8220 are 0.7 pM and 0.5 pM 
respectively [Davis et al., 1989]. Ro 31-8220 shows a slight selectivity for PKC-a over 
PKC -131, PKC-J3II, PKC-y or PKC-e, but not enough to differentiate between the different 
isozymes. The effects on PKC- 8  and PKC-£ are not yet known [Wilkinson et al., 1993].
In order to establish the dependence of a process on PKC, it is necessary to use an 
inhibitor specific for this enzyme, such as the bisindolylmaleimide described. 
Staurosporine and H-7 are not appropriate for such studies. Therefore, the results 
presented in this thesis suggest that PKC-a, PKC-fil, PKC-J3II, PKC-y and PKC-e are not 
involved in the early phase of insulin- or PDGF-stimulated glucose transport in 3T3-L1 
fibroblasts.
4.3.4 The basal rate of glucose transport
Down-regulation of PKC causes a significant increase in the basal rate of 2-deoxyglucose 
uptake {Table 4.2}. A similar increase in the basal rate of 2 -deoxyglucose uptake has 
also been observed in 3T3-L1 adipocytes [Gibbs et al., 1991] and BC3H-1 myocytes 
[Standaert et al., 1988]. It is possible tha t PKC inhibits the basal rate of glucose 
transport in resting cells, and tha t down-regulation of PKC removes this inhibition. 
Therefore, incubation in a PKC inhibitor should also cause an increase in the basal rate 
of 2-deoxyglucose uptake. However, incubation of 3T3-L1 fibroblasts in the PKC 
inhibitor, Ro 31-8220 had no effect on the basal rate of 2-deoxyglucose uptake {Table 
4.3}, suggesting tha t this is not the case.
It is also possible tha t depletion of PKC does not occur immediately in response to a long 
incubation in a high concentration of a phorbol ester and so, initially, the phorbol ester 
stimulates PKC activity and various PMA-stimulated effects occur, for example, an 
increase in the total G lutl level. Analysis of the total G lutl level by W estern blotting of 
3T3-L1 fibroblast lysates prepared from control cells and from PKC-deficient cells 
showed th a t the basal total G lutl level was higher in PKC-deficient cells than in control 
cells {Figure 4.6}. This is in agreement with studies of G lutl levels in 3T3-L1 
adipocytes, where G lutl level was approximately two fold higher after down-regulation
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of PKC [Gibbs et al., 1991], Furthermore, preliminary work showed th a t the increase in 
the basal rate of 2-deoxyglucose transport observed after down-regulation of PKC was 
abolished by incubating the 3T3-L1 fibroblasts in the PKC inhibitor, Ro 31-8220, before 
incubation in the phorbol esters (results not shown).
Therefore, the increase in the basal rate of 2-deoxyglucose uptake observed after down- 
regulation of PKC arises because depletion of PKC does not occur immediately on 
incubation in a high concentration of a phorbol ester. Consequently, during the early 
part of the incubation, the phorbol ester can stimulate the activation of PKC, leading to, 
among other things, an increase in the total G lutl level and consequently an increase in 
the basal rate of glucose transport.
4.3.5 Summary
The results presented suggest that in 3T3-L1 fibroblasts PKC is not necessary for the 
early phase of either insulin- or PDGF-stimulated glucose transport, but th a t it is 
necessary for the early phase of PMA-stimulated glucose transport. In addition, these 
results show that PDGF and PMA each stimulate DAG accumulation, and PKC activity 
in 3T3-L1 fibroblasts, while insulin does not. Furthermore, the increase in the basal 
rate of 2-deoxyglucose transport observed after down-regulation of PKC occurs due to an 
increase in the total G lutl level.
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The activation of MAPK in 3T3-L1 fibroblasts
5.1 Introduction
The growth factors, insulin and PDGF, and the tumour promoter, PMA, have similar 
effects on the rate of glucose transport in 3T3-L1 fibroblasts {Sections 3.2.2 and 3.2.3}, 
therefore, it is possible tha t the intracellular signal transduction pathways tha t mediate 
these effects are similar. The role of signal transduction pathways involving DAG and 
PKC have been examined with respect to the early phase of growth factor-stimulated 
glucose transport. DAG and PKC appear to be unnecessary {Section 4.3}. Mitogen- 
activated protein kinases (MAPKs) are activated in response to many growth factors, 
therefore, it is possible tha t the early phase of growth factor-stimulated glucose 
transport may be mediated by a signal transduction pathway involving MAPK 
Therefore, the effects of insulin and PDGF on the activation of MAPK were investigated.
5.1.1 Mitogen-activated protein kinases 
The mammalian isozymes
The MAPK isozymes, also known as extracellular signal-regulated kinase (ERK), are a 
group of serine/ threonine protein kinases tha t are activated in response to many 
ligands [Sturgill and Wu, 1991]. These include ligands which bind to tyrosine protein 
kinase receptors, such as FGF, and those which bind to G protein-coupled receptors, 
such as thrombin [Kahan et al., 1992].
There are several mammalian MAPK isozymes, the two best characterised being, 
p4 2 mapk ( p42 MAPK or ERK2) and p44maPk (p44 MAPK or ERK1) [Boulton et al.,
1990; Boulton et al., 1991]. The MAPK isozymes are unique in th a t they are the only 
serine/ threonine protein kinase known to require both threonine and tyrosine 
phosphorylation for their activation [Anderson et al., 1990]. The phosphorylation sites 
have been identified as Thr-183 and Tyr-185 in p42maPk . The threonine and tyrosine 
residues are separated by a single glutamate residue; the Thr-Glu-Tyr motif lies 13 
amino acids upstream of the Ala-Pro-Glu motif common to all protein kinases [Nishida 
and Gotoh, 1993]. The sequence of amino acids containing the Thr-Glu-Tyr motif and 
the Ala-Pro-Glu motif is highly conserved between all known MAPK isozymes [Nishida 
and Gotoh, 1993].
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Activation of the MAPK isozymes is catalysed by a single serine/ threonine/ tyrosine 
protein kinase known as MAPK kinase (MAPKK) or MAPK/ ERK kinase (MEK) {Section 
5.1.2} [Nakielny et al., 1992a,b; Rossomando et al., 1992; Wu et al., 1992; Kosako et al.,
1993].
Substrates
MAPK catalyses the in vitro phosphorylation of many proteins. The consensus sequence 
for phosphorylation by MAPK is Pro-Xaa-Ser/ Thr-Pro, where Xaa is a neutral or basic 
residue [Davis, 1993]. However, other kinases, including GSK-3 and cyclin-dependent 
protein kinases, also preferentially catalyse the phosphorylation of serine and threonine 
residues in proline-rich regions [Alvarez et al., 1991].
MAPK catalyses the in vitro phosphorylation of several proteins tha t function as 
transcription factors [Hunter and Karin, 1992]. These include, c-Jun [Alvarez et al., 
1991; Pulverer et al., 1991], c-Myc [Seth et al., 1992], p6 2 ^CF (Elk-1) [Gille et al., 1992; 
Marais et al., 1993], NF-IL6 (C/EBPJ3) [Nakajima et al., 1993], and ATF-2 [Abdel-Hafiz 
et al., 1992].
One of the early events of the cell cycle is a rapid increase in the expression of 
immediate-early genes, for example c-fos,c-jun and c-myc [Greenberg and Ziff, 1984; 
Stumpo and Blackshear, 1986]. The increase in the rate of transcription of these genes 
occurs independently of protein synthesis, therefore, it is regulated by the modification 
of the activity of existing transcription factors [Almendral et al., 1988]. The growth 
factor-stimulated transcription of the immediate-early genes may be mediated by a 
MAPK signal transduction pathway, since MAPK catalyses the in vitro phosphorylation 
of several transcription factors and at least one isoform of MAPK moves rapidly to the 
nucleus in response to serum [Seth et al., 1992].
MAPK catalyses the phosphorylation of several protein kinases. These include the 
90 kDa S6 kinases (p90rsk) [Nguyen et al., 1993], MAPK-activated protein kinase-1 
(MAPKAP kinase-1) [Lavoinne et al., 1991], and MAPK-activated protein kinase-2 
(MAPKAP kinase-2) [Stokoe et al., 1992a].
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The p90rsk isozymes are a group of serine/ threonine protein kinases tha t catalyse the 
phosphorylation of the ribosomal protein S6, a component of the eukaryotic 40 S subunit 
[Erikson and Mailer, 1986]. Phosphorylation of S6 occurs when quiescent cells re-enter 
the cell cycle [Sturgill and Wu, 1991], and is thought to have a role in the regulation of 
protein synthesis during the cell cycle [Thomas et al., 1982]. Activation of p90rs^by 
MAPK is rapid, but transient [Ballou et al., 1991].
MAPKAP kinase-1, previously known as insulin-stimulated protein kinase-1 (ISPK1), is 
a mammalian skeletal muscle p90rs^ homologue [Lavoinne et al., 1991]. It is part of the 
signal transduction pathway that mediates insulin-stimulated glycogen synthesis. 
MAPKAP kinase-1 catalyses the phosphorylation of the regulatory subunit of the 
glycogen-associated protein phosphatase-1 (PP Iq) [Dent et al., 1990] and GSK-36 
[Sutherland et al., 1993]. The phosphorylation of P P Ig  leads to its activation, and 
therefore to the dephosphorylation and activation of glycogen synthase and the 
dephosphorylation and inactivation of phosphorylase kinase [Dent et al., 1990]. The 
phosphorylation of GSK-36 leads to its inactivation, and therefore, also to the 
dephosphorylation and inactivation of glycogen synthase [Sutherland et al., 1993].
MAPKAP kinase-2 is another mammalian skeletal muscle serine/ threonine protein 
kinase th a t is a in vitro substrate for p42mapk [Stokoe et al., 1992a]. The function of 
MAPKAP kinase-2 is unknown; it catalyses the phosphorylation of the heat shock 
proteins Hsp25, and Hsp27 [Stokoe et al., 1992b].
MAPKs catalyse the in vitro phosphorylation of several cytoskeletal proteins. These 
include microtubule-associated protein-2 [Ray and Sturgill, 1987], myelin basic protein 
[Erickson et al., 1990], and Tau [Drewes et al., 1992]. The phosphorylation of 
cytoskeletal proteins may regulate the reorganisation of the cytoskeleton which is 
observed during the cell cycle.
MAPKs catalyse the in vitro phosphorylation of several membrane proteins and 
membrane-associated proteins. These include the EGF receptor [Northwood et al.,
1991] and the 85 kDa cytosolic PLA2  [Lin et al., 1993; Nemenoff et al., 1993]. MAPK- 
catalysed phosphorylation of the EGF receptor is thought to regulate its internalisation 
and intrinsic tyrosine protein kinase activity [Northwood et al., 1991]. MAPK-catalysed
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phosphorylation of PLA2  is thought to stimulate its activity [Lin et al., 1993; Nemenoff 
et al., 1993].
Therefore, MAPK catalyses the in vitro phosphorylation of many proteins, including 
transcription factors, protein kinases, cytoskeletal proteins, and membrane proteins. 
Many of these could have important roles in cell proliferation.
Inactivation
The activation of the mammalian MAPK isozymes is transient under many conditions, 
therefore, their inactivation must be rapid. However, much less is known about the 
inactivation of MAPK.
Several protein tyrosine/ threonine phosphatases tha t are specific for MAPK have been 
identified recently. These phosphatases include the protein products of the human 
genes, CL100 (mouse homologue, 3HC134/erp), HVH1 and PAC1 [Alessi et al., 1993; 
Nebreda, 1994; Ward et al., 1994] These are immediate-early genes [Charles et al.,
1992; Rohan et al., 1993], their expression being induced in response to the same growth 
factors that stimulate MAPK activity. Since, many of the potential substrates of MAPK 
are transcription factors, it is possible that the induction of these phosphatases could be 
regulated by the MAPK cascade, thus providing a negative feedback mechanism [Alessi 
et al., 1993; Nebreda, 1994]. In addition, PAC1, which is predominantly expressed in 
haematopoietic tissues, is localised to the nucleus in growth factor-stimulated cells 
[Rohan et al., 1993], suggesting that PAC1 may have a role in the regulation of nuclear 
events [Ward et al., 1994].
Other protein phosphatases can inactivate MAPK in vitro by the selective 
dephosphorylation of either the tyrosine or the threonine residue. For example, the 
dephosphorylation of the threonine residue by protein phosphatase 2A (PP2A) or of the 
tyrosine residue by a protein tyrosine phosphatase, CD45, leads to inactivation of MAPK 
[Anderson et al., 1990; Gomez et al., 1990]. It is not known whether this is of 
physiological significance.
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5.1.2 MAPK kinase
Initially, it was thought tha t either the phosphorylation of the tyrosine and threonine 
residues in MAPK was catalysed by two separate protein kinases, tha t is a serine/ 
threonine protein kinase and a tyrosine protein kinase, or th a t the phosphorylation of 
one of the residues was catalysed by a single protein kinase, and the phosphorylation of 
the second residue occurred as a result of autophosphorylation. However, the use of 
kinase-inactive MAPK mutants showed tha t the phosphorylation of MAPK is catalysed 
by a single serine/ threonine/ tyrosine protein kinase, MAPKK, the only known example 
of a dual specificity protein kinase [Nakielny et al., 1992a,b; Rossomando et al., 1992; 
Wu et al., 1992; Kosako et al., 1993]. MAPKK isozymes from several organisms have 
been purified and cloned. The molecular masses range from 45 to 50 kDa [Nakielny et 
al., 1992a; Kosako et al., 1993; Zheng and Guan, 1993]. The only known substrate of 
MAPKK is MAPK [Nakielny et al., 1992a,b].
MAPKK is activated by serine/ threonine phosphorylation [Nakielny et al., 1992a; 
Rossomando et al., 1992; Kosako et al., 1993; Matsuda et al., 1993]. In mammalian cells 
MAPKK phosphorylation is catalysed by three serine/ threonine protein kinases, Raf-1 
(p7 4 ra/‘-l) [Howe et al., 1992; Kyriakis et al., 1992], MAPKK kinase (MAPKKK) [Lange- 
Carter et al., 1993] and Mos (p39mos) [Posada et al., 1993]. The role of p74m/11 and 
MAPKKK are discussed in this chapter, p39mos is not expressed in somatic cells and 
therefore will be discussed later {Section 6.1.2}.
The phosphorylation of MAPKK is also catalysed by MAPK [Matsuda et al., 1993], 
however, this occurs on different serine/ threonine residues to those which are 
substrates for MAPKKK, suggesting tha t the phosphorylation of MAPKK by MAPK has 
either a negative or positive-feedback role [Matsuda et al., 1993].
5.1.3 p74raM
Tyrosine protein kinase receptors
The activation of p74m/ '1 and MAPK by ligands tha t bind to tyrosine protein kinase 
receptors requires Ras (p21ros), a small guanine nucleotide binding protein [Thomas et 
al., 1992; Wood et al., 1992]. There are three mammalian Ras isoforms, H-Ras, Ki-Ras,
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and N-Ras. These are all 21 kDa isoprenylated, membrane-associated proteins with a 
single high-affinity binding site for guanine nucleotides.
Guanine nucleotide-binding proteins cycle between an inactive GDP-bound form and an 
active GTP-bound form. Their activity is controlled by guanine nucleotide-releasing 
proteins (GNRPs) and GTPase-activating proteins (GAPs). GNRPs activate guanine 
nucleotide binding proteins by catalysing the release of GDP. Since the cellular 
concentration of GTP is higher than that of GDP, GTP preferentially binds to the empty 
guanine nucleotide binding site. GAPs inactivate guanine nucleotide-binding proteins 
by stimulating their normally low intrinsic GTPase activity so tha t GTP is hydrolysed to 
produce GDP [Hall, 1990; Bollag and McGdrmick, 1991].
The activity of p21ras is regulated by Sos (a GNRP) [Shou et al., 1992] and RasGAP (a 
GAP) [Trahey and McCormick, 1987] {Figure 5.1}. Activation of tyrosine protein kinase 
receptors stimulates p21ms activity by increasing the rate of guanine nucleotide 
exchange [Gibbs et al., 1990], but has no effect on the nucleotide exchange activity of Sos 
[Buday and Downward, 1993]. Instead, the rate of guanine nucleotide exchange is 
controlled by altering the intracellular location of Sos. In quiescent cells Sos, has little 
effect on p21ms activity, because it is cytosolic, while p21ms is always membrane- 
associated, however, after activation of a tyrosine protein kinase receptor, Sos associates 
with the receptor and so can stimulate p21ms activity [Buday and Downward, 1993; 
Egan et al., 1993; Gale et al., 1993; Rozakis-Adcock et al., 1993]. The growth factor- 
dependent association of Sos with the receptor, is mediated by Grb2, a 25 kDa protein, 
consisting of one SH2 domain and two Src homology-3 (SH3) domains [Koch et al.,
1991]. As previously described, after the activation of tyrosine protein kinase receptors, 
Grb2 binds to specific phosphotyrosine-containing sequences in the receptors or in IRS -1 
via the SH2 domain [Section 3.1.1}. Grb2 also binds to Sos, the interaction occurring 
between the SH3 domains of Grb2 and a proline-rich region in Sos {Figure 5.2} [Buday 
and Downward, 1993; Egan et al., 1993; Li et al., 1993; Rozakis-Adcock et al., 1993]. 
Consequently, Grb2-Sos complexes move from the cytosol to the membrane and p21ms 
activity increases in response to the activation of tyrosine protein kinase receptors 
[Buday and Downward, 1993; Egan et al., 1993; Gale et al., 1993; Rozakis-Adcock et al., 
1993].
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Figure 5.1 The activation of guanine nucleotide binding proteins
A schematic representation of receptor-mediated activation of a) p21ms and b) Gq, 
where the GNRPs are Sos and a G protein-coupled receptor, and the GAPs are RasGAP 
and PLC -13 respectively.
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(inactive)
GTP
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Figure 5.2 Signal transduction pathways leading to the activation of MAPK
A schematic representation of the activation of MAPK by ligands tha t bind to a) tyrosine 
protein kinase receptors and b) G protein-coupled receptors.
Ligand Ligand
Grb2) Sos
PLC-B
MAPKKK
MAPKK
T
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Active p21ras interacts directly with the amino-terminal regulatory domain of p74ra/-lj 
but does not stimulate the kinase activity of p74m/"1 in vitro [Moodie et al., 1993; Vojtek 
et al., 1993; Zhang et al., 1993]. However, after its activation, p74ra/"1 is associated 
with the plasma membrane, but not with p21ms, suggesting th a t the role of p21ras is to 
localise p74ra/-l to the plasma membrane where it is activated by another signal 
[Leevers and Marshall, 1992]. It is possible th a t plasma membrane-associated p74m/"1 
is activated by hyperphosphorylation or by a conformational change in proteins with 
which it is associated. The hyperphosphorylation of p74mf' 1 occurs in response to 
growth factors, however the kinase which catalyse the phosphorylation of p74m/ '1 is 
unknown [Morrison et al., 1988; Blackshear et al., 1990; Morrison et al., 1993]. In 
addition, p74raf~  ^ is found in a large complex of 300 to 500 kDa, in both quiescent and 
activated cells. Two other proteins in this complex are the heat shock protein, hsp90, 
and a 50 kDa protein often found in complexes with hsp90 [Wartmann and Davis, 1994]. 
The hsp90-p50 complex regulates the activity of other proteins with which it also 
associates, such as the glucocorticoid receptor and casein kinase II, and therefore may 
be involved in the regulation of p74m/11 activity [Wartmann and Davis, 1994].
Seven membrane-spanning domain receptors
The activation of p74m/-l and MAPK in response to ligands tha t bind to G protein- 
coupled receptors occurs by p21ras-dependent and -independent pathways. G proteins 
are another class of guanine nucleotide binding proteins tha t are similar to small 
guanine nucleotide binding proteins in that the GTP-bound form is active, while the 
GDP-bound form is inactive. However, G proteins are trimeric complexes, the a-subunit 
containing a single guanine nucleotide binding site and the GTPase. Nucleotide 
exchange is stimulated when a ligand binds to the G protein-coupled receptor, also 
causing the a-subunit to dissociate from the By-subunits. Certain G protein effectors, 
such as PLC-B, are thought to act as GAPs [Figure 5.1b] [Berstein et al., 1992].
The G protein-coupled receptors that stimulate p74ra/"1 and MAPK activity bind to 
members of the Gi and Gq families. The GTP-bound aq-subunit stimulates PLC-B 
activity, leading to the activation of PKC [Smrcka et al., 1991; Stemweis and Smrcka,
1992]. PKC catalyses the phosphorylation of p74m/ '1, but it is not known whether this 
affects p74ra "^1 activity [MacDonald et al., 1993]. In addition, PKC may also stimulate 
p2 i  ras activity, probably by stimulation of nucleotide exchange [Downward et al., 1990].
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The GTP-bound ai-subunit stimulates p21ms activity, probably by stimulation of 
nucleotide exchange [van Corven et al., 1993; Winitz et al., 1993].
The By-complex also stimulates the activities of PLC-B [Carozzi et al., 1993] and p21ras 
[Crespo et al., 1994]. The By-complex is thought to bind to the pleckstrin homology (PH) 
domain, which is found in many proteins including the B-adrenergic receptor kinase, 
PLC-B [Parker et al., 1994], Sos and RasGAP. The By-complex is thought to activate the 
B-adrenergic receptor kinase by interaction with its PH domain [Shaw, 1993], therefore, 
it is also possible th a t the activities of PLC-B and p21ras are regulated in a similar 
manner [Figure 5.2] [Parker et al., 1994; Touhara et al., 1994].
Inhibition ofp21ras and p74mf'1
The activity of p21ms may be reduced by stimulation of the activity of RasGAP [Trahey 
and McCormick, 1987]. After activation of tyrosine protein kinase receptors, RasGAP 
binds to specific phosphotyrosine-containing sequences in the receptors [Section 3.1.1], 
then undergoes tyrosine phosphorylation [Kazlauskas et al., 1990]. However, the 
physiological effect of growth factor-stimulated tyrosine phosphorylation of RasGAP 
remains uncertain [Gibbs et al., 1990],
MAPK also catalyses the in vitro phosphorylation of p74m/ 'l  [Lee et al., 1992], again 
this may have a negative or a positive-feedback role .
5.1.4 MAPK kinase kinase
MAPKKKs were initially isolated from yeasts which do not express p74m/"1 and p39mos. 
Recently several mammalian MAPKKK isozymes have been cloned from mice [Lange- 
Carter et al., 1993; Blumer and Johnson, 1994], Some of the mammalian MAPKKK 
isozymes are activated in response to growth factors; others may be activated in 
response to changes similar to those known to activate the yeast homologues, such as 
osmotic stress [Brewster, 1993].
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5.1.5 The relationship with cell proliferation
MAPK is thought to have an important role in cell proliferation, in particular in control 
of the GO to G1 transition. Virtually all growth factors rapidly stimulate the activity of 
one or more MAPK isozymes. For example, MAPK activity and cell proliferation 
increase in thrombin- and basic FGF-treated CCL39 cells [Kahan et al., 1992], foetal calf 
serum-treated Chinese ham ster ovary cells [Tamemoto et al., 1992] and EGF-treated 
PC 12 cells [Nguyen et al., 1993]. In addition, cells with defects in PMA-stimulated cell 
proliferation, also have defects in PMA-stimulated MAPK activity [L'Allemain et al.,
1991], and growth factor-stimulated MAPK activity and cell proliferation are inhibited 
by the expression of dominant-negative p74raf~  ^mutants [Kolch et al., 1991]. 
Furthermore, the mammalian MAPK isozymes have a high sequence identity with 
enzymes tha t are required for cell cycle control from S. cerevisiae and 
Schizosaccharomyces pombe [Errede and Levin, 1993].
However, MAPK is also activated by many non-proliferative signals [Wood et al., 1992] 
suggesting tha t MAPK may not be sufficient for cell proliferation. In addition, 
transformation does not always stimulate MAPK activity, for example, MAPK activity is 
not affected by the transformation of Rat 1 fibroblasts with v-ras or v-raf [Gupta et al.,
1992], or of Swiss 3T3 fibroblasts with v-myc [Howe et al., 1992], suggesting th a t MAPK 
may not be necessary for the stimulation of cell proliferation. This also suggests tha t 
there may be cell-specific expression of some components of the signal transduction 
pathways tha t mediate the activation of MAPK
Therefore, although the MAPK is activated in response to many growth factors th a t also 
stimulate cell proliferation it is not clear whether MAPK itself is necessary or sufficient 
for cell proliferation. However, MAPK may be sufficient to stimulate some of the early 
events of cell proliferation.
5.1.6 The relationship with glucose transport
Since the early phase of growth factor-stimulated glucose transport is an early event of 
the cell cycle, it is possible tha t it could be mediated by a signal transduction pathway 
involving the activation of MAPK. When this work was initiated, there was little
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evidence in support or against this hypothesis. Given th a t MAPK appears to be 
important with respect to cell proliferation, it was necessary to investigate the 
possibility that MAPK may mediate the early phase of growth factor-stimulated glucose 
transport.
In order to examine whether the early phase of growth factor-stimulated glucose 
transport is mediated by a signal transduction pathway involving MAPK, several 
approaches were taken. Firstly, the effects of insulin and PDGF on tyrosine 
phosphorylation in 3T3 -LI fibroblasts and the requirement for PKC activity were 
established. Secondly, the effects of insulin and PDGF on MAPK activity in 3T3 -LI 
fibroblast and the requirement for PKC activity were established.
5.2 Results
5.2.1 The effect of growth factors on tyrosine phosphorylation
The effect of insulin and PDGF on tyrosine phosphorylation was established by Western 
blotting of cellular proteins. Lysates were prepared from 3T3-L1 fibroblasts after 
incubation in 1 pM insulin or 25 ng/ml PDGF {Section 2.13.2}. The proteins were 
separated by SDS-PAGE {Section 2.15}, and then transferred onto nitrocellulose 
membranes. The membranes were probed with a rabbit anti-phosphotyrosine antibody 
[Pang et al., 1985], and then with a HRP-conjugated donkey anti-rabbit IgG antibody. 
The antibody binding sites were visualised using an ECL detection system {Section 
2.16.2}.
The anti-phosphotyrosine antibody recognised proteins with approximate molecular 
masses ranging from 30 to 200 kDa in lanes containing the untreated 3T3-L1 fibroblast 
lysate samples. A representative Western blot is shown in Figure 5.3.
During a 60 minute incubation in 1 pM insulin there were large increases in the 
tyrosine phosphorylation of proteins with approximate molecular masses of 42, 44, 120 
and 166 kDa, and small increases in the tyrosine phosphorylation of a protein with an 
approximate molecular mass of 60 kDa and of several proteins with approximate
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Figure 5.3 A time course for insulin-stimulated tyrosine phosphorylation
After incubation of quiescent 3T3-L1 fibroblasts with 1 pM insulin for the times shown, 
lysates were prepared {Section 2.13.2}. Approximately 30 pg of protein was loaded 
onto 10% (w/v) polyacrylamide large gels, the proteins were separated by SDS-PAGE 
(Section 2.15}, and then transferred onto nitrocellulose membranes. The membranes 
were probed with a rabbit anti-phosphotyrosine antibody, and then with a HRP- 
conjugated donkey anti-rabbit IgG antibody. The sites of antibody binding were 
visualised using an ECL detection system {Section 2.16.2}. This is a representative 
Western blot from a group of two lysate preparations.
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molecular masses of 90 to 120 kDa. The tyrosine phosphorylation of the 42 and 44 kDa 
proteins increased within 2 minutes of exposure to insulin and reached a maximum by 
5 minutes. The tyrosine phosphorylation of the 90 to 120 kDa proteins increased within 
1 minute of exposure to insulin and was still elevated by 60 minutes. The tyrosine 
phosphorylation of the 166 kDa protein increased within 1 minute of exposure to 
insulin, was still elevated by 20 minutes, and then decreased. Other phosphotyrosine - 
containing proteins were observed, but the bands were too faint or blurred to determine 
if there were any changes {Figure 5.3}.
During a 60 minute incubation in 1 pM IGF -I, the changes in tyrosine phosphorylation 
were similar to those observed in response to insulin. A representative Western blot is 
shown in Figure 5.4.
During a 60 minute incubation in 25 ng/ml PDGF there were large increases in the 
tyrosine phosphorylation of proteins with approximate molecular masses of 42, 44, 120, 
155 and 190 kDa and a small increase in the tyrosine phosphorylation of a protein with 
an approximate molecular mass of 170 kDa. The tyrosine phosphorylation of the 42 and 
44 kDa proteins increased within 2 minutes of exposure to PDGF and reached a 
maximum by 5 minutes. The tyrosine phosphorylation of the 120, 155, 170 and 190 kDa 
proteins increased within 1 minute of exposure to PDGF, was still elevated by 
30 minutes, and decreased nearly to basal levels by 60 minutes. Other phosphotyrosine - 
containing proteins were observed, but the bands were too faint or blurred to determine 
if there were any changes. A representative Western blot is shown in Figure 5.5.
The effect of insulin and PDGF on tyrosine phosphorylation was also examined by 
Western blotting of membrane proteins. Membrane proteins were prepared from 3T3-L1 
fibroblasts after incubation in 1 pM insulin or 25 ng/ml PDGF {Section 2.13.1}. The 
proteins were separated by SDS-PAGE {Section 2.15}, and then transferred onto 
nitrocellulose membranes. The membranes were probed with the rabbit anti- 
phosphotyrosine antibody, and then with the HRP-conjugated donkey anti-rabbit IgG 
antibody. The antibody binding sites were visualised using an ECL detection system 
{Section 2.16.2}.
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Figure 5.4 A time course for IGF-l-stimulated tyrosine phosphorylation
After incubation of quiescent 3T3-L1 fibroblasts with 1 pM IGF-I for the times shown, 
lysates were prepared (Section 2.13.2}. Approximately 30 pg of protein was loaded 
onto 10% (w/v) polyacrylamide large gels, the proteins were separated by SDS-PAGE 
(Section 2.15}, and then transferred onto nitrocellulose membranes. The membranes 
were probed with a rabbit anti-phosphotyrosine antibody, then with a HRP-conjugated 
donkey anti-rabbit IgG antibody. The antibody binding sites were visualised using an 
ECL detection system (Section 2.16.2}. This is a representative Western blot from a 
group of two lysate preparations.
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Figure 5.5 A time course for PDGF-stimulated tyrosine phosphorylation
After incubation of quiescent 3T3-L1 fibroblasts with 25 ng/ml PDGF for the times 
shown, lysates were prepared {Section 2.13.2}. Approximately 30 pg of protein was 
loaded onto 10% (w/v) polyacrylamide large gels, the proteins were separated by SDS- 
PAGE {Section 2.15}, and then transferred onto nitrocellulose membranes. The 
membranes were probed with a rabbit anti-phosphotyrosine antibody, then with a 
HRP-conjugated donkey anti-rabbit IgG antibody. The antibody binding sites were 
visualised using an ECL detection system {Section 2.16.2}. This is a representative 
Western blot from a group of two lysate preparations.
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The anti-phosphotyrosine antibody recognised proteins with approximate molecular 
masses of 42, 44, and 60 kDa in lanes containing untreated 3T3-L1 fibroblast membrane 
protein samples. A representative Western blot is shown in Figure 5.6.
During a 10 minute incubation in 1 (iM insulin there were large increases in the 
tyrosine phosphorylation of membrane proteins with approximate molecular masses of 
20, 42, and 44 kDa and small increases in the tyrosine phosphorylation of membrane 
proteins with approximate molecular masses of 60 and 90 kDa. The tyrosine 
phosphorylation of the 42, 44, 60, 90 and 190 kDa proteins increased by 2 minutes of 
exposure to insulin and was still evident by 10 minutes. The tyrosine phosphorylation of 
the 20 kDa protein increased by 2 minutes of exposure to insulin and deceased to basal 
levels by 10 minutes. Other phosphotyrosine-containing proteins were observed, but the 
bands were too faint or blurred to determine if there were any changes {Figure 5.6}.
During a 10 minute incubation in 25 ng/ml PDGF there were large increases in the 
tyrosine phosphorylation of membrane proteins with approximate molecular masses of 
20, 42, 44 and 190 kDa and small increases in the tyrosine phosphorylation of 
membrane proteins with approximate molecular masses of 60 and 155 kDa. Tyrosine 
phosphorylation of the 42, 44 and 190 kDa proteins increased by 2 minutes of exposure 
to PDGF and was still evident by 10 minutes. Tyrosine phosphorylation of the 20 kDa 
protein increased by 2 minutes of exposure to PDGF and deceased to basal levels by 
10 minutes. Other phosphotyrosine-containing proteins were observed, but the bands 
were too faint or blurred to determine if there were any changes {Figure 5.6}.
5.2.2 The effect of a tumour promoter on tyrosine phosphorylation
The effect of PMA on tyrosine phosphorylation was established by Western blotting of 
cellular proteins. Lysates were prepared from 3T3-L1 fibroblasts after incubation in 
100 nM PMA {Section 2.13.2}. The proteins were separated by SDS-PAGE {Section 
2.15}, and then transferred onto nitrocellulose membranes. The membranes were 
probed with the rabbit anti-phosphotyrosine antibody, and then with the HRP- 
conjugated donkey anti-rabbit IgG antibody. The antibody binding sites were visualised 
using an ECL detection system {Section 2.16.2}.
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Figure 5.6 The effect of PDGF and insulin on the tyrosine phosphorylation of
membrane proteins
After incubation of quiescent 3T3-L1 fibroblasts with 25 ng/ml PDGF or 1 pM insulin, 
for the times shown, membrane proteins were prepared {Section 2.13.1}.
Approximately 20 pg of protein was loaded onto 10% (w/v) polyacrylamide large gels, 
the proteins were separated by SDS-PAGE {Section 2.15}, and then transferred onto 
nitrocellulose membranes. The membranes were probed with an anti-phosphotyrosine 
antibody, then with a HRP-conjugated donkey anti-rabbit IgG antibody. The antibody 
binding sites were visualised using an ECL detection system {Section 2.16.2}. This is a 
representative Western blot from a group of two membrane protein preparations.
Lane A: basal; lane B: 2 minutes insulin; lane C: 10 minutes insulin; lane D: 2 minutes 
PDGF; lane E: 10 minutes PDGF.
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The anti-phosphotyrosine antibody recognised proteins with approximate molecular 
masses ranging from 30 to 200 kDa in lanes containing untreated 3T3 -LI fibroblast 
lysate samples. During a 60 minute incubation in 100 nM PMA there were large 
increases in the tyrosine phosphorylation of proteins with approximate molecular 
masses of 42, 44, 90 and 120 kDa and a small increase in the tyrosine phosphorylation of 
a protein with an approximate molecular mass of 60 kDa. The tyrosine phosphorylation 
of the 42 and 44 kDa proteins increased within 2 minutes of exposure to PMA and 
reached a maximum by 5 minutes. Other phosphotyrosine-containing proteins were 
observed, but the bands were too faint or blurred to determine if there were any 
changes. A representative Western blot is shown in Figure 5.7.
5.2.3 The effect of PKC on the pattern of tyrosine phosphorylation
The effect of PKC on the patterns of insulin-, PDGF- and PMA-stimulated tyrosine 
phosphorylation was established by Western blotting of cellular proteins. Lysates were 
prepared from 3T3-L1 fibroblasts treated with 1 pM insulin, 25 ng/ml PDGF or 100 nM 
PMA {Section 2.13.2}, after down-regulation of PKC {Section 2.11}. The proteins were 
separated by SDS-PAGE {Section 2.15}, and then transferred onto nitrocellulose 
membranes. The membranes were probed with the rabbit anti-phosphotyrosine 
antibody, and then with the HRP-conjugated donkey anti-rabbit IgG antibody. The 
antibody binding sites were detected using an ECL detection system {Section 2.16.2}.
Again, the anti-phosphotyrosine antibody recognised proteins with approximate 
molecular masses ranging from 30 to 200 kDa in lanes containing untreated 3T3-L1 
fibroblast lysate samples.
The patterns of tyrosine phosphorylation observed in response to 1 pM insulin after a 
16 hour incubation in 1 pM 4a-PDD or in 1 pM PMA were similar. During a 60 minute 
incubation in 1 pM insulin there were large increases in the tyrosine phosphorylation of 
proteins with approximate molecular masses of 42, 44, 120 and 166 kDa, and small 
increases in the tyrosine phosphorylation of a protein with an approximate molecular 
mass of 60 kDa and of a group of proteins with approximate molecular masses of 90 to 
120 kDa. A representative Western blot is shown in Figure 5.8.
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Figure 5.7 A time course for PMA-stimulated tyrosine phosphorylation
After incubation of quiescent 3T3-L1 fibroblasts with 100 nM PMA for the times 
shown, lysates were prepared {Section 2.13.2}. Approximately 30 pg of protein was 
loaded onto 10% (w/v) polyacrylamide large gels, the proteins were separated by SDS- 
PAGE {Section 2.15), and then transferred onto nitrocellulose membranes. The 
membranes were probed with a rabbit anti-phosphotyrosine antibody, then with a 
HRP-conjugated donkey anti-rabbit IgG antibody. The antibody binding sites were 
visualised using an ECL detection system {Section 2.16.2}. This is a representative 
Western blot from a group of two lysate preparations.
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Figure 5.8 A time course for insulin-stimulated tyrosine phosphorylation, after the
down-regulation of PKC
After incubation of quiescent 3T3-L1 fibroblasts with a) 1 pM 4a-PDD or b) 1 pM PMA 
for 16 hours (Section 2.11}, then with 1 pM insulin for the times shown, lysates were 
prepared (Section 2.13.2}. Approximately 30 pg of protein was loaded onto 10% (w/v) 
polyacrylamide large gels, the proteins were separated by SDS-PAGE (Section 2.15}, 
and then transferred onto nitrocellulose membranes. The membranes were probed 
with a rabbit anti-phosphotyrosine antibody, then with a HRP-conjugated donkey anti­
rabbit IgG antibody. The sites of antibody binding were visualised using an ECL 
detecton system (Section 2.16.2}. This is a Western blot from a group of two lysate 
preparations.
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The patterns of tyrosine phosphorylation observed in response to 25 ng/ml PDGF after a 
16 hour incubation in 1 pM 4a-PDD or in 1 pM PMA were similar. During a 60 minute 
incubation in 25 ng/ml PDGF there were large increases in the tyrosine phosphorylation 
of proteins with approximate molecular masses of 42, 44, 120, 155 and 190 kDa and 
small increases in the tyrosine phosphorylation of proteins with approximate molecular 
masses of 60 and 170 kDa. A representative Western blot is shown in Figure 5.9.
The patterns of tyrosine phosphorylation observed in response to 100 nM PMA after a 
16 hour incubation in 1 pM 4a-PDD or in 1 pM PMA were different. After the 16 hour 
incubation in 1 pM 4a-PDD, there were large increases in the tyrosine phosphorylation 
of proteins with approximate molecular masses of 42, 44, 90 and 120 kDa and a small 
increase in the tyrosine phosphorylation of a protein with an approximate molecular 
mass of 60 kDa. After the 16 hour incubation in 1 pM PMA, there were large increases 
in the tyrosine phosphorylation of proteins with approximate molecular masses of 90 
and 120 kDa and a small increase in the tyrosine phosphorylation of a protein with an 
approximate molecular mass of 60 kDa. However, there was no change in the tyrosine 
phosphorylation of the 42 and 44 kDa proteins. A representative Western blot is shown 
in Figure 5.10.
5.2.4 The effect of growth factors on MAPK activity
The effect of insulin, PDGF and PMA on the mobility of MAPK during SDS-PAGE was 
examined by Western blotting of cellular proteins. Lysates were prepared from 3T3-L1 
fibroblasts after incubation in 1 pM insulin, 25 ng/ml PDGF or 100 nM PMA {Section 
2.13.2}. The proteins were separated by SDS-PAGE {Section 2.15}, and then transferred 
onto nitrocellulose membranes. The membranes were probed with a mouse anti-MAPK 
antibody, and then with a HRP-conjugated sheep anti-mouse IgG antibody. The 
antibody binding sites were visualised using an ECL detection system {Section 2.16.2}.
The anti-MAPK antibody recognised proteins with approximate molecular masses of 
42 kDa (p42maPk) and 44 kDa (p44maP^) in all 3T3-L1 fibroblast lysate samples. The 
electrophoretic mobility of both isozymes decreased in response to 1 pM insulin,
25 ng/ml PDGF and 100 nM PMA. However, the decrease in the mobility of p44maPk 
was typically less pronounced than the decrease in the mobility p42maPk. The decrease
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Figure 5.9 A time course for PDGF-stimulated tyrosine phosphorylation, after the
down-regulation of PKC
After incubation of quiescent 3T3-L1 fibroblasts with a) 1 pM 4a-PDD or b) 1 pM PMA 
for 16 hours (Section 2.11}, and then with 25 ng/ml PDGF for the times shown, lysates 
were prepared (Section 2.13.2}. Approximately 30 pg of protein was loaded onto 10% 
(w/v) polyacrylamide large gels, the proteins were separated by SDS-PAGE (Section 
2.15}, and then transferred onto nitrocellulose membranes. The membranes were 
probed with a rabbit anti-phosphotyrosine antibody, then with a HRP-conjugated 
donkey anti-rabbit IgG antibody. The antibody binding sites were visualised using an 
ECL detection system (Section 2.16.2}. This is a representative Western blot from a 
group of two lysate preparations.
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Figure 5.10 A time course for PMA-stimulated tyrosine phosphorylation, after the
down-regulation of PKC
After incubation of quiescent 3T3-L1 fibroblasts with a) 1 pM 4oc-PDD or b) 1 pM PMA 
for 16 hours {Section 2.11}, and then with 100 nM PMA for the times shown, lysates 
were prepared {Section 2.13.2}. Approximately 30 pg of protein was loaded onto 10% 
(w/v) polyacrylamide large gels, the proteins were separated by SDS-PAGE {Section 
2.15}, and then transferred onto nitrocellulose membranes. The membranes were 
probed with a rabbit anti-phosphotyrosine antibody, then with a HRP-conjugate donkey 
anti-rabbit IgG antibody. The antibody binding sites were visualised using an ECL 
detection system {Section 2.16.2}. This is a representative Western blot from a group of 
two lysate preparations.
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in mobility was observed within 1 minute of exposure to each of the ligands. 
Representative Western blots are shown in Figure 5.11.
The effect of PKC on insulin-, PDGF- and PMA-stimulated decreases in the 
electrophoretic mobility MAPK was established by Western blotting of cellular proteins. 
Lysates were prepared from 3T3-L1 fibroblasts treated with 1 pM insulin, 25 ng/ml 
PDGF or 100 nM PMA {Section 2.13.2}, after down-regulation of PKC {Section 2.11}.
The proteins were separated by SDS-PAGE {Section 2.15}, and then transferred onto 
nitrocellulose membranes. The membranes were probed with the anti-MAPK antibody, 
and then with the HRP-conjugated donkey anti-mouse IgG antibody. The antibody 
binding sites were visualised using an ECL detection system {Section 2.16.2).
After a 16 hour incubation in 1 pM 4a-PDD, the mobility of both p42maPk and p 4 4 m a P k  
during SDS-PAGE decreased in response to 1 pM insulin, 25 ng/ml PDGF and 100 nM 
PMA. After a 16 hour incubation in 1 pM PMA, the mobility of both isozymes during 
SDS-PAGE decreased in response to 1 pM insulin and 25 ng/ml PDGF but not in 
response to 1 pM PMA. Representative Western blots are shown in Figure 5.12.
5.2.5 The effect of growth factors and a tumour promoter on p125FAK
The effect of insulin, PDGF and PMA on the tyrosine phosphorylation of p l 2 5 FA^  was 
examined by Western blotting of immunoprecipitated phosphotyrosine proteins. Lysates 
were prepared from 3T3-L1 fibroblasts after incubation in 1 pM insulin, 25 ng/ml PDGF 
or 100 nM PMA. The phosphotyrosine proteins were immunoprecipitated using a rabbit 
anti-phosphotyrosine antibody {Section 2.13.3}. The immunoprecipitated proteins were 
separated by SDS-PAGE {Section 2.15}, and then transferred onto nitrocellulose 
membranes. The membranes were probed with a mouse an ti-p l2 5 FAK antibody, and 
then with the HRP-conjugated sheep anti-mouse IgG antibody. The antibody binding 
sites were visualised using an ECL detection system {Section 2.16.2}.
The anti-pl25FAK antibody recognised a protein with an approximate molecular mass of 
120 kDa in each lane containing 3T3-L1 fibroblast lysate samples. The tyrosine 
phosphorylation of this protein increased in response to 1 pM insulin, 25 ng/ml PDGF 
and 100 nM PMA. A representative Western blot is shown in Figure 5.13.
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Figure 5.11 Time courses for insulin-, PDGF- and PMA-stimulated activation of MAPK
After incubation of quiescent 3T3-L1 fibroblasts with A) 1 pM insulin, B) 25 ng/ml 
PDGF or C) 100 nM PMA for the times shown, lysates were prepared {Section 2.13.2}. 
Approximately 30 pg of protein was loaded onto 10% (w/v) polyacrylamide large gels, 
the proteins were separated by SDS-PAGE {Section 2.15}, and then transferred onto 
nitrocellulose membranes. The membranes were probed with a mouse anti-MAPK 
antibody, then with a HRP-conjugated sheep anti-mouse IgG antiboby. The sites of 
antibody binding were visualised using an ECL detection system {Section 2.16.2}. 
These are representative Western blots from groups of two lysate preparations.
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Figure 5.12 Time courses for insulin-, PDGF- and PMA-stimulated activation of
MAPK, after the down-regulation of PKC
After incubation of quiescent 3T3-L1 fibroblasts with a) 1 pM 4a-PDD or b) 1 pM PMA 
for 16 hours (Section 2.11}, and then with A) 1 pM insulin, B) 25 ng/ml PDGF or C)
100 nM PMA for the times shown, lysates were prepared (Section 2.13.2}. 
Approximately 30 pg of protein was loaded onto 10% (w/v) polyacrylamide large gels, 
the proteins were separated by SDS-PAGE (Section 2.15}, and then transferred onto 
nitrocellulose membranes. The membranes were probed with a mouse anti-MAPK 
antibody, then with a HRP-conjugated sheep anti-mouse IgG antibody. The antibody 
binding sites were visualised using an ECL detection system (Section 2.16.2}. These 
are representative Western blots from groups of two lysate preparations.
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Figure 5.13 The effect of insulin, PDGF and PMA on the tyrosine phosphorylation of 
p125FAK
After incubation of quiescent 3T3-L1 fibroblasts with 1 pM insulin, 25 ng/ml PDGF or 
100 nM PMA for the times shown, lysates were prepared and the phosphotyrosine- 
containing proteins were immunoprecipitated {Section 2.13.3). Approximately 33% of 
the sample (from a 10 cm plate) was loaded onto 10% (w/v) polyacrylamide mini-gels, 
the proteins were separated by SDS-PAGE {Section 2.15}, and then transferred onto 
nitrocellulose membranes. The membranes were probed with a mouse anti-pl25FA^  
antibody, then with a HRP-conjugated sheep anti-mouse IgG antibody. The antibody 
binding sites were visualised using an ECL detection system {Section 2.16.2}. This is a 
representative Western blot from a group of two lysate preparations.
Lane A: basal; lane B: 2 minutes insulin; lane C: 10 minutes insulin; lane D: 2 minutes 
PDGF; lane E: 10 minutes PDGF; lane F: 2 minutes PMA; lane G: 10 minutes PMA.
A B C D E F G
1 5 3
5.3 Discussion
In order to examine whether the early phase of growth factor-stimulated glucose 
transport is mediated by a signal transduction pathway involving MAPK, several 
approaches were taken. Firstly, the effects of insulin and PDGF on tyrosine 
phosphorylation and the requirement for PKC activity were established. Secondly, the 
effects of insulin and PDGF on MAPK activity and the requirement for PKC activity 
were established.
5.3.1 Phosphotyrosine-containing proteins
Western blotting of 3T3-L1 fibroblast lysate and membrane proteins with antibodies 
raised against phosphotyrosine, showed tha t the tyrosine phosphorylation of several 
proteins changed in response to all the ligands, whilst the tyrosine phosphorylation of 
other proteins changed in response to specific ligands only.
All ligands
Insulin, IGF-I, PDGF and PMA all stimulated an increase in the tyrosine 
phosphorylation of proteins with approximate molecular masses of 42 and 44 kDa in 
3T3-L1 fibroblasts. The tyrosine phosphorylation was transient, increasing within 
2 minutes of exposure to each ligand and reaching a maximum by 5 minutes {Figures 
5.3, 5.4, 5.5 and 5.7}. In addition, the tyrosine phosphorylation of proteins with 
approximate molecular masses of 42 and 44 kDa were increased in both membrane 
{Figure 5.6} and cytosolic preparations (results not shown). The molecular masses of 
these proteins suggest th a t they could be the mammalian MAPKs, p42maPk and 
P4 4 mapk {Section 5.1.1}.
Insulin, IGF-I, PDGF and PMA all also stimulated an increase in the tyrosine 
phosphorylation of a protein with an approximate molecular mass of 120 kDa in 3T3-L1 
fibroblasts. The tyrosine phosphorylation of this protein increased within 1 minute of 
exposure to each ligand, was still elevated by 30 minutes, then decreased nearly to basal 
levels by 60 minutes {Figures 5.3, 5.4, 5.5 and 5.7}. In addition, this phosphotyrosine 
protein was not seen in membrane samples {Figure 5.6}. There are several proteins,
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tha t have an approximate molecular mass of 120 kDa, tha t have a potential role in 
signal transduction. These include RasGAP and pl25^AK
RasGAP binds to a specific phosphotyrosine sequence in the PDGF B-receptor 
[Kashishian et al., 1992], and it undergoes tyrosine phosphorylation in response to 
PDGF [Kazlauskas et al., 1990]. However, it does not appear to bind to the insulin 
receptor or to IRS-1 [Sun et al., 1993a], therefore although RasGAP may be undergo 
tyrosine phosphorylation response to PDGF, it is unlikely to do so in response to insulin 
or IGF-I.
Activation of p l 2 5 ^AK occurs in response to integrin-mediated cell adhesion [Zachary 
and Rozengurt, 1992] and to the neuropeptide growth factors, bombesin, endothelin and 
vasopressin, which bind to G protein-coupled receptors [Zachary and Rozengurt, 1992; 
Schaller and Parsons, 1993]. However, the mechanism by which p l 2 5 ^ K  js activated 
by extracellular stimuli is unclear, since, p l 2 5 ^ ^  is activated by tyrosine 
phosphorylation, even though, the neuropeptide receptors and integrins have no 
intrinsic tyrosine kinase activity. There have been no previous reports of p l 2 5 ^AK 
activation in response to ligands that bind to tyrosine protein kinase receptors, however, 
in 3T3-1 fibroblasts both insulin and PDGF stimulated the tyrosine phosphorylation of 
p l 2 5 FAK within 2 minutes of exposure to ligand [Figure 5.13].
In Swiss 3T3 fibroblasts, PKC is not necessary for bombesin-stimulated p l25^ j!^  
tyrosine phosphorylation, but it is necessary for PMA stimulation [Sinnett-Smith et al.,
1993]. This is surprising because the bombesin receptor is a G protein coupled receptor 
that activates Gq, then PLC-J3. However, several growth factors, for example, LPA and 
thrombin, which bind to G protein-coupled receptors, activate both Gj and Gq [Magnaldo 
et al., 1988; van Corven et al., 1989], therefore it is possible th a t bombesin stimulation 
of p l 2 5 ^AK tyrosine phosphorylation is mediated by a Gq independent pathway.
As there are several proteins with a similar molecular mass to p l 2 5 ^AK th a t may 
undergo tyrosine phosphorylation in response to growth factors, it is not possible to 
draw definitive conclusions concerning the requirement of PKC for p l 2 5 ^AK tyrosine 
phosphorylation from the Western blots presented in this thesis.
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Insulin and IGF-I
When 3T3-L1 fibroblasts were incubated with insulin or IGF-I, there was an increase in 
the tyrosine phosphorylation of a protein with an approximate molecular mass of 
166 kDa. The tyrosine phosphorylation increased within 1 minute of exposure to each 
ligand, was still elevated by 20 minutes, then decreased {Figures 5.3 and 5.4}. This 
protein could be IRS-1, which is a substrate for the tyrosine protein kinase of both the 
insulin and IGF-I receptors, and has an approximate molecular mass of 160 kDa in 
3T3-L1 adipocytes [Yu et al., 1987] and of 180 kDa in hepatocytes [White et al., 1985]. 
The tyrosine phosphorylation of a membrane protein with an approximate molecular 
mass of 90 kDa also increased [Figure 5.6}. This protein could be the IGF-I (or insulin) 
receptor B-subunit, which has an approximate molecular mass of 95 kDa, and undergoes 
autophosphorylation in response to ligand binding [Herrera and Rosen, 1986].
PDGF
When 3T3-L1 fibroblasts were incubated with PDGF there were increases in the 
tyrosine phosphorylation of proteins with approximate molecular masses of 155, 170 and 
190 kDa. The tyrosine phosphorylation increased within 1 minute of exposure to PDGF, 
was still elevated by 30 minutes, then decreased nearly to basal levels by 60 minutes 
[Figure 5.5}. The tyrosine phosphorylation of membrane proteins with similar 
approximate molecular masses also increased [Figure 5.6}. The 190 kDa protein is 
likely to be the PDGF receptor, which has an approximate molecular mass of 190 kDa, 
and undergoes autophosphorylation in response to PDGF binding [Kelly et al., 1991]. 
The 155 kDa protein could be PLC-y, which has an approximate molecular mass of 
145 kDa [Section 4.1.1}. PLC-y binds to the PDGF receptor [Meisenhelder et al., 1989; 
Wahl et al., 1989] and undergoes tyrosine phosphorylation in response to PDGF [Rhee 
and Choi, 1992].
Insulin, IGF-I and PDGF
When 3T3-L1 fibroblasts were incubated with insulin or PDGF, there was an increase in 
the tyrosine phosphorylation of a membrane protein with an approximate molecular 
mass of 20 kDa. The tyrosine phosphorylation increased within 2 minutes of exposure 
to PDGF or insulin, and decreased to basal levels by 10 minutes [Figure 5.6}. This 
protein was not observed in lysate samples. There are previous no reports of a 20 kDa 
phosphotyrosine protein.
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When 3T3-L1 fibroblasts were incubated with insulin, IGF-I, or PDGF, there was clearly 
an increase in tyrosine phosphorylation of proteins with molecular masses between 60 
and 120 kDa however, this region was blurred and so clear bands could not be observed. 
Another protein known to be a substrate for the insulin, IGF-I and PDGF receptors 
include Syp (p64) [Kazlauskas et al., 1993]. In addition, the regulatory subunit of 
Ptdlns 3'-K (p85) binds to the PDGF receptor and to IRS-1 [Backer et al., 1992b; Hu et 
al., 1992]. There have been reports that p85 undergoes tyrosine phosphorylation in 
response to insulin and PDGF [Kaplan et al., 1987], however, this is disputed [Backer et 
al., 1992b], and it now appears that p85 only undergoes tyrosine phosphorylation when 
it is overexpressed [Hu et al., 1992].
The effect of PKC
When control 3T3-L1 fibroblasts (incubated for 16 hours with 1 pM 4a-PDD) were 
incubated with PDGF, insulin or PMA, or when PKC-depleted 3T3-L1 fibroblasts 
(incubated for 16 hours with 1 pM PMA) were incubated with PDGF or insulin, the 
time-dependent changes in tyrosine phosphorylation of all the observed proteins were 
similar to those observed in the absence of phorbol ester treatm ent [Figures 5.8, 5.9 and 
5.10}. When PKC-depleted 3T3-L1 fibroblasts were incubated with PMA, the time- 
dependent changes in tyrosine phosphorylation of the 6 6  and 120 kDa were also similar 
to those observed in the absence of phorbol ester treatment, however, there were no 
changes in the tyrosine phosphorylation of the 42 and 44 kDa [Figure 5.10}.
This suggests th a t PKC is not necessary for PDGF- or insulin-stimulated tyrosine 
phosphorylation of any of the observed proteins, nor for PMA-stimulated tyrosine 
phosphorylation of the 6 6 , 90 and 120 kDa proteins. However, PKC appears to be 
necessary for PMA-stimulated tyrosine phosphorylation of the 42 and 44 kDa proteins.
These results are in agreement with the suggestions of the identities of the various 
phosphotyrosine proteins. For example, insulin-stimulated tyrosine phosphorylation of 
the insulin receptor 13-subunit and PDGF-stimulated tyrosine phosphorylation of the 
PDGF 13-receptor are known only to be dependent on the intrinsic receptor tyrosine 
protein kinase and not on other tyrosine protein kinases.
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5.3.2 MAPK
Stimulation of MAPK activity
MAPK is activated in response to many growth factors by the phosphorylation of a 
single threonine and a single tyrosine residue. The phosphorylation and activation of 
MAPK can be estimated in many ways. For example, the changes in tyrosine 
phosphorylation in response to various treatm ents can be followed by Western blotting 
of cellular proteins with an anti-phosphotyrosine antibody or with an anti-MAPK 
antibody. Phosphorylation of MAPK causes a decrease in its electrophoretic mobility 
[Posada et al., 1991]. Consequently, anti-MAPK Western blots of partially activated 
MAPK show a doublet, the band with the lower molecular mass corresponding to 
inactive MAPK (p42maPk and p4 4 maPk) and the band with the higher molecular mass 
corresponding to active MAPK (pp42maPk and pp4 4 maPk).
As previously described, PDGF, insulin, IGF-I and PMA stimulated increases in the 
tyrosine phosphorylation of two proteins with approximate molecular masses of 42 and 
44 kDa in 3T3-L1 fibroblasts. The increase in tyrosine phosphorylation was rapid, 
tyrosine phosphorylation being evident within 2  minutes of exposure to each ligand and 
reaching a maximum by 5 minutes {Figures 5.3, 5.4, 5.5 and 5.7}. The molecular masses 
of these proteins suggest that they could be the mammalian MAPKs, p42maPk and 
p4 4 mapk jf  these phosphoproteins are the mammalian MAPKs and if the threonine and 
tyrosine phosphorylation of these proteins occurs in parallel, then the observed increase 
in the tyrosine phosphorylation of these proteins would correlate with an increase in 
MAPK activity. This suggests tha t PDGF, insulin, IGF -I and PMA stimulate a rapid 
increase in p42maPk and p44maPk activity, which reaches a maximum within 5 minutes 
of exposure to ligand.
When 3T3 -LI fibroblasts were incubated with PDGF, insulin or PMA, there were also 
decreases in the electrophoretic mobility of p42maPk and of p4 4 mapk. However, the 
decrease in the mobility of p44maP^ was typically less pronounced than the decrease in 
the mobility of p42maPk, and was best observed in response to PDGF {Figure 5.11b}.
The decrease in the mobility of each MAPK isozyme was rapid, being evident within 
2  minutes of exposure to each ligand and reaching a  maximum by 5 minutes 
{Figure 5.11}. This also suggests that PDGF, insulin and PMA stimulate a rapid
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increase in p42maPk and of p44maPk activity, which reaches a maximum within 
5 minutes of exposure to ligand.
Since the time-dependent changes in tyrosine phosphorylation of the 4 2  kDa and 4 4  kDa 
proteins and in mobility during SDS-PAGE of p 4 2 m a P k  and of p 4 4 m a p k  are similar, it  is 
most probable that the 4 2  and 4 4  kDa phosphotyrosine-containing proteins are the 
p 4 2 m a P k  and of p 4 4 m a P k  respectively.
Rapid increases in the activity of the mammalian MAPK isozymes have been observed 
in other cells in response to many growth factors [Kahan et al., 1992; Tamemoto et al., 
1992; Nguyen et al., 1993]. In some cases the increase in MAPK activity is transient, 
returning to basal levels by 30 minutes, while in others the increase is sustained over 
several hours. For example, when PC 12 cells are treated with EGF, a growth factor, the 
increase in MAPK activity is transient, however when they are treated with nerve 
growth factor, a differentiation factor, it is sustained [Nguyen et al., 1993]. In contrast, 
when CCL39 fibroblasts are treated with thrombin, a growth factor, the increase in 
MAPK activity is sustained [Kahan et al., 1992]  ^ Therefore the role of MAPK in cell 
proliferation is unclear.
However, the interest in this project, is to examine whether MAPK could mediate the 
early phase of growth factor-stimulated glucose transport. In each experiment, the 
3T3 -LI fibroblasts were incubated with ligand at a concentration sufficient to stimulate 
a maximum increase in the rate of 2-deoxyglucose uptake. Therefore, a concentration of 
each ligand sufficient to stimulate a maximal increase in the rate of 2 -deoxyglucose 
uptake by 60 minutes, was also sufficient to stimulate a maximal increase in MAPK 
activity by 5 minutes. Since the apparent increase in MAPK activity precedes the 
increase in the rate of 2 -deoxyglucose uptake, the early phase of growth factor- 
stimulated 2 -deoxyglucose uptake could be mediated by a signal transduction pathway 
involving MAPK
The effect of PKC
When control 3T3-L1 fibroblasts (incubated for 16 hours with 1 pM 4a-PDD) were 
incubated with PDGF, insulin or PMA, or when PKC-depleted 3T3-L1 fibroblasts were 
incubated with PDGF or insulin, the time-dependent changes in the tyrosine
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phosphorylation of the 42 kDa and 44 kDa proteins {Figures 5.8, 5.9 and 5.10}, and in 
the electrophoretic mobility of p42maPk and of p4 4 maPk {Figure 5.12} were similar to 
those observed in the absence of phorbol ester treatment. However, when PKC-depleted 
3T3-L1 fibroblasts were incubated with PMA, there were no changes in the tyrosine 
phosphorylation of the 42 kDa and 44 kDa proteins {Figure 5.10} or in the 
electrophoretic mobility of p42maPk and of p4 4 mapk {Figure 5.12c}.
Therefore PKC is not necessary for either insulin- or PDGF-stimulated tyrosine 
phosphorylation of the 42 and 44 kDa proteins, or for insulin- or PDGF-stimulated 
decreases in the electrophoretic mobility of p42maPk and of p4 4 maPk. However, PKC is 
necessary for PMA-stimulated tyrosine phosphorylation of the 42 and 44 kDa proteins 
and decreases in the electrophoretic mobility of p42 maPk and 0f p4 4 mapk
Since the PKC dependence of tyrosine phosphorylation of the 42 kDa and 44 kDa 
proteins and of the decrease in the mobility of p42maPk and of p4 4 mapk are similar, ti t is 
likely tha t the 42 and 44 kDa phosphoproteins are the mammalian MAPK isozymes, 
p42maPk and p4 4 mapk Therefore, PKC is not necessary for PDGF- or insulin- 
stimulated MAPK activation, but is necessary for PMA-stimulated MAPK activation. 
Similar results have been obtained using other cells, for example, insulin-stimulated 
MAPK activity in BC3H-1 myocytes is unaffected by down-regulation of PKC [Sturgill 
and Wu, 1991].
Since the increases in MAPK activity and the increases in the rate of 2-deoxyglucose 
uptake have the same dependency on PKC {Section 4.2.4}, it is possible th a t the early 
phase of 2 -deoxyglucose uptake is mediated by a signal transduction pathway involving 
MAPK in 3T3-L1 fibroblasts.
5.3.3 Summary
Many proteins undergo tyrosine phosphorylation in response to PDGF, insulin and 
IGF-I. Many of these proteins have approximate molecular masses tha t suggest th a t 
they could be components of the signal transduction pathways stimulated by these 
growth factors, in particular, the tyrosine protein kinase receptors to which these 
growth factors bind, and substrates of these receptors. In addition, some proteins which
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are not known to be substrates for the receptors also undergo tyrosine phosphorylation. 
These were identified as p l2 5 ^ K , p42maPk and of p4 4 maPk.
In 3T3-L1 fibroblasts, PKC is not necessary for insulin- or PDGF-stimulated activation 
of MAPK, but tha t it is necessary for PMA-stimulated activation of MAPK. PKC is not 
necessary for the early phase of insulin- or PDGF-stimulated glucose transport, but tha t 
it is necessary for PMA-stimulated glucose transport {Chapter 4}. Therefore, given tha t 
the activation of MAPK and the increase in the rate of glucose transport have the same 
dependency on PKC, and th a t the activation of MAPK precedes the increase in the rate 
of glucose transport, it is possible that the early phase of growth factor-stimulated 
glucose transport is mediated by a signal transduction pathway involving MAPK. 
However, this does not prove that MAPK and increases in the rate glucose transport are 
connected.
In order to examine the role of specific proteins in an ligand-stimulated process, there 
are various techniques th a t can be used. A common technique is to use specific 
inhibitors, however, there are no specific inhibitors yet available for MAPK. A second 
technique is to express a protein in a stable or transient manner. An advantage of this 
technique is tha t the sequence of events leading to a process can be determined in vivo 
by expressing various forms of a protein, such as constitutively-active or dominant- 
negative mutants. However, plasmids containing the DNA sequence of the relevant 
proteins were not available. A third technique is to inject proteins into cells. This is 
probably the most technically demanding of the various methods given the small size of 
most cells, but, can be simplified by using larger cells such as the oocytes from the South 
African toad, Xenopus laevis. The facilities for the maintenance of X. laevis and for the 
injection of their oocytes were available. Therefore, the role of various components of 
the MAPK signal transduction pathway in mediating glucose transport was examined 
by injection of purified or recombinant proteins into X. laevis oocytes.
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The activation of MAPK in Xenopus laevis oocytes
6.1 Introduction
The growth factors, insulin and PDGF, and the tumour promoter, PMA, all stimulate 
the rate of glucose transport in a similar manner in 3T3-L1 fibroblasts {Section 3.3}. 
These effects are not additive, therefore, the effects of these ligands on the rate of 
glucose transport may be mediated by a similar signal transduction pathway. Signal 
transduction pathways involving DAG and PKC do not appear to mediate the early 
phase of growth-factor stimulated glucose transport in 3T3-L1 fibroblasts {Section 4.3}. 
However, there is circumstantial evidence tha t a signal transduction pathway involving 
MAPK may mediate the early phase of growth factor-stimulated glucose transport 
{Section 5.3}.
The increase in MAPK activity precedes the increase in the rate of glucose transport in 
response to insulin or PDGF. In addition PKC is not necessary for insulin or PDGF- 
stimulated MAPK activation or glucose transport {Section 5.3}. However, this does not 
prove that a signal transduction pathway involving MAPK mediates growth factor- 
stimulated glucose transport. Therefore, the effects of MAPK on glucose transport were 
examined by injecting components of a signal transduction pathway involving MAPK 
into X. laevis oocytes.
6.1.1 Oocytes 
Meiosis
Meiosis is a complex series of events which consists of a single nuclear division and two 
cytoplasmic divisions, producing four daughter cells, each with half the chromosome 
number of the parent cell. The daughter cells are either female gametes (eggs), or male 
gametes (sperm). Like mitosis, meiosis can be divided into phases, which separate into 
two division cycles, each of which consists of an interphase and a meiotic division.
Egg development takes several years. The first stages of meiosis occur in embryonic 
cells, producing the oocyte, which arrests between G2 and the M phase of its first 
meiotic cycle; a t this point, DNA replication has occurred, but nuclear division has not 
[Mailer, 1990]. During the G2 arrest, all the materials required for the construction of
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the early embryo (other than DNA) are synthesised, hence the mature oocyte is a large 
cell. The G2 arrest is broken by progesterone, which is released at the time of ovulation. 
The oocyte then completes the first meiotic cycle and proceeds through the second 
meiotic cycle as far as the metaphase of meiosis II. The second arrest is broken by 
fertilisation. Meiosis is then quickly completed and followed by a rapid sequence of 
mitotic cell divisions in which the single giant cell cleaves to generate an embryo 
consisting of thousands of smaller cells. In X. laevis, the first division takes about 
90 minutes, while the next 11 cleavage division occur more or less synchronously a t 
30 minute intervals, producing 4096 cells within about 7 hours. The prior accumulation 
of materials in the egg eliminates the time normally required for cell growth in each 
cycle, so tha t practically no growth occurs, although DNA is synthesised to create the 
necessary number of nuclei [Mailer, 1990].
Comparison with mitosis
The activation of GO-arrested somatic cells and G2-arrested oocytes leads to different 
cell cycle stage-specific responses. For example, growth factors stimulate transcription 
in GO-arrested somatic cells, while hormones stimulate transcriptional shut-down in G2- 
arrested oocytes. However, many of the earliest events occurring during re-entry into 
the somatic or meiotic cell cycles are similar. For example, there are rapid changes in 
phospholipid metabolism, a transient elevation of free intracellular calcium, a rise in the 
intracellular pH, and an alteration of the cytoskeleton in both cases [Ruderman, 1993]. 
Therefore, both somatic cells and oocytes provide valid systems to study re-entry into 
the cell cycle.
6.1.2 The activation of MAPK 
X. laevis homologues
A comparison of the mammalian MAPK amino acid sequences with sequences from 
other species shows that highly similar proteins are found in many species, including 
amphibians (X. laevis), insects (Drosophila melanogaster), budding yeast (S. cerevisiae) 
and fission yeast (S. pombe) [Nishida and Gotoh, 1993].
There are two X. laevis MAPK isozymes, with approximate molecular masses of 42 and 
44 kDa [Posada et al., 1991]. The 42 kDa MAPK isozyme is activated by
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phosphorylation on Thr-188 and Tyr-190 [Posada and Cooper, 1992]. The X. laevis 
MAPKK is a 45 kDa protein tha t activates MAPK by dual threonine and tyrosine 
phosphorylation [Matsuda et al., 1992]. X. laevis MAPKK may be activated by p39mos 
[Posada et al., 1993] and MAPKKK [Matsuda et al., 1993]. p39mos is involved in the 
release of oocytes from G2 arrest [Yew et al., 1992].
Release from G2 arrest
p3 9 m°s js necessary for progesterone-induced oocyte maturation [Sagata et al., 1988]. It 
is absent from immature oocytes, its expression being induced within 1  hour of exposure 
to progesterone [Sagata et al., 1989]. It remains active until 30 minutes after 
fertilisation, when it is degraded by proteolysis [Watanabe et al., 1991].
p3 9  mos activates MAPKK leading to the activation of MAPK [Posada et al., 1993]. 
MAPK exists in the immature oocyte and is activated during oocyte maturation about 2 
hours after progesterone treatm ent and remains active until approximately 30 minutes 
after fertilisation [Ferrell et al., 1991].
Insulin and IGF-I also stimulate the release of oocytes from G2 arrest [El-Etr et al.,
1979]. p21ms is necessary for insulin- and IGF-I-induced maturation [Korn et al., 1987], 
but it is not necessary for progesterone-induced maturation [Dominguez et al., 1991]. 
Addition of p21v'ros to oocytes activates MAPK and MAPKK, suggesting th a t insulin 
and IGF-I both stimulate a signal transduction pathway involving MAPK in X. laevis 
oocytes [Hattori et al., 1992]. X. laevis oocytes express few if any insulin receptors, the 
effects of both insulin and IGF-I being mediated by the IGF -I receptor [Janicot et al., 
1991].
6.1.3 Oocytes and glucose transport
X. laevis oocytes express low levels of a G lutl homologue [Hainaut et al., 1991]. Insulin 
and IGF-I stimulate the rate of glucose transport in G2-arrested oocytes. The EC5 0  
values for insulin- and IGF-I-stimulated glucose transport are 200 to 250 nM and 3 to 
3.5 nM respectively. There is a lag, of 20 to 30 minutes following exposure to insulin or 
IGF-I, during which the rate of glucose transport remains a t the basal level. Then the 
rate of glucose transport increases rapidly reaching a maximum of three to four fold by
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60 minutes and remains constant for several hours [Janicot and Lane, 1989]. However, 
the rate of glucose transport returns to the basal level before the onset of maturation 
[Hainaut et al., 1991].
Since, the rate of glucose transport through G lutl is regulated by growth factors tha t 
bind to tyrosine protein kinase receptors in mammalian somatic cells and in X. laevis 
oocytes, it is possible tha t these effects are mediated by a similar signal transduction 
pathway. It is possible tha t a signal transduction pathway involving MAPK mediates 
the early phase of growth factor-stimulated glucose transport in somatic cells, however, 
it is difficult to examine this thoroughly in these cells. Therefore, in order to examine 
whether growth factor-stimulated glucose transport could be mediated by a signal 
transduction pathway involving MAPK, several approaches were taken. The effect of 
IGF -I on endogenous X. laevis oocyte MAPK activity, and the effect of components of a 
signal transduction pathway involving MAPK on the rate of glucose transport in X. 
laevis oocytes were examined.
6.2 Results
6.2.1 The effect of IGF-I on MAPK activity
The effect of IGF-I on the mobility of MAPK during SDS-PAGE was examined by 
Western blotting of cellular proteins. Lysates were prepared from X  laevis oocytes after 
incubation with 250 nM IGF -I {Section 2.13.4}. The proteins were separated by SDS- 
PAGE {Section 2.15}, and then transferred onto nitrocellulose membranes. The 
membranes were probed with a mouse anti-MAPK antibody, and then with a HRP- 
conjugated sheep anti-mouse IgG antibody. The antibody-binding sites were visualised 
using an ECL detection system {Section 2.16.2}.
The anti-MAPK antibody recognised two proteins with approximate molecular masses of 
42 and 44 kDa in all the oocyte lysate samples. The mobility during SDS-PAGE of both 
proteins decreased in response to 1 pM IGF-I. The decrease in mobility was observed at 
2 minutes and 10 minutes of exposure to IGF-I. The effect of incubation with IGF-I for 
other times was not examined. A representative Western blot is shown in Figure 6.1.
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Figure 6.1 The effect of IGF-I on MAPK
After incubation of X. laevis oocytes with 250 nM IGF-I for the times shown, lysates 
were prepared (Section 2.13.4}. The lysate from two oocytes was loaded onto 10% (w/v) 
polyacrylamide mini-gels, the proteins were separated by SDS-PAGE (Section 2.15}, and 
then transferred onto nitrocellulose membranes. The membranes were probed with a 
mouse anti-MAP kinase antibody, and then with a HRP-conjugated sheep anti-mouse 
IgG antibody. The antibody binding sites were visualised using an ECL detection 
system (Section 2.16.2}. This is a representative Western blot from a group of two lysate 
preparations.
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6.2.2 The effect of p42maPk on the rate of glucose transport
The effect of MAPK on the rate of glucose transport in X. laevis oocytes was examined by 
measuring the rates of 2-deoxyglucose uptake {Section 2.8.2} and zero-trans 
3-O-methylglucose transport {Section 2.8.3}, after the microinjection {Section 2.6} of a 
recombinant p42maPk . Before injection, the p42maPk was activated by 
thiophosphorylation by incubating with ATP[S] and MAPKK {Section 2.5.1}.
2-deoxyglucose uptake
After injection of 50 nl of 450 U/ml p42maPk and incubation for 15, 30 and 120 minutes 
the rate of 2-deoxyglucose uptake increased 2.2 to 2.8 fold. After injection of 50 nl of 
Buffer A and incubation for 60 minutes, there was no change in the rate of
2-deoxyglucose uptake, while after injection of 50 nl of Buffer B and incubation for 
60 minutes, there was a slight, but insignificant increase in the rate of 2 -deoxyglucose 
uptake. After a 60 minute incubation with 250 nM IGF-I, the rate of 2 -deoxyglucose 
uptake increased 2.8 to 3.5 fold. The results from a representative experiment are 
shown in Table 6.1.
After injection of 50 nl of 450 U/ml p42maPk and a incubation with 250 nM IGF-I for 60 
minutes, the rate of 2-deoxyglucose uptake increases 2.2 to 3.5 fold. After injection of 
50 nl of 450 U/ml p42maPk and a incubation with 10 fiM cyclohexiunide for 60 minutes, 
the rate of 2-deoxyglucose uptake increased 2.2 to 2.8 fold. The results from a 
representative experiment are shown in Table 6.2.
Zero-trans 3-O-methylglucose transport
After injection of 50 nl of Buffer B or 450 U/ml MAPK and incubation for 60 minutes the 
amount of 3-O-methylglucose transported was such tha t the oocyte water space was 
completely equilibrated by 8  hours (results not shown). During the first 2 hours, the 
kinetics of transport were first order; the rate constant over this period was 
approximately 2 fold higher after the injection of p42maPk , than after the injection of 
Buffer B. The results from a representative experiment are shown in Figure 6.2.
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Table 6.1 The effect of p42maPk on the rate of 2-deoxyglucose uptake
After incubation of X. laevis oocytes with 250 nM IGF -I for 60 minutes a t room 
temperature, or after injection ofX  laevis oocytes with 50 nl of w ater (basal), Buffer A, 
Buffer B or thiophosphorylated recombinant MAPK (450 U/ml) and incubation for the 
times shown a t room temperature, a 60 minute uptake of 2-dexoy-D-[2,6-^H]glucose was 
measured {Section 2.8.2}. Each result shows the mean rate of specific 2-deoxyglucose 
uptake (± SD) for eight oocytes. This is a representative experiment from a  group of 
four; basal rates were 0.2 to 0.5 pmoles/ min/ oocyte and the maximal stimulation in 
response to IGF-I was between 2.5 and 3.5 fold, and to MAPK was between 2.2 and 2.8 
fold. * p < 0.05
Buffer A: 50 mM Tris hydrochloride (pH 7.3), 2 mM sodium EDTA, 2 mM sodium EGTA, 
5% (v/v) glycerol, 0.2 mM sodium vanadate, 0.03% (w/w) Brij 35, 0.1% (v/v) 
B-mercaptoethanol, 6  mM specific peptide inhibitor of cyclic AMP-dependent protein 
kinase.
Buffer B: 10 mM magnesium acetate, 0.2 mM ATP[S] and MAPKK in Buffer A.
Rate of 2-deoxyglucose 
uptake 
(pmoles/ min/ oocyte)
Basal (60 minutes water) 0.42 ± 0.03
60 minutes IGF-I 1.26 ± 0.09*
60 minutes Buffer A 0.46 ±0.03
60 minutes Buffer B 0.66 ±0.03
15 minutes MAPK 1.23 ± 0.08*
30 minutes MAPK 1 . 2 0  ±0.06*
120 minutes MAPK 1.17 ±0.02*
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Table 6.2 The effect of p42maPk and MAPKK on the rate of 2-deoxyglucose uptake
After incubation of X. laevis oocytes with 250 nM IGF-I or 10 fig/ml cyclohextmide for 
60 minutes at room temperature, or after injection ofX  laevis oocytes with 50 nl of 
water (basal), thiophosphorylated recombinant MAPK (450 U/ml), or rabbit skeletal 
muscle MAPKK (1.4 U per oocyte) and incubation for the times shown at room 
temperature, a 60 minute uptake of 2-dexoy-D-[2,6 -^H] glucose was measured {Section 
2.8.2}. Each result shows the mean rate of specific 2-deoxyglucose uptake (± SD) for 
eight oocytes. This is a representative experiment from a group of three; basal rates 
were 0.2 to 0.5 pmoles/ min/ oocyte and the maximal stimulation in response to IGF-I 
was between 2.5 and 3.5 fold, to MAPK was between 2.2 and 2.8 fold, and to MAPKK 
was between 2.0 and 3.0 fold. * p < 0.05
Rate of 2-deoxyglucose 
uptake 
(pmoles/ min/ oocyte)
Basal (60 minutes water) 0.24 ±0.03
60 minutes IGF-I 0.60 ±0.05*
120 minutes MAPK 0.54 ±0.05*
60 minutes MAPK and 
IGF-I
0.57 ± 0.06*
60 minutes MAPK and 
cyclohexcmide
0.53 ± 0.03*
60 minutes MAPKK 0.61 ± 0.05*
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Figure 6.2 The effect of p42maPk on 3- O-methylglucose transport
After injection of X. laevis oocytes with 50 nl of Buffer A (o) or thiophosphorylated 
recombinant MAPK(m) (450 units/ml), then incubation for the 60 minutes a t room 
temperature, 3 -0-methyl-D-[l-3 H]glucose transport, for the times shown, was measured 
{Section 2.8.3}. Each result shows the mean rate of specific 3-O-methylglucose transport 
(± SD) for five oocytes. This is a representative experiment from a group of three; basal 
rates were between 0.2 and 0.5 pmoles/ min/ oocytes.
Buffer A: 50 mM Tris hydrochloride (pH 7.3), 2 mM sodium EDTA, 2 mM sodium EGTA, 
5% (v/v) glycerol, 0.2 mM sodium vanadate, 0.03% (w/w) Brij 35, 0.1% (v/v) 
B-mercaptoethanol, 6  mM specific peptide inhibitor of cyclic AMP-dependent protein 
kinase.
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6.2.3 The effect of MAPKK on the rate of glucose transport
The effect of MAPKK on the rate of glucose transport in X. laevis oocytes was examined 
by measuring the rate of 2-deoxyglucose uptake {Section 2.8.2}, after injection of a 
MAPKK purified from rabbit skeletal muscle {Sections 2.5.2 and 2.6}. After injection of 
50 nl of 44 800 U/ml MAPKK and incubation for 60 minutes the rate of 2-deoxyglucose 
uptake increased 2.5 to 3.0 fold. The results from a representative experiment are 
shown in Table 6.2.
6.2.4 The effect of MalE-Mos on the rate of glucose transport
The effect of Mos on the rate of glucose transport in X  laevis oocytes was examined by 
measuring the rate of 2-deoxyglucose uptake {Section 2.8.2}, after injection of a 
MalE-Mos fusion protein {Sections 2.5.3 and 2.6}.
After injection of 50 nl of 250 pg/ml MalE-Mos and incubation for 30, 60, 120 and 
180 minutes the rate of 2-deoxyglucose uptake increased 2.0 to 2.8 fold. After injection 
of 50 nl of Buffer C and incubation for 60 minutes, there was no change in the rate of 
2-deoxyglucose uptake. After a 60 minute incubation with 250 nM IGF-I, the rate of 
2-deoxyglucose uptake increased 2.8 to 3.5 fold. The results from a representative 
experiment are shown in Table 6.3.
6.3 Discussion
In order to examine whether growth factor-stimulated glucose transport could be 
mediated by a signal transduction pathway involving MAPK, the effect of IGF-I on 
endogenous X. laevis oocyte MAPK activity, and the effect of components of a signal 
transduction pathway involving MAPK on the rate of glucose transport in X. laevis 
oocytes were examined.
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Table 6.3 The effect of MalE-Mos on the rate of 2-deoxyglucose uptake
After incubation of X  laevis oocytes with 250 nM IGF -I for 60 minutes a t room 
temperature, or injection of X. laevis with 50 nl of water, Buffer C or MalE-Mos (250 
(Xg/ml) and incubation for the times shown a t room temperature, a 60 minute uptake of 
2-dexoy-D-[2,6- ^ HJglucose was measured {Section 2.8.2}. Each result shows the mean 
rate of specific 2-deoxyglucose uptake (± SD) for eight oocytes. This is a representative 
experiment from a group of three; basal rates were 0.2 to 0.5 pmoles/ min/ oocyte and 
the maximal stimulation in response to IGF-I was between 2.8 and 3.5 fold, and to 
MalE-Mos was between 2.0 to 2.8 fold. * p < 0.05
Buffer C: 50 mM NaCl, 20 mM Tris, pH 7.5
Rate of 2-deoxyglucose 
uptake 
(pmoles/ min/ oocyte)
Basal (60 minutes water) 0.42 ± 0.07
60 minutes IGF-I 1.31 ± 0.09*
60 minutes Buffer C 0.46 ±0.04
30 minutes MalE -Mos 0.70 ±0.02*
60 minutes MalE -Mos 0.81 ± 0 .1 2 *
120 minutes MalE-Mos 1.05 ± 0.09*
180 minutes MalE-Mos 1.15 ±0.09*
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6.3.1 The effect of IGF-I on MAPK activity
The phosphorylation and activation of MAPK were examined by Western blotting of 
cellular proteins with an anti-MAPK antibody. As previously described, anti-MAP 
kinase Western blots of partially activated MAPK show a doublet, the band with the 
lower molecular mass corresponding to inactive MAPK and the band with the higher 
molecular mass corresponding to active MAPK {Section 5.3.2}.
When X  laevis oocytes were incubated with IGF-I there was a decrease in the mobility 
during SDS-PAGE ofX. laevis p42maPk and p4 4 mapk The decrease in mobility was 
observed from 2 to 10 minutes after exposure to IGF -I {Figure 6.1}. This suggests that 
IGF -I stimulates a rapid increase in MAPK activity in X. laevis oocytes. The effects of 
longer incubations with IGF -I were not examined, therefore these results do not show 
the length of time for which p 4 2 m a P k  and p 4 4 m a P k  were active. MAPK is also activated 
in by progesterone in G2-arrested oocytes. However, progesterone-stimulated MAPK 
activation does not occur until 2 hours after progesterone treatm ent [Ferrell et al.,
1991]. This difference probably occurs because progesterone-stimulated M ^PK 
activation is dependent upon p39mos [Posada et al., 1993], which is not present in 
immature oocytes and therefore must be synthesised, before MAPK activation can occur, 
while the effects of IGF-I are dependant on p21ms [Korn et al., 1987], which is expressed 
by the oocyte.
6.3.2 The effect of MAPK on the rate of glucose transport
The ability of MAPK to stimulate glucose transport in X. laevis oocytes was; examined by 
measuring the rate of 2-deoxyglucose uptake after injection of a recombinant MAPK 
The recombinant MAPK was activated by phosphorylation by incubating w ith MAPKK 
prior to microinjection. In order for the MAPK to have the maximum possible activity, 
thiophosphate was included in the incubation buffer. Thiophosphate groupis are more 
resistant to in vivo dephosphorylation than are phosphate groups, therefore, 
thiophosphorylation in effect constitutively activates MAPK The thiophosphorylated, 
recombinant MAPK had a specific activity similar to th a t of MAPK isolated from 
mammalian tissues (results not shown).
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Since X. laevis oocytes express very low levels of the G lutl homologue, the rate of 
glucose transport is quite low in comparison to cultured mammalian cells. Therefore, 
when measuring the rate of glucose transport, a short uptake time, for example 
5 minutes, would not be accurate. Consequently, it is not possible to easily carry out 
accurate kinetic studies, tha t is determine the Km and Vmax. Instead, the uptakes were 
measured over 60 minutes. Therefore, the oocytes incubated for 15 minutes with MAPK 
were then incubated for 60 minutes with 2-deoxyglucose, a total of 75 minutes with 
MAPK
The rate of 2-deoxyglucose uptake increased after incubation with MAPK, the maximal 
increase, of 2.8 fold, occurring after 75 minutes, then decreasing slightly but remaining 
significantly above the basal rate for a t least 180 minutes {Table 6.1}. The effects on 
2-deoxyglucose uptake of two buffers was also examined. The rate of 2-deoxyglucose 
uptake did not change after microinjection of Buffer A, but increased slightly, although 
not significantly after microinjection of Buffer B. Buffer B had the same composition as 
Buffer A, with the additions of magnesium acetate, ATP[S] and MAPKK Thus, only 
Buffer B was capable of activating MAPK Therefore, the small increase in the rate of 
2-deoxyglucose uptake in oocytes after microinjection of Buffer B was probably due to 
the activation of endogenous oocyte MAPK by the MAPKK in Buffer B {Table 6.1}.
Since 2-deoxyglucose undergoes phosphorylation by hexokinase, 2-deoxyglucose uptake 
consists of both transport and phosphorylation {Section 2.8}. I t has been assumed that 
transport is the rate-limiting step in these experiments. In contrast, 3-O-methylglucose 
is not metabolised, and therefore undergoes only transport. Therefore, in order confirm 
that the effect of p42maPk on 2 -deoxyglucose uptake was on the transport step and not 
the phosphorylation step, the effect of p42maPk on 3-O-methylglucose transport was also 
determined. The rate constant for zero-trans 3-O-methylglucose transport was 
approximately 2 fold higher after injection of p42maPk, than after injection of Buffer A. 
Therefore, the effect of MAPK was on the transport process and not on phosphorylation 
{Figure 6.2}. In addition, the effect of p42maPk on the rate of 2-deoxyglucose uptake was 
not an artefact caused by excess levels of p42maPk , since the amount injected into the 
oocytes was only 25 to 50 percent of the endogenous MAPK activity [Gotoh et al., 1991].
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In addition, the effects of IGF-I and MAPK on the rate of glucose transport were not 
additive {Table 6.2}, therefore, IGF-I and MAPK may increase the rate of glucose 
transport by a common mechanism. Furthermore, the microinjection of CL100, a 
protein tyrosine/ threonine phosphatase that is specific for MAPK [Alessi et al., 1993], 
into X. laevis oocytes inhibited p42maPk- and IGF-I-stimulated glucose tran sp o rt, while 
an inactive m utant had no effect [Arbuckle et al., 1994].
Therefore, given th a t IGF-I stimulates both glucose transport and MAPK activity, that 
the injection of a recombinant p42maPk also stimulates 2 -deoxyglucose uptake, and that 
inhibition of MAPK activity abolishes IGF -I-stimulated glucose transport, it is likely 
that IGF-I-stimulated glucose transport may be mediated by a signal transduction 
pathway involving MAPK in X. laevis oocytes.
6.3.3 The effect of MAPKK on the rate of glucose transport
The ability of MAPKK to stimulate glucose transport in X. laevis oocytes was examined 
by measuring the rate of 2-deoxyglucostuptake after microinjection of a MAPKK purified 
from rabbit skeletal muscle after intravenous injection of insulin [Nakielny et al.,
1992a]. The MAPKK was purified in an active form, therefore, thiophosphorylation was 
not necessary. The purified MAPKK stimulated the rate of 2-deoxyglucose uptake by 2 
to 3 fold {Table 6.2}. Therefore, it is likely tha t the slight increase in the rate of 
2-deoxyglucose uptake observed after injection of Buffer B was due to the MAPKK in 
this buffer. The residual level of MAPKK in Buffer B was 20 fold lower than the amount 
used for the microinjection of oocytes, thus explaining the small effect of Buffer B.
Therefore, the enzyme th a t activates MAPK also stimulates glucose transport.
6.3.4 The effect of p39/nos on the rate of glucose transport
The ability of p39mos to stimulate glucose transport in X. laevis oocytes was also 
examined by measuring the rate of 2 -deoxyglucose uptake after injection of a fusion 
protein consisting of the maltose-binding protein from E. coli and p39c_mos (MalE-Mos). 
This fusion protein has p39mos activity, being able to stimulate MAPK activity in X.
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laevis oocyte extracts [Nebreda and Hunt, 1993], and able to activate MAPKK in vitro 
[Posada et al., 1993]. MalE-Mos stimulated the rate of 2 -deoxyglucose uptake 2.0 to 2.8 
fold after incubation with for 90 to 240 minutes {Table 6.3}. MalE-Mos also stimulates 
MAPK activity within 10 minutes in oocyte extracts in a dose-dependant manner 
[Nebreda and Hunt, 1993], suggesting that MalE-Mos-stimualted 2-deoxyglucose uptake 
is mediated by MAPK In addition, the effect of MalE-Mos on 3 -O-methylglucose 
transport was examined. Again, MalE-Mos stimulated the rate of 3 -O-methylglucose 
transport (results not shown), confirming that the effect of MalE-Mos was on transport 
and not a  subsequent step.
Therefore, an enzyme tha t activates MAPKK also stimulates glucose transport.
6.3.5 The effect of other serine/ threonine protein kinases on the rate of glucose 
transport
The effect of the some of the in vitro MAPK substrates {Section 5.1.1} on the rate of 
2-deoxyglucose uptake was examined. MAPKAP kinase-1 and MAPKAP kinase-2, 
purified from rabbit skeletal muscle1, were injected into X. laevis oocytes. The rate of 
2 -deoxyglucose uptake did not change, in response to either of these kinases, after 
incubations of one to four hours. Unfortunately, it is not possible to determine whether 
the kinases remained active after microinjection into the oocyte. However, since both 
MAPKAP kinase-1 and MAPKAP kinase-2 are skeletal muscle proteins, it is not 
improbable tha t their physiological roles are restricted to myocytes and th a t they are 
not normally expressed in other cells.
1 MAPKAP kinase-1 and MAPKAP kinase-2 were gifts from Professor P Cohen, Medical 
Research Council Protein Phosphorylation Unit, Department of Biochemistry, 
University of Dundee, Dundee, Tayside, UK.
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6.3.6 Summary
IGF-I stimulates both glucose transport and MAPK activity inX. laevis oocytes. The 
activation of MAPK precedes the increase in the rate of glucose transport.
In addition, the microinjection of recombinant p42maP^, purified MAPKK or p3977105 
fusion protein, results in an increase in the rate of glucose transport. Since p39mos 
activates MAPKK, which in turn activates MAPK, it seems th a t components of a signal 
transduction pathway involving MAPK are able to stimulate glucose transport.
Furthermore, IGF-I stimulated glucose transport is inhibited by the microinjection of 
CL100 (a protein tyrosine/ threonine phosphatase tha t is specific for MAPK).
Therefore, given tha t IGF-I stimulates both glucose transport and MAPK activity, that 
components of a signal transduction pathway involving MAPK also stimulate the rate of 
glucose transport, and tha t inhibition of MAPK activity abolishes IGF-I-stimulated 
glucose transport, it is likely th a t IGF-I-stimulated glucose transport is mediated by a 
signal transduction pathway involving MAPK in X. laevis oocytes.
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Discussion
3T3 -LI fibroblasts express only Glutl. The growth factors, insulin and PDGF, and the 
tumour promoter, PMA, all stimulate the rate of glucose transport in a similar manner. 
These effects are not additive, therefore, the effects of these ligands on the rate of 
glucose transport may be mediated by a similar signal transduction pathway.
Insulin has no effect on either DAG accumulation or PKC activity in 3T3 -LI fibroblasts, 
so neither DAG nor PKC is necessary for the early phase of insulin-stimulated glucose 
transport. PDGF stimulates both DAG accumulation and PKC activity; however, 
PDGF-stimulated glucose transport is unaffected by the down-regulation or the 
inhibition of PKC, so PKC is not necessary for the early phase of PDGF-stimulated 
glucose transport. PMA also stimulates both DAG accumulation and PKC activity, and 
PMA-stimulated glucose transport is abolished by the down-regulation and the 
inhibition of PKC, so PKC is necessary for the early phase of PMA-stimulated glucose 
transport. Therefore, a signal transduction pathway involving PKC is not necessary for 
the early phase of insulin- or PDGF-stimulated glucose transport in 3T3-L1 fibroblasts, 
but it is necessary for the early phase of PMA-stimulated glucose transport.
Insulin, PDGF and PMA stimulate MAPK activity in 3T3-L1 fibroblasts. Insulin has no 
effect on either DAG accumulation or PKC activity, so neither DAG nor PKC is 
necessary for insulin-stimulated activation of MAPK PDGF stimulates both DAG 
accumulation and PKC activity: however, PDGF-stimulated activation of MAPK is 
unaffected by the down-regulation or the inhibition of PKC, so PKC is not necessary for 
PDGF-stimulated activation of MAPK PMA also stimulates both DAG accumulation 
and PKC activity, and PMA-stimulated activation of MAPK is abolished by the down- 
regulation and the inhibition of PKC, so PKC is necessary for PMA-stimulated 
activation of MAPK Therefore, a signal transduction pathway involving PKC is not 
necessary for insulin- or PDGF-stimulated activation of MAPK in 3T3-L1 fibroblasts, 
but it is necessary for PMA-stimulated activation of MAPK
In addition, insulin-, PDGF- and PMA-stimulated activation of MAPK precedes the 
increase in the rate of glucose transport.
Therefore, given that the activation of MAPK and the increase in the rate of glucose 
transport have the same dependency on PKC, and tha t the activation of MAPK precedes
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the increase in the rate of glucose transport, it is possible th a t the early phase of growth 
factor-stimulated glucose transport is mediated by a signal transduction pathway 
involving MAPK in 3T3-L1 fibroblasts.
X. laevis oocytes also express only G lutl. IGF-I stimulates both glucose transport and 
MAPK activity. Again, the activation of MAPK precedes the increase in the rate of 
glucose transport.
In addition, the microinjection intoX. laevis oocytes of recombinant p42maPk, purified 
MAPKK or p39mos fusion protein, results in an increase in the rate of glucose transport. 
Since p39mos activates MAPKK, which in turn activates MAPK, it seems tha t 
components of a signal transduction pathway involving MAPK are able to stimulate 
glucose transport.
Furthermore, IGF-I stimulated glucose transport in X. laevis oocytes is inhibited by the 
microinjection of CL100 (a protein tyrosine/ threonine phosphatase tha t is specific for 
MAPK).
Therefore, given tha t IGF-I stimulates both glucose transport and MAPK activity, that 
components of a signal transduction pathway involving MAPK also stimulate the rate of 
glucose transport, and tha t inhibition of MAPK activity abolishes IGF -I-stimulated 
glucose transport, it is likely tha t IGF-I-stimulated glucose transport is mediated by a 
signal transduction pathway involving MAPK in X. laevis oocytes.
The insulin and IGF-I receptors are both tyrosine protein kinases with a similar 
structure, and either ligand cam bind to either receptor, so it is likely tha t insulin- and 
IGF-I-stimulated glucose transport are mediated by a similar signal transduction 
pathway.
Therefore, given tha t it is possible tha t the early phase of insulin-stimulated glucose 
transport is mediated by a signal transduction pathway involving MAPK in 3T3-L1 
fibroblasts, tha t it is likely tha t IGF-I-stimulated glucose transport is mediated by a 
signal transduction pathway involving MAPK in X. laevis oocytes, and tha t it is likely 
tha t insulin- and IGF-I-stimulated glucose transport are mediated by a similar signal
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transduction pathway, it seems tha t the early phase of insulin-stimulated glucose 
transport in 3T3-L1 fibroblasts is, in fact, mediated by a pathway involving MAPK
Furthermore, PDGF, which also binds to a tyrosine protein kinase receptor, has similar 
effects to insulin on the rate of glucose transport and the activation of MAPK in 3T3-L1 
fibroblasts. Therefore, it is also likely the early phase of PDGF-stimulated glucose 
transport is also mediated by a signal transduction pathway involving MAPK
There are few, if any, published studies concerning the role of M ^PK in the early phase 
of growth factor-stimulated glucose transport. However, several recent studies have 
examined the role of signal transduction pathways involving MAPK in insulin - 
stimulated glucose transport in 'insulin-responsive' tissues. These studies have used the 
differentiated form of 3T3-L1 fibroblasts; these cells have a phenotype characteristic of 
adipocytes {Section 3.1.2}. Importantly, they express both G lutl and Glut4, and the rate 
of glucose transport increases 15 to 20 fold in response to insulin [Calderhead et al., 
1990a], arising primarily from the translocation of Glut4 [Holman et al., 1990].
In one study [Inoue et al., 1993], when 3T3-L1 adipocytes were treated with ML-9, 
reported to be an inhibitor of myosin light chain kinase, insulin-stimulated glucose 
transport and translocation to the plasma membrane of both G lutl and Glut4 were 
inhibited. However, further analysis showed that, in fact, the activity of myosin light 
chain kinase had been unaffected by the ML-9. The study concluded th a t ML-9 inhibits 
the activation of MAPK instead, and tha t insulin stimulation of glucose transport 
through both G lutl and Glut4 is mediated by a signal transduction pathway involving 
MAPK
Other recent studies also suggest tha t a signal transduction pathway involving MAPK 
may mediate the effect of growth factors on glucose transport through G lutl. In 
contrast, however, they suggest tha t the effect of insulin on glucose transport through 
Glut4 is not mediated by the same pathway.
Firstly, EGF and PDGF stimulated the rate of glucose transport by approximately two 
fold in 3T3-L1 adipocytes, while insulin stimulated the rate by approximately 20 fold. 
EGF, PDGF and insulin all stimulated the translocation of G lutl, bu t only insulin
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stimulated the translocation of Glut4. Since the differences between the effects of EGF, 
PDGF and insulin were not due to cell-specific expression, the stimulation of glucose 
transport through G lutl and Glut4 must have been mediated by different signal 
transduction pathways. Furthermore, it was suggested th a t since EGF, PDGF and 
insulin all stimulate MAPK activity, glucose transport through G lutl, but not through 
Glut4, is mediated by a signal transduction pathway involving MAPK [Fingar and 
Bimbaum, 1994a; Gould et al., 1994].
Secondly, expression of a constitutively active Raf-1, p35m ‘^1, in  3T3-L1 adipocytes 
resulted in an elevated G lutl level, while the Glut4 level and intracellular distribution 
remained normal [Fingar and Bimbaum, 1994b]. After microinjection with a dominant 
negative p21ras mutant, N17Ras, insulin-stimulated G lutl translocation was abolished, 
while insulin-stimulated Glut4 translocation remained unaffected [Hausdorff et al.,
1994]. Thus, given tha t p21ras and p74raf~  ^both appear to be involved in the regulation 
of glucose transport through G lutl and not through Glut4, and tha t both activate the 
kinase cascade leading to the activation of MAPK, it is likely tha t a signal transduction 
pathway involving MAPK mediates glucose transport through G lutl, but not through 
Glut4.
This thesis concludes th a t the early phase of growth factor-stimulated glucose transport 
is mediated by a signal transduction pathway involving MAPK
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